Inspire Veterinary Partners (IVP) S-1 13 Jun 24 IPO registration Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Mar. 31, 2024
Document Information Line Items
Entity Registrant Name	INSPIRE VETERINARY PARTNERS, INC.
Document Type	S-1
Amendment Flag	false
Entity Central Index Key	0001939365
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	NV

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 69,077	$ 178,961	$ 444,253
Accounts receivable, net	341,488	28,573
Due from former owners		32,519	269,883
Inventory	545,660	571,512	582,019
Refundable income tax	151,796	151,796	192,139
Prepaid expenses and other current assets	2,031,311	388,759	253,795
Total current assets	3,139,332	1,352,120	1,742,089
Restricted cash - non-current	200,000	200,000
Property and equipment, net	7,966,721	7,949,144	7,323,050
Right-of-use assets	1,562,367	1,616,198	746,973
Other intangibles, net	2,305,014	2,513,028	2,729,574
Goodwill	8,147,590	8,147,590	7,614,553
Other assets	73,989	12,895	29,456
Total assets	23,395,013	21,790,975	20,185,695
Current liabilities:
Accounts payable	3,521,759	3,206,594	1,018,931
Accrued expenses	455,227	858,334	690,740
Cumulative Series A preferred stock dividends payable	2,250	92,322
Operating lease liabilities	133,113	141,691	91,152
Loan payable, net of discount	2,338,067	1,713,831
Bridge note, net of discount			3,899,156
Convertible note payable	500,000
Convertible debentures, net of issuance costs		100,000
Notes payable, net of discount	1,501,562	1,469,043	1,549,861
Total current liabilities	8,451,978	7,581,815	7,249,840
Operating lease liabilities, non-current	1,482,514	1,514,044	666,179
Convertible debentures, net of issuance costs			3,688,805
Notes payable - noncurrent	13,190,668	13,483,375	13,716,352
Total liabilities	23,125,160	22,579,234	25,321,176
COMMITMENTS AND CONTINGENCIES (Note 12)
STOCKHOLDER’S EQUITY (DEFICIT)
Additional paid in capital	25,118,701	20,426,562	1,107,439
Accumulated deficit	(24,849,319)	(21,215,257)	(6,243,448)
Total stockholder’s equity (deficit)	269,853	(788,259)	(5,135,481)
Total liabilities and stockholder’s equity (deficit)	23,395,013	21,790,975	20,185,695
Class A Common Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Common stock value	74	7
Class B Common Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Common stock value	389	389	430
Convertible Series A Preferred Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Preferred stock value	$ 8	40
Previously Reported
Current assets:
Cash and cash equivalents		178,961
Accounts receivable, net		28,573
Due from former owners		32,519
Inventory		571,512
Refundable income tax		151,796
Prepaid expenses and other current assets		388,759
Total current assets		1,352,120
Restricted cash - non-current		200,000
Property and equipment, net		7,949,144
Right-of-use assets		1,616,198
Other intangibles, net		2,513,028
Goodwill		8,147,590
Other assets		12,895
Total assets		21,790,975
Current liabilities:
Accounts payable		3,206,594
Accrued expenses		858,334
Cumulative Series A preferred stock dividends payable		92,322
Operating lease liabilities		141,691
Loan payable, net of discount		1,713,831
Bridge note, net of discount
Convertible debentures, net of issuance costs		100,000
Notes payable, net of discount		1,469,043
Total current liabilities		7,581,815
Operating lease liabilities, non-current		1,514,044
Convertible debentures, net of issuance costs
Notes payable - noncurrent		13,483,375
Total liabilities		22,579,234
STOCKHOLDER’S EQUITY (DEFICIT)
Additional paid in capital		20,425,864
Accumulated deficit		(21,215,257)
Total stockholder’s equity (deficit)		(788,259)	(5,135,481)
Total liabilities and stockholder’s equity (deficit)		21,790,975
Previously Reported | Class A Common Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Common stock value		705	$ 98
Previously Reported | Class B Common Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Common stock value		389
Previously Reported | Convertible Series A Preferred Stock
STOCKHOLDER’S EQUITY (DEFICIT)
Preferred stock value		$ 40

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Class A Common Stock
Common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000	1,000,000	100,000,000
Common stock, shares, outstanding	742,563	70,421	970,457
Common stock, shares, issued	742,563	70,421	970,457
Class B Common Stock
Common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	20,000,000	20,000,000	20,000,000
Common stock, shares, outstanding	3,891,500	3,891,500	4,300,000
Common stock, shares, issued	3,891,500	3,891,500	4,300,000
Convertible Series A Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	2,000,000	2,000,000	1,000,000
Preferred stock, shares outstanding	81,142	403,640	0
Preferred stock, shares issued	81,142	403,640	0
Previously Reported | Class A Common Stock
Common stock par value (in Dollars per share)		$ 0.0001
Common stock, shares authorized		100,000,000
Common stock, shares, outstanding		7,042,106
Common stock, shares, issued		7,042,106
Previously Reported | Class B Common Stock
Common stock par value (in Dollars per share)		$ 0.0001
Common stock, shares authorized		20,000,000
Common stock, shares, outstanding		3,891,500
Common stock, shares, issued		3,891,500
Previously Reported | Convertible Series A Preferred Stock
Preferred stock, par value (in Dollars per share)		$ 0.0001
Preferred stock, shares authorized		1,000,000
Preferred stock, shares outstanding		403,640
Preferred stock, shares issued		403,640

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 4,831,567	$ 4,282,515	$ 16,675,393	$ 9,834,778
Operating expenses
General and administrative expenses	2,873,343	1,801,659	9,476,287	5,467,642
Debt extinguishment loss	728,278		16,105
Depreciation and amortization	367,197	298,492	1,252,539	596,124
Total operating expenses	7,694,072	5,287,454	23,866,409	13,352,916
Loss from operations	(2,862,505)	(1,004,939)	(7,191,016)	(3,518,138)
Other income (expenses):
Interest income	2	1	21	1,021
Interest expense	(559,289)	(545,435)	(2,538,710)	(1,425,260)
Other income		11,424	1,134	357
Total other expenses	(559,287)	(534,010)	(7,601,870)	(1,423,882)
Other income (expenses):
Loss on debt modification			(927,054)
Beneficial conversion feature			(4,137,261)
Loss before income taxes	(3,421,792)	(1,538,949)	(14,792,886)	(4,942,020)
Benefit for income taxes				30,094
Net loss	(3,421,792)	(1,538,949)	(14,792,886)	(4,911,926)
Dividend on convertible series A preferred stock	(214,520)		(271,245)
Net loss attributable to class A and B common stockholders	(3,636,312)	(1,538,949)	(15,064,131)	(4,911,926)
Service
Total revenue	3,545,599	3,072,885	11,879,934	7,032,800
Operating expenses
Cost of service revenue (exclusive of depreciation and amortization, shown separately below)	2,709,147	2,307,903	9,700,963	5,308,104
Product
Total revenue	1,285,968	1,209,630	4,795,459	2,801,978
Operating expenses
Cost of service revenue (exclusive of depreciation and amortization, shown separately below)	$ 1,016,107	$ 879,400	$ 3,420,515	$ 1,981,046
Class A and B Common Shares
Net loss per Class A and B common shares:
Basic (in Dollars per share)	$ (8.97)	$ (29.2)	$ (2.25)	$ (0.95)
Weighted average shares outstanding per Class A and B common shares:
Basic (in Shares)	405,484	52,705	6,692,515	5,160,182

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Operations (Parentheticals) - Class A and B Common Shares - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Diluted	$ (8.97)	$ (29.20)	$ (2.25)	$ (0.95)
Diluted	405,484	52,705	6,692,515	5,160,182

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit - USD ($)	Preferred Stock Convertible Series A Previously Reported	Preferred Stock Convertible Series A	Common Stock Class A Previously Reported	Common Stock Class A	Common Stock Class B Previously Reported	Common Stock Class B	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital	Accumulated Deficit (As Restated) Previously Reported	Accumulated Deficit (As Restated)	Previously Reported	Total
Balance (in Shares) at Dec. 31, 2021				845,456		4,300,000
Balance at Dec. 31, 2021				$ 85		$ 430		$ 461,916		$ (1,331,522)		$ (869,091)
Issuance of warrants as part of bridge loan received								429,284				429,284
Issuance of class A common stock for services				$ 13				216,239				216,252
Issuance of class A common stock for services (in Shares)				125,001
Net Loss										(4,911,926)		(4,911,926)
Balance at Dec. 31, 2022			$ 98	$ 1	$ 430	$ 430	$ 1,107,439	1,107,536	$ (6,243,448)	(6,243,448)	$ (5,135,481)	(5,135,481)
Balance (in Shares) at Dec. 31, 2022			970,457	9,705	4,300,000	4,300,000
Issuance of warrants to CEO								2,701				2,701
Net Loss										(1,538,949)		(1,538,949)
Balance at Mar. 31, 2023				$ 1		$ 430		1,110,663		(7,782,397)		(6,671,729)
Balance (in Shares) at Mar. 31, 2023				9,705		4,300,000
Balance (in Shares) at Dec. 31, 2022			970,457	9,705	4,300,000	4,300,000
Balance at Dec. 31, 2022			$ 98	$ 1	$ 430	$ 430	1,107,439	1,107,536	(6,243,448)	(6,243,448)	(5,135,481)	(5,135,481)
Issuance of warrants to CEO								2,701				2,701
Issuance of class A common stock in connection with initial public offering, net of issuance costs				$ 160				5,439,411				5,439,571
Issuance of class A common stock in connection with initial public offering, net of issuance costs (in Shares)				1,600,000
Conversion of convertible debentures into class A common stock				$ 149				4,414,168				4,414,317
Conversion of convertible debentures into class A common stock (in Shares)				1,495,928
Conversion of class B common stock into class A common stock				$ 41		$ (41)
Conversion of class B common stock into class A common stock (in Shares)				408,500		(408,500)
Issuance of common stock in connection with business acquisition				$ 41				399,959				400,000
Issuance of common stock in connection with business acquisition (in Shares)				408,163
Beneficial conversion feature on convertible debentures								1,569,395				1,569,395
Beneficial conversion feature on convertible series A preferred stock								2,567,866				2,567,866
Issuance of convertible series A preferred stock		$ 44						4,440,644				4,440,688
Issuance of convertible series A preferred stock (in Shares)		442,459
Issuance of class A common stock for services				$ 18				397,874				397,892
Issuance of class A common stock for services (in Shares)				180,192
Conversion of convertible series A preferred stock into class A common stock		$ (6)		$ 198				(192)
Conversion of convertible series A preferred stock into class A common stock (in Shares)		(56,711)		1,978,866
Convertible series A preferred stock cumulative dividends								(92,322)				(92,322)
Convertible series A preferred stock dividend		$ 2						178,921		(178,923)
Convertible series A preferred stock dividend (in Shares)		17,892
Net Loss										(14,792,886)		(14,792,886)
Balance at Dec. 31, 2023	$ 40	$ 40	$ 705	$ 7	$ 389	$ 389	$ 20,425,864	20,426,562	$ (21,215,257)	(21,215,257)	$ (788,259)	(788,259)
Balance (in Shares) at Dec. 31, 2023	403,640	403,640	7,042,106	70,421	3,891,500	38,915
Issuance of class A common stock and pre-funded warrants, net of issuance costs (in Shares)				28,599
Issuance of class A common stock and pre-funded warrants, net of issuance costs				$ 3				3,375,455				3,375,458
Exercise of pre-funded warrants				$ 44				(44)
Exercise of pre-funded warrants (in Shares)				441,989
Issuance of Class A common stock and pre-funded warrants in connection with commitment shares				$ 1				599,999				600,000
Issuance of Class A common stock and pre-funded warrants in connection with commitment shares (in Shares)				12,143
Issuance of convertible series A preferred stock		$ 2						200,000				200,000
Issuance of convertible series A preferred stock (in Shares)		20,000
Issuance of class A common stock for services				$ 4				286,692				286,696
Issuance of class A common stock for services (in Shares)				39,051
Issuance of class A common stock in connection with gernal release agreement								20,000				20,000
Issuance of class A common stock in connection with gernal release agreement (in Shares)				2,460
Conversion of convertible series A preferred stock into class A common stock		$ (36)		$ 15				(15)
Conversion of convertible series A preferred stock into class A common stock (in Shares)		(363,725)		147,899
Convertible series A preferred stock cumulative dividends								(2,250)				(2,250)
Convertible series A preferred stock dividend		$ 2						212,270		(212,270)
Convertible series A preferred stock dividend (in Shares)		21,227
Net Loss										(3,421,792)		(3,421,792)
Balance at Mar. 31, 2024		$ 8		$ 74		$ 389		$ 25,118,701		$ (24,849,319)		$ 269,853
Balance (in Shares) at Mar. 31, 2024		81,142		742,563		3,891,500

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (3,421,792)	$ (1,538,949)	$ (14,792,886)	$ (4,911,926)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	347,382	298,492	1,252,539	595,627
Bad debt provision			123,513
Amortization of debt issuance costs	15,825	70,212	128,583	189,414
Amortization of debt discount	379,313	242,631	864,350	689,554
Amortization of operating right of use assets	53,831	59,036	162,298	13,958
Debt extinguishment loss	728,278		16,105
Issuance of warrants to CEO		2,701	2,701
Issuance of class A common stock for services	286,696		397,892	216,252
Loss on debt modification	728,278		927,054
Beneficial conversion feature			4,137,261
Issuance of class A common stock in connection with general release agreement	20,000
Issuance of Class A common stock and pre-funded warrants in connection with commitment shares	600,000
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(312,915)	(70,553)	(152,086)
Due from former owners	32,519	37,425	237,364	(233,898)
Inventory	25,852	(18,459)	84,912	(230,125)
Refundable income tax			40,343
Prepaid expenses and other current assets	(1,642,552)	60,414	(134,964)	(187,931)
Other assets	(61,094)	(70,431)	16,561
Accounts payable	315,165	550,043	2,187,663	974,040
Accrued expenses	(403,107)	118,450	813,144	230,326
Cumulative Series A preferred stock dividends payable	(92,322)
Operating lease liabilities	(40,108)	(50,467)	(133,119)	(3,600)
Net cash used in operating activities	(3,169,029)	(309,455)	(3,820,772)	(2,658,309)
Cash flows from investing activities:
Purchase of property and equipment	(156,945)	(14,002)	(383,729)	(134,971)
Purchase of intangible assets				(41,819)
Payment for acquisition of businesses			(1,485,800)	(14,511,804)
Advances for target acquisitions				21,798
Net cash used in investing activities	(156,945)	(14,002)	(1,869,529)	(14,666,796)
Cash flows from financing activities:
Proceeds from issuance of class A common stock and pre-funded warrants, net of issuance costs	3,375,458
Proceeds from issuance of class A common stock in connection with initial public offering, net of offering costs			5,439,571
Net proceeds from loan payable	549,185		2,038,531
Payments on loan payable	(1,032,540)		(1,923,474)
Proceeds from note payable, net of discount				12,253,585
Debt issuance costs				(260,611)
Proceeds from issuance of convertible series A preferred stock	200,000
Proceeds from convertible note payable	500,000
Repayment of note payable	(276,013)	(176,931)	(329,620)	(494,034)
Proceeds from issuance of bridge notes				2,600,000
Proceeds from issuance of convertible debentures		650,000	650,000	1,612,000
Repayment of convertible debentures	(100,000)		(250,000)
Net cash provided by financing activities	3,216,090	473,069	5,625,009	15,710,940
Net increase (decrease) in cash, cash equivalents and restricted cash	(109,884)	149,612	(65,292)	(1,614,165)
Cash, cash equivalents and restricted cash, beginning of period	378,961	444,253	444,253	2,058,418
Cash, cash equivalents and restricted cash, end of period	269,077	593,865	378,961	444,253
Supplemental Disclosure of Cash Flow Information
Interest payments during the year	1,316,378	239,430	1,316,378	239,430
Income taxes paid (refunded)		(188,952)		192,139
Noncash investing and financing activity
Acquisition of assets through operating leases			1,031,523	760,931
Series A Preferred Stock Dividend Paid-in-Kind	$ 212,270		271,245
Issuance of common stock in connection with business acquisition			400,000
Issuance of convertible series A preferred stock due to conversion of bridge notes			4,440,688
Issuance of class A common stock due to conversion of convertible debentures			$ 4,414,317

Description of Business

Description of Business	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Description of Business [Abstract]
Description of Business	1. Description of Business Business Description Inspire Veterinary Partners, Inc. (the “Company” or “Inspire”) is a C-corporation which incorporated in the state of Delaware on December 2, 2020. On June 29, 2022, the Company converted into a Nevada C-corporation (“Conversion”). The Conversion did not result in any change in the corporate name, business, management fiscal year, accounting, location of the principal executive officer, capitalization structure, or assets or liabilities of the Company. The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds. As the Company expands, additional modalities are becoming a part of the offerings at its hospital, including equine care. With 14 clinics located in 10 states as of the date of this filing, Inspire purchases existing hospitals which have the financial track record, marketplace advantages and future growth potential to make them worthy acquisition targets. Because the company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. The Company operates its business as one operating and one reportable segment. Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings. The Company is the managing member of IVP Practice Holdings Co., LLC (“Holdco”), a Delaware limited liability company, which is the managing member of IVP CO Holding, LLC (“CO Holdco”), a Delaware limited liability company, IVP FL Holding Co., LLC (“FL Holdco”), a Delaware limited liability company, IVP Texas Holding Company, LLC (“TX Holdco”), a Delaware limited liability company, KVC Holding Company, LLC (“KVC Holdco”), a Hawaii limited liability company, and IVP CA Holding Co., LLC (“CA Holdco”), a Delaware limited liability company, IVP MD Holding Company, LLC (“MD Holdco”), a Delaware limited liability company, IVP OH Holding (“OH Holdco”), Co, LLC, a Delaware limited liability company, IVP IN Holding Co., LLC (“IN Holdco”), a Delaware limited liability company, IVP MA Managing Co., LLC, a Delaware limited liability company (“MA Holdco”), and IVP PA Holding Company, LLC, a Delaware limited liability company (“PA Holdco”). The Company through Holdco, operates and controls all business and affairs of CO Holdco, FL Holdco, TX Holdco, KVC Holdco, CA Holdco, MD Holdco. Holdco, OH Holdco, IN Holdco, MA Holdco and PA Holdco is used to acquire hospitals in various states and jurisdictions. The Company is the managing member of IVP Real Estate Holding Co., LLC (“IVP RE”), a Delaware limited liability company, which is the managing member of IVP CO Properties, LLC (“CO RE”), a Delaware limited liability company, IVP FL Properties, LLC (“FL RE”), a Delaware limited liability company, IVP TX Properties, LLC (“TX RE”), a Delaware limited liability company, KVC Properties, LLC, (“KVC RE”), a Hawaii limited liability company, IVP CA Properties, LLC (“CA RE”), a Delaware limited liability company, IVP MD Properties, LLC (“MD RE”), a Delaware limited liability company, IVP OH Properties, LLC (“OH RE”), a Delaware limited liability company, IVP IN Properties, LLC (“IN RE”), a Delaware limited liability company, and IVP PA Properties, LLC (“PA RE”), a Delaware limited liability company. The Company through IVP RE operates and controls all business and affairs of CO RE, FL RE, TX RE, KVC RE, CA RE, MD RE, OH RE, IN RE and PA RE. IVP RE is used to acquire real property in various states and jurisdictions. Initial Public Offering On August 31, 2023, we closed our IPO of 16,000 shares of class A common stock, at a public price of $400.00 per share. The total net proceeds we received in the IPO were approximately $5.4 million after deducting underwriting discounts and commissions of $512,000 and offering expenses of $448,429. The Company’s class A common shares are traded on the Nasdaq Capital Market (“NASDAQ”) under the symbol IVP.	1. Description of Business Business Description Inspire Veterinary Partners, Inc. (the “Company” or “Inspire”) is a C-corporation which incorporated in the state of Delaware on December 2, 2020. On June 29, 2022, the Company converted into a Nevada C-corporation (“Conversion”). The Conversion did not result in any change in the corporate name, business, management, fiscal year, accounting, location of the principal executive officer, capitalization structure, or assets or liabilities of the Company. The Company owns and operates veterinary hospitals throughout the United States. The Company specializes in small animal general practice hospitals which serve all manner of companion pets, emphasizing canine and feline breeds. As we expand, additional modalities are becoming a part of the services offered at our hospitals, including equine care. With 14 clinics located in 11 states as of March 31, 2024, Inspire purchases existing hospitals which have the financial track record, marketplace advantages and future growth potential to make them worthy acquisition targets. Because the Company leverages a leadership and support structure which is distributed throughout the United States, acquisitions are not centralized to one geographic area. The Company operates its business as one operating and one reportable segment. Services provided at owned hospitals include preventive care for companion animals consisting of annual health exams which include: parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; skin and coat health and many breed specific preventive care services. Surgical offerings include all soft tissue procedures such as spays and neuters, mass removals, splenectomies and can also include gastropexies, orthopedic procedures and other types of surgical offerings based on a doctor’s training. In many locations additional means of care and alternative procedures are also offered such as acupuncture, chiropractic and various other health and wellness offerings. The Company is the managing member of IVP Practice Holdings Co., LLC (“Holdco”), a Delaware limited liability company, which is the managing member of IVP CO Holding, LLC (“CO Holdco”), a Delaware limited liability company, IVP FL Holding Co., LLC (“FL Holdco”), a Delaware limited liability company, IVP Texas Holding Company, LLC (“TX Holdco”), a Delaware limited liability company, KVC Holding Company, LLC (“KVC Holdco”), a Hawaii limited liability company, and IVP CA Holding Co., LLC (“CA Holdco”), a Delaware limited liability company, IVP MD Holding Company, LLC (“MD Holdco”), a Delaware limited liability company, IVP OH Holding (“OH Holdco”), Co, LLC, a Delaware limited liability company, IVP IN Holding Co., LLC (“IN Holdco”), a Delaware limited liability company, IVP MA Managing Co., LLC, a Delaware limited liability company (“MA Holdco”), and IVP PA Holding Company, LLC, a Delaware limited liability company (“PA Holdco”). The Company through Holdco, operates and controls all business and affairs of CO Holdco, FL Holdco, TX Holdco, KVC Holdco, CA Holdco, MD Holdco. Holdco, OH Holdco, IN Holdco, MA Holdco and PA Holdco are used to acquire hospitals in various states and jurisdictions. The Company is the managing member of IVP Real Estate Holding Co., LLC (“IVP RE”), a Delaware limited liability company, which is the managing member of IVP CO Properties, LLC (“CO RE”), a Delaware limited liability company, IVP FL Properties, LLC (“FL RE”), a Delaware limited liability company, IVP TX Properties, LLC (“TX RE”), a Delaware limited liability company, KVC Properties, LLC, (“KVC RE”), a Hawaii limited liability company, IVP CA Properties, LLC (“CA RE”), a Delaware limited liability company, IVP MD Properties, LLC (“MD RE”), a Delaware limited liability company, IVP OH Properties, LLC (“OH RE”), a Delaware limited liability company, IVP IN Properties, LLC (“IN RE”), a Delaware limited liability company, and IVP PA Properties, LLC (“PA RE”), a Delaware limited liability company. The Company through IVP RE operates and controls all business and affairs of CO RE, FL RE, TX RE, KVC RE, CA RE, MD RE, OH RE, IN RE and PA RE. IVP RE are used to acquire real property in various states and jurisdictions.

Retrospective Adjustments

Retrospective Adjustments	3 Months Ended
	Mar. 31, 2024
Retrospective Adjustments [Abstract]
RETROSPECTIVE ADJUSTMENTS	2. RETROSPECTIVE ADJUSTMENTS On May 8, 2024, the Company effected a 100-for-1 reverse stock split (“Reverse Split”) of the Company’s authorized and outstanding shares of Class A common stock. All information included in these financial statements have been adjusted, on a retrospective basis for all periods presented to reflect the Reverse Split, unless otherwise stated.

Significant Accounting Policies

Significant Accounting Policies and Basis of Presentation	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Significant Accounting Policies and Basis of Presentation [Abstract]
Significant Accounting Policies and Basis of Presentation	3. Significant Accounting Policies and Basis of Presentation Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2023, which are included with the Company’s Annual Report on Form 10-K and related amendments filed with the United States Securities Exchange Commission (“SEC”). Furthermore, the Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December 31, 2023 and 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC. Since the date of those audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below. The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification(“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the Company’s financial position, results of operations, and cash flows. The December 31, 2023, condensed consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. On October 20, 2022, the Company amended and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas the Class A common stock prior to the amendment had 25 votes per share is now designated Class B common stock and the Class B common stock prior the amendment had 1 vote per share is now designated Class A common stock. All information included in these unaudited condensed consolidated financial statements have been adjusted, on a retrospective basis to reflect the change in designation. Going Concern These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of March 31, 2024, had an accumulated deficit of $24,849,319. For the three months ending March 31, 2024, the Company sustained a net loss of $3,421,792. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months from the date of issuance of these financial statements. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable consist of amounts due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current expected credit losses was $123,513 as of March 31, 2024 and December 31, 2023. Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: March 31, 2024 2023 Warrants 28,540 - Convertible Series A Preferred Shares 27,047 - Total 55,587 - Emerging Growth Company Status The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.	2. Significant Accounting Policies and Basis of Presentation Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). On October 20, 2022, the Company amended and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas the Class A common stock prior to the amendment had 25 votes per share is now designated Class B common stock and the Class B common stock prior the amendment had 1 vote per share is now designated Class A common stock. All information included in these consolidated financial statements has been adjusted, on a retrospective basis to reflect the change in designation. Going Concern These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of December 31, 2023, had an accumulated deficit of $21,215,257. For the year ending December 31, 2023, the Company sustained a net loss of $15,064,131. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months from the date of issuance of these financial statements. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022 the Company had no cash equivalents. Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. Cash is deposited in checking accounts at accredited financial institutions with high credit-quality and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, which at times, may exceed federally insured limits. The excess amounts as of December 31, 2023 and 2022, were $114,080 and $43,094, respectively. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these high-quality financial institutions. Restricted Cash Restricted Cash consisted of cash designated to settle a holdback agreement related to our acquisition of Valley Veterinary Services, Inc. to be settled by February 8, 2026 if specific contingencies are met (see note 12 for more information). Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable consist of amounts due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current expected credit losses was $123,513 and $0 as of December 31, 2023 and 2022, respectively. Due from Former Owners The Company enters into asset purchase agreements related to the acquisitions of veterinary hospitals and as part of these agreements contractually obligates the former owners of the veterinary hospitals to reimburse the Company for any monies collected by the former owners for revenues earned subsequent to the closing date of the acquisition, less monies paid by the former owner on behalf of the Company for expenses incurred subsequent to the closing date of the acquisition. Any adjustments relating to pre-acquisition amounts will be reflected in goodwill. Inventory Inventory is recorded at the lower of cost or net realizable value. Cost is using the weighted average method. Inventory consists of inventoriable supplies used for veterinary care and services. Leases The Company reviews all arrangements for potential leases, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. Lease term, discount rate, variable lease costs and future minimum lease payment determinations require the use of judgment and are based on the facts and circumstances related to the specific lease. Lease terms are generally based on their initial non-cancellable terms, unless there is a renewal option that is reasonably certain to be exercised. Various factors, including economic incentives, intent, past history and business needs are considered to determine if a renewal option is reasonably certain to be exercised. The implicit rate in a lease agreement is used when it can be determined to value the lease obligation. Otherwise, the Company’s incremental borrowing rate, which is based on information available as of the lease commencement date, including applicable lease terms and the current economic environment, is used to determine the value of the lease obligation. Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight line method over the estimated useful lives of the related assets up to the salvage value. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major Improvements are capitalized and depreciated over the remaining useful lives of the assets. The carrying amount of the assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal, with resulting gains or losses included in operations. Estimated useful lives are as follows for major classes of property and equipment: Computers and equipment 3 – 7 years Furniture and fixtures 5 – 7 years Automobile 5 – 7 years Leasehold improvements 5 – 15 years Buildings 5 – 15 years Acquisitions The Company enters into acquisitions primarily with existing veterinary hospitals throughout the United States. When we acquire a business or assets that are determined to meet the definition of a business, we allocate the purchase consideration paid to acquire the business to the assets and liabilities acquired based on estimated fair values at the acquisition date, with the excess of purchase price over the estimated fair value of the net assets acquired recorded as goodwill. If during the measurement period (a period not to exceed 12 months from the acquisition date) we receive additional information that existed as of the acquisition date but at the time of the original allocation described above was unknown to us, we make the appropriate adjustments to the purchase price allocation in the reporting period that the amounts are determined. Goodwill Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include significant changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value. The Company has recorded Goodwill in connection with business acquisitions during the years ended December 31, 2023 and 2022 (see Note 5). During the years ended December 31, 2023 and 2022, the Company recorded no impairment of Goodwill. Intangible Assets Intangible assets consist of client list, trademark and non-compete intangibles that result from the acquisition of veterinary hospitals or practices. Client list intangible assets represent the value of the long-term client relationship from the veterinary hospitals and practices. Trademark intangible assets represent the value associated with the brand names in place at the date of the acquisition. Non-compete intangible assets represent the value associated with non-compete agreements for former employees and owners in place at the date of the acquisition. The client lists and trademarks’ are included in intangible assets reported in the balance sheet which are being amortized over a 5-year term based on the estimated economic useful life of the client list and trademark. The non-compete intangible asset included in other intangibles, net is amortized over a 2-year term based on the estimated useful life of the asset. The amortization of the intangible asset is computed using the straight-line method. The intangibles are evaluated for impairment on an annual basis or more frequently whenever events or circumstances occur indicating that the carrying amount may not be recoverable. Revenue Recognition The Company recognizes service revenue from veterinary care services once the service is completed, as this is when the customer has the ability to direct the use of and obtain the benefits of the service. Payment terms are typically at the point of sale but may also occur upon completion of the service. The Company’s service contracts are primarily with veterinary customers. Product revenue is recognized when control passes, which occurs at a point in time when the customer completes a transaction at our animal hospitals or clinics and receives the product. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations are the delivery of veterinary services at the estimated net realizable amount for those services and goods. The Company’s accounting methodologies and processes include an evaluation of the historical collection and consideration of whether contractual allowances are necessary based on historical experience. Revenue is reported net of sales discounts and excludes sales taxes. Cost of service revenue (exclusive of depreciation and amortization) Cost of service revenue consists of cost directly related to the animal services provided at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, laboratory costs, pet supply costs, third-party veterinarian contractors, office rent, utilities, supplies, and other cost arising as a result of the services being performed, excluding depreciation and amortization. Cost of product revenue (exclusive of depreciation and amortization) Cost of product revenue consists of cost directly related to the product sales at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, purchase price of the medication we dispense, and purchase price of product sold, excluding depreciation and amortization. General and administrative expenses General and administrative expenses include personnel-related compensation costs for corporate employees, such as management, accounting, legal, acquisition related and non-recurring expenses, insurance and other expenses used to operate the business. Depreciation and Amortization Expense Depreciation and amortization expenses mainly relate to the assets used in generating revenue. Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company recognized a beneficial conversion feature of $1,569,395 during the year ended December 31, 2023. The Company records a discount to convertible notes and convertible preferred stock for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note, if applicable. Debt discounts under these arrangements are amortized to noncash interest expense using the effective interest rate method over the term of the related debt to their date of maturity. If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved. Beneficial Conversion Feature of Convertible Debt The Company accounts for convertible debt in accordance with the guidelines established by FASB ASC 470-20, “Debt with Conversion and Other Options”. The Beneficial Conversion Feature (“BCF”) of convertible debt is normally characterized as the convertible portion or feature of certain debt that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of convertible debt when issued, and also records the estimated fair value. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the event is resolved. Debt Issuance Costs Debt issuance costs are specifically identifiable costs associated with issuance of a new debt instrument. Debt issuance costs are reported on the consolidated balance sheet as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized to interest expense over the term of the related debt. Advertising Costs The Company expenses advertising costs as they are incurred. Advertising expenses were $107,766 and $28,469 for the years ending December 31, 2023 and 2022, respectively. These costs are included in “General and administrative expenses” in the accompanying consolidated statements of operations. Stock Warrants Certain warrants that were granted by the Company for lenders through convertible bridge loans transactions (see also Note 6 Debt - Bridge Note) are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price and thus, are considered as indexed to the Company’s own stock. In addition, the warrants must require physical settlement and may not provide any guarantee of value or return. We present the allocated value for the warrants within additional paid-in capital in our consolidated balance sheet. The value assigned to the warrants was determined based on a relative fair value allocation between the warrants and related debt. The fair value of the warrants was determined using a Black Scholes valuation and applying a discount for the lack of marketability for the warrants. Stock-Based Compensation The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods, which typically conform to the performance period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees. Income Tax The Company and its U.S. subsidiaries file a consolidated federal income tax return and is taxed as a C-Corporation, whereby it is subject to federal and state income taxes. The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 requires an asset and liability approach for financial accounting and reporting for income taxes and established for all the entities a minimum threshold for financial statement recognition of the benefit of tax positions and requires certain expanded disclosures. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse. The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary. Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive. The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: December 31, 2023 2022 Warrants 959,610 - Convertible Series A Preferred Shares 16,145,600 - Total 17,105,210 - Recently Issued Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instrument (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 was effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial position, results of operations and cash flows. The FASB and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2023. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. Emerging Growth Company Status The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Property and Equipment

Property and Equipment	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
Property and equipment	4. Property and equipment As of March 31, 2024, and December 31, 2023, property and equipment, net, consisted of the following: March 31, December 31, 2024 2023 Land $ 1,983,810 $ 1,839,596 Computers and equipment 1,425,774 1,425,774 Furniture and fixtures 143,874 143,874 Automobile 101,269 101,269 Leasehold improvements 656,255 499,310 Buildings 4,607,874 4,607,874 8,918,856 8,761,911 Less - accumulated depreciation (952,135 ) (812,767 ) Property and Equipment, net $ 7,966,721 $ 7,949,144 Depreciation expense was $139,368 and $118,368 for the three months ended March 31, 2024 and 2023, respectively.	3. Property and equipment As of December 31, 2023 and 2022, property and equipment, net, consisted of the following: December 31, December 31, 2023 2022 Land $ 1,983,810 $ 1,839,596 Buildings 4,607,874 4,162,088 Computers and equipment 1,425,774 1,321,708 Furniture and fixtures 143,874 143,874 Automobile 101,269 69,083 Leasehold improvements 499,310 95,991 8,761,911 7,632,340 Less - accumulated depreciation (812,767 ) (309,290 ) Property and Equipment, net $ 7,949,144 $ 7,323,050 Depreciation expense was $503,477 and $263,387 for the years ended December 31, 2023 and 2022, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets The following summarizes the Companies’ intangibles assets as of March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Client List $ 2,071,000 $ 2,071,000 Noncompete Agreement 398,300 398,300 Trademark 1,117,200 1,117,200 Other Intangible Assets 45,836 45,836 Accumulated amortization (1,327,322 ) (1,119,308 ) $ 2,305,014 $ 2,513,028 Amortization expense was $208,014 and $180,124 for the three months ended March 31, 2024 and December 31, 2023, respectively. Expected future amortization expense of intangible assets as of March 31, 2024, is as follows: Remainder of 2024 578,763 2025 664,166 2026 600,139 2027 379,382 2028 82,564 $ 2,305,014	4. Goodwill and Intangible Assets The following table shows the changes in the carrying amount of goodwill for the years ended December 31, 2023 and 2022:: Goodwill as of December 31, 2021 $ 1,610,843 Acquisitions 6,003,710 Goodwill as of December 31, 2022 7,614,553 Acquisitions 533,037 Goodwill as of December 31, 2023 $ 8,147,590 There was no goodwill impairment recognized in the years ended December 31, 2023 and 2022. The following summarizes the Company’s intangibles assets not including goodwill as of December 31, 2023 and 2022: December 31, December 31, 2023 2022 Client List $ 2,071,000 $ 1,851,000 Noncompete Agreement 398,300 354,300 Trademark 1,117,200 852,700 Other Intangible Assets 45,836 41,819 Accumulated amortization (1,119,308 ) (370,245 ) $ 2,513,028 $ 2,729,574 Amortization expenses were $749,062 and $332,240 for the years ended December 31, 2023 and 2022, respectively. Expected future amortization expense of intangible assets as of December 31, 2023 is as follows: 2024 $ 786,776 2025 664,166 2026 600,139 2027 379,382 2028 82,564 $ 2,513,028

Business Acquisitions

Business Acquisitions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Business Acquisitions [Abstract]
Business Acquisitions	6. Business acquisitions Valley Veterinary Service On November 8, 2023, the Company acquired the animal hospital and related assets of Valley Veterinary Service, Inc., a Pennsylvania corporation (“Valley Vet Practice”) by entering into an Asset Purchase Agreement (“Valley Vet APA”) with Michelle Bartus, VMD and Peter Nelson, VMD (“Valley Vet”) in exchange for the payment of $800,000 in cash, issuance of restricted shares of the Company’s Class A common stock equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A common stock as reported by the Nasdaq Capital Market on the trading date immediately prior to the closing and a holdback agreement for $200,000 in cash that may be paid out at the end of the two year period following the acquisition based on continued employment by the two former owners and revenue targets for year 1 and year 2 following the effective date of the acquisition, which is not included in the consideration transferred through the Company’s wholly owned subsidiary IVP PA Holding Company, LLC. Simultaneously, the real estate operations (land and building) utilized by the Valley Vet animal hospital were purchased through a Real Estate Purchase Agreement in exchange for $590,000 from Valley Vet through the Company’s wholly owned subsidiary, IVP PA Properties, LLC. The total consideration paid for the combined acquisitions from the Valley Vet animal hospital in the amount of $1,790,000 was accounted for as single business combinations, in accordance with ASC Topic 805. The Company will record the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. Due to the timing of the acquisition, the Company’s purchase accounting related to the valuation of the inventory, fixed assets, intangible assets, goodwill and liabilities assumed is not yet complete and subject to revision. Consideration: Cash paid prior to the time of closing $ 1,390,000 Convertible Note Payable 400,000 Acquisition costs included in general and administrative 39,535 Recognized amounts of identifiable assets acquired Inventory 74,405 Building 445,786 Land 144,214 Furniture, fixtures & equipment 64,058 Trademark (5-year life) 264,500 Non-compete agreement (2-year life) 44,000 Client list (5-year life) 220,000 Total identifiable net assets assumed 1,256,963 Goodwill 533,037 Total $ 1,790,000 Pro-Forma Financial Information (Unaudited) The following unaudited pro forma information presents the consolidated results of Valley Vet Practice included in the Company’s consolidated statement of operations for the three months ended March 31, 2023, as if the acquisitions were made on January 1, 2023. The unaudited pro forma information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods, or the results of operations that actually would have been realized had the entities been a single company during the periods presented or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of the companies. As a result of the adjustment, $4,954 of amortization expense for the acquired intangible assets was applied in calculating the Net Loss, for the three months ended March 31, 2023. The unaudited pro forma consolidated results of operations, assuming the acquisitions had occurred on January 1, 2023, are as follows: For the Revenue $ 4,723,308 Net Income (Loss) (1,488,111 )	5. Business acquisitions Advanced Veterinary Care of Pasco On January 14, 2022, the Company acquired the veterinary practice and related assets of Advanced Veterinary Care of Pasco in Hudson, FL by entering into an Asset Purchase Agreement (“Advanced Veterinary APA”) with Advanced Veterinary Care of Pasco, LLC (“AVP”) and DJA Asset Management, LLC, (“DJA”) (the “Pasco Practice” or collectively “Pasco”) in exchange for the payment of $1,014,000 through the Company’s wholly owned subsidiary, IVP FL Holding Company, LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville Kentucky for a total of $817,135 (See Note 6 – Debt – Master Lending and Credit Facility) and convertible note payable due to the sellers on or before September 9, 2027 in the amount of $164,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the combined acquisitions from the Pasco Practice in the amount of $1,014,000 was accounted for the acquisition as single business combinations, in accordance with ASC Topic 805. The Company has recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 850,000 Note Payable 164,000 Acquisition costs included in general and administrative 25,315 Recognized amounts of identifiable assets acquired Inventory 35,000 Furniture, fixtures & equipment 144,904 Trademark (5-year life) 97,600 Non-compete agreement (2-year life) 25,500 Client list (5-year life) 157,000 Total identifiable net assets assumed 460,004 Goodwill 553,996 Total $ 1,014,000 Since we first reported the preliminary purchase price allocation for the Pasco transaction as of June 30, 2022, the Company made measurement periodic adjustment, which composed of a $74,904 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Lytle Veterinary Clinic On March 15, 2022, the Company acquired the veterinary practice and related assets of Lytle Veterinary Clinic in Texas by entering into an Asset Purchase Agreement (“Lytle APA”) with Lytle Veterinary Clinic, Inc. (“Lytle”) in exchange for the payment of $662,469 through the Company’s wholly owned subsidiary IVP Texas Holding Company, LLC and its wholly owned subsidiary, IVP Texas Managing Co., LLC. Simultaneously, the Company the real estate operations (land and buildings) utilized by the Lytle Practice was purchased through a Bill of Sale in exchange for $ 780,000 from the Lytle Practice through the Company’s wholly owned subsidiary, IVP Texas Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville Kentucky for a total of $1,141,098 (See Note 6 – “Debt – Master Lending and Credit Facility) and convertible note payable due to the sellers on or before September 9, 2027 in the amount of $100,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the combined acquisitions from the Lytle Practice in the amount of $1,442,469 was accounted for the acquisition as single business combinations, in accordance with ASC Topic 805. The Company has recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 1,342,469 Note Payable 100,000 Acquisition costs included in general and administrative 43,605 Recognized amounts of identifiable assets acquired Inventory 28,894 Buildings 660,000 Land 120,000 Furniture, fixtures & equipment 22,991 Tradename – trademarks (5-year life) 40,300 Non-compete agreement (2-year life) 23,200 Client list (5-year life) 116,000 Total identifiable net assets assumed 1,011,385 Goodwill 431,084 Total $ 1,442,469 Since we first reported the preliminary purchase price allocation for the Lytle transaction as of June 30, 2022, the Company made measurement period adjustment, which composed of a $46,563 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Southern Kern Veterinary Clinic On March 22, 2022, the Company acquired the veterinary practice and related assets of Southern Kern Veterinary Clinic in California by entering into an Asset Purchase Agreement (“Kern APA”) with Southern Kern Veterinary Clinic, Inc. (“Kern”) in exchange for the payment of $1,500,000 through the Company’s wholly owned subsidiary IVP CA Holding Co., LLC and its wholly owned subsidiary, IVP Texas Managing Co., LLC. Simultaneously, the real estate operations (land and buildings) utilized by the Kern Practice was purchased through a Bill of Sale in exchange for $500,000 from the Kern Practice through the Company’s wholly owned subsidiary, IVP CA Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville Kentucky for a total of $1,700,000 (See Note 6 – “Debt – Master Lending and Credit Facility). The total cash consideration paid for the combined acquisitions from the Kern Practice in the amount of $2,000,000 was accounted for the acquisition as single business combinations, in accordance with ASC Topic 805. The Company has recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 2,000,000 Acquisition costs included in general and administrative 34,812 Recognized amounts of identifiable assets acquired Inventory 25,000 Buildings 425,156 Land 74,844 Furniture, fixtures & equipment 176,862 Tradename – Trademarks (5-year life) 57,800 Non-compete agreement (2-year life) 38,600 Client list (5-year life) 249,000 Total identifiable net assets assumed 1,047,262 Goodwill 952,738 Total $ 2,000,000 Since we first reported the preliminary purchase price allocation for the Kern transaction as of June 30, 2022, the Company made measurement period adjustment, which composed of a $76,862 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Bartow Animal Clinic On May 18, 2022, the Company acquired the veterinary practice and related assets of Bartow Animal Clinic in Bartow, FL by entering into an Asset Purchase Agreement (“Bartow APA”) with Winter Park Veterinary Clinic, Inc. (“Bartow”) in exchange for the payment of $1,055,000 through the Company’s wholly owned subsidiary IVP FL Holding Company LLC. Simultaneously, the real estate operations (land and buildings) utilized by the Bartow Practice was purchased through a Bill of Sale in exchange for $350,000 from the Bartow Practice through the Company’s wholly owned subsidiary, IVP CA Properties, LLC. This acquisition was financed by two loans provided by Farmers National Bank of Danville Kentucky for a total of $969,000 (See Note 6 – “Debt – Master Lending and Credit Facility) and convertible note payable due to the sellers on or before September 9, 2027 in the amount of $100,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the combined acquisitions from the Bartow Practice in the amount of $1,405,000 was accounted for the acquisition as single business combinations, in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 1,305,000 Notes Payable 100,000 Acquisition costs included in general and administrative 14,960 Recognized amounts of identifiable assets acquired Inventory 15,000 Buildings 230,000 Land 60,000 Furniture, fixtures & equipment 171,984 Tradename – Trademarks (5-year life) 49,800 Non-compete agreement (2-year life) 13,900 Client list (5-year life) 90,000 Total identifiable net assets assumed 630,684 Goodwill 774,316 Total $ 1,405,000 Since we first reported the preliminary purchase price allocation for the Bartow transaction as of June 30, 2022, the Company made measurement period adjustment, which composed of a $96,984 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Dietz Family Pet Hospital On June 15, 2022, the Company acquired the veterinary practice and related assets of Dietz Family Pet Hospital in Richmond, TX by entering into an Asset Purchase Agreement (“Dietz APA”) with Dietz Family Pet Hospital, P.A. (“Dietz”) in exchange for the payment of $500,000 through the Company’s wholly owned subsidiary IVP Texas Holding Company LLC and its wholly owned subsidiary, IVP Texas Managing Co. LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville Kentucky for a total of $382,500 (See Note 6 – “Debt – Master Lending and Credit Facility) and note payable due to the sellers on or before September 9, 2027 in the amount of $50,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition of the Dietz Practice in the amount of $500,000 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 450,000 Notes Payable 50,000 Acquisition costs included in general and administrative 20,193 Recognized amounts of identifiable assets acquired Inventory 21,000 Furniture, fixtures & equipment 59,151 Tradename – trademarks (5-year life) 37,800 Non-compete agreement (2-year life) 12,200 Customer Lists (5-year life) 32,000 Total identifiable net assets assumed 162,151 Goodwill 337,849 Total $ 500,000 Since we first reported the preliminary purchase price allocation for the Dietz transaction as of June 30, 2022, the Company made measurement period adjustment, which composed of a $15,849 decrease to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Aberdeen Veterinary Clinic On July 29, 2022, the Company acquired the veterinary practice and related assets of Aberdeen Veterinary Clinic in Aberdeen, MD (“Aberdeen Practice”) by entering into an Asset Purchase Agreement (“Aberdeen APA”) with Fritz Enterprises, Inc. in exchange for the payment of $574,683 through the Company’s wholly owned subsidiary, IVP MD Holding Company, LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville Kentucky for a total of $445,981 (See Note 6 – Debt – Master Lending and Credit Facility) and a convertible note payable due to the sellers on or before September 9, 2027 in the amount of $50,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition from the Aberdeen Practice in the amount of $574,683 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 524,683 Convertible Notes Payable 50,000 Acquisition costs included in general and administrative 17,762 Recognized amounts of identifiable assets acquired Inventory 20,000 Furniture, fixtures & equipment 145,982 Trademark (5-year life) 18,600 Non-compete agreement (2-year life) 9,700 Client list (5-year life) 25,000 Total identifiable net assets assumed 219,282 Goodwill 355,401 Total $ 574,683 Since we first reported the preliminary purchase price allocation for the Aberdeen transaction as of June 30, 2022, the Company made measurement period adjustment, which composed of a $30,882 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. All Breed Pet Care On August 12, 2022, the Company acquired the veterinary practice and related assets of All Breed Pet Care veterinary clinic in Newburgh, IN by entering into an Asset Purchase Agreement (“All Breed APA”) with Tejal Rege (the “All Breed Practice” or collectively “All Breed”) in exchange for the payment of $952,000 through the Company’s wholly owned subsidiary IVP IN Holding Company, LLC. Simultaneously, the real estate operations (land and building) utilized by the All Breed practice was purchased through a Bill of Sale in exchange for $1,200,000 from All Breed Pet Care, LLC through the Company’s wholly owned subsidiary, IVP IN Properties, LLC. These acquisitions were financed by three loans provided by Farmers National Bank of Danville Kentucky for a total $1,765,450 (See Note 6 – Debt – Master Lending and Credit Facility) and convertible note payable due to the sellers on or before September 9, 2027 in the amount of $75,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition of the All Breed Practice in the amount of $2,122,000 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 2,077,000 Convertible Notes Payable 75,000 Acquisition costs included in general and administrative 15,000 Recognized amounts of identifiable assets acquired Inventory 45,000 Building 1,045,000 Land 155,000 Furniture, fixtures & equipment 170,013 Trademark (5-year life) 63,600 Non-compete agreement (2-year life) 31,800 Client list (5-year life) 196,000 Total identifiable net assets assumed 1,706,413 Goodwill 445,587 Total $ 2,152,000 Since we first reported the preliminary purchase price allocation for the All Breed transaction as of June 30, 2022, the Company made measurement period adjustments, which composed of a $20,000 increase to Inventory and a $70,013 increase to Furniture, fixtures & equipment. This adjustment did not have a significant impact on our consolidated statements of operations in the period previously presented. The adjustment was recognized in the reporting period in which the adjustment amounts is determined, which was the fourth quarter of 2022. Pony Express On October 31, 2022, the Company acquired the veterinary practice and related assets of Pony Express Veterinary Clinic in Xenia, OH (“Pony Express Practice” or collectively “Pony Express”) by entering into an Asset Purchase Agreement (“Pony Express APA”) with Pony Express Veterinary Hospital, Inc. in exchange for the payment of $2,608,652 through the Company’s wholly owned subsidiary, IVP OH Holding Company, LLC. Simultaneously, the real estate operations (land and building) utilized by the Pony Express practice was purchased through a Bill of Sale in exchange for $500,000 from Pony Expressions Enterprises, Ltd through the Company’s wholly owned subsidiary, IVP OH Properties, LLC. This acquisition was financed by three loans provided by First Southern National Bank for a total of $2,853,314 (See Note 6 – Debt – Master Lending and Credit Facility) and a convertible note payable due to the sellers on or before September 9, 2027 in the amount of $200,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition from the Pony Express Practice in the amount of $3,108,652 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 2,908,652 Convertible Note Payable 200,000 Acquisition costs included in general and administrative 6,077 Recognized amounts of identifiable assets acquired Inventory 44,000 Building 234,221 Land 265,779 Furniture, fixtures & equipment 253,072 Trademark (5-year life) 276,900 Non-compete agreement (2-year life) 120,400 Client list (5-year life) 556,000 Total identifiable net assets assumed 1,760,372 Goodwill 1,348,280 Total $ 3,108,652 Williamsburg On December 9, 2022, the Company acquired the veterinary practice and related assets of Williamsburg Veterinary Clinic in Williamsburg, MA (“Williamsburg Practice”) by entering into an Asset Purchase Agreement (“Williamsburg APA”) with Williamsburg Animal Clinic, LLC in exchange for the payment of $850,000 through the Company’s wholly owned subsidiary, IVP MA Holding Company, LLC. This acquisition was financed by a loan provided by Farmers National Bank of Danville Kentucky for a total of $637,500 (See Note 6 – Debt – Master Lending and Credit Facility) and a convertible note payable due to the sellers on or before September 9, 2027 in the amount of $100,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition from the Williamsburg Practice in the amount of $850,000 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 750,000 Convertible Note Payable 100,000 Acquisition costs included in general and administrative 19,196 Recognized amounts of identifiable assets acquired Inventory 61,196 Building - Land - Furniture, fixtures & equipment 28,202 Trademark (5-year life) 79,500 Non-compete agreement (2-year life) 56,300 Client list (5-year life) 190,000 Total identifiable net assets assumed 415,198 Goodwill 434,802 Total $ 850,000 Old 41 On December 16, 2022, the Company acquired the veterinary practice and related assets of The Old 41 Veterinary Clinic in Bonita Springs, FL (“Old 41 Practice” or collectively “Old 41”) by entering into an Asset Purchase Agreement (“Old 41 APA”) with The Old 41 Animal Hospital, LLC in exchange for the payment of $665,000 through the Company’s wholly owned subsidiary, IVP FL Holding Company, LLC. Simultaneously, the real estate operations (land and building) utilized by the Old 41 practice was purchased through a Bill of Sale in exchange for $800,000 from Scott A. Gregory DVM, LLC through the Company’s wholly owned subsidiary, IVP FL Properties, LLC. This acquisition was financed by two loans provided by First Southern National Bank for a total of $1,208,000 (See Note 6 – Debt – Master Lending and Credit Facility) and a convertible note payable due to the sellers on or before September 9, 2027 in the amount of $50,000 with an interest rate per annum of 6% payable on the first business day of January annually beginning in 2023, convertible into the Company’s Series B Common Stock at a 25% discount upon of the opening price of the Company’s public offering, or upon a liquidation event. The total cash consideration paid for the acquisition from the Old 41 Practice in the amount of $1,465,000 was accounted for in accordance with ASC Topic 805. The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 1,415,000 Convertible Note Payable 50,000 Acquisition costs included in general and administrative 12,820 Recognized amounts of identifiable assets acquired Inventory 15,804 Building 570,000 Land 300,000 Furniture, fixtures & equipment 103,239 Trademark (5-year life) 44,900 Non-compete agreement (2-year life) 17,400 Client list (5-year life) 44,000 Total identifiable net assets assumed 1,095,343 Goodwill 369,657 Total $ 1,465,000 Valley Veterinary Service On November 8, 2023, the Company acquired the animal hospital and related assets of Valley Veterinary Service, Inc., a Pennsylvania corporation (“Valley Vet Practice”) by entering into an Asset Purchase Agreement (“Valley Vet APA”) with Michelle Bartus, VMD and Peter Nelson, VMD (“Valley Vet”) in exchange for the payment of $800,000 in cash, issuance of restricted shares of the Company’s Class A common stock equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A common stock as reported by the Nasdaq Capital Market on the trading date immediately prior to the closing and a holdback agreement for $200,000 in cash that may be paid out at the end of the two year period following the acquisition based on continued employment by the two former owners and revenue targets for year 1 and year 2 following the effective date of the acquisition, which is not included in the consideration transferred through the Company’s wholly owned subsidiary IVP PA Holding Company, LLC. Simultaneously, the real estate operations (land and building) utilized by the Valley Vet animal hospital were purchased through a Real Estate Purchase Agreement in exchange for $590,000 from Valley Vet through the Company’s wholly owned subsidiary, IVP PA Properties, LLC. The total consideration paid for the combined acquisitions from the Valley Vet animal hospital in the amount of $1,790,000 was accounted for as single business combinations, in accordance with ASC Topic 805. The Company will record the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. Due to the timing of the acquisition, the Company’s purchase accounting related to the valuation of the inventory, fixed assets, intangible assets, goodwill and liabilities assumed is not yet complete and subject to revision. Consideration: Cash paid prior to the time of closing $ 1,390,000 Consideration paid in Common Stock 400,000 Acquisition costs included in general and administrative 39,535 Recognized amounts of identifiable assets acquired Inventory 74,405 Building 445,786 Land 144,214 Furniture, fixtures & equipment 64,058 Trademark (5-year life) 264,500 Non-compete agreement (2-year life) 44,000 Client list (5-year life) 220,000 Total identifiable net assets assumed 1,256,963 Goodwill 533,037 Total $ 1,790,000 Pro-Forma Financial Information (Unaudited) The following unaudited pro forma information presents the consolidated results of Valley Vet Practice included in the Company’s consolidated statement of operations for the year end December 31, 2023, as if the acquisitions were made on January 1, 2023. The following unaudited pro forma information presents the consolidated results of Pasco Practice, Kern Practice, Lytle Practice, Bartow Practice, Dietz Practice, Aberdeen Practice, All Breed Practice, Pony Express Practice, Williamsburg Practice, Old 41 Practice and Valley Vet Practice included in the Company’s consolidated statement of operations for the year end December 31, 2022, as if the acquisitions were made on January 1, 2022. The unaudited pro forma information is presented for illustrative purposes only. It is not necessarily indicative of the results of operations of future periods, or the results of operations that actually would have been realized had the entities been a single company during the periods presented or the results that the combined company will experience after the acquisition. The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition. The unaudited pro forma information also does not include any integration costs or remaining future transaction costs that the companies may incur related to the acquisition as part of combining the operations of the companies. As a result of the adjustment, $23,220 and $111,045 of amortization expense for the acquired intangible assets was applied in calculating the Net Loss, for the years ended December 31, 2023 and 2022, respectively. The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on January 1, 2023 and 2022, are as follows: Year Ended Year Ended December 31, December 31, Revenue $ 18,438,565 $ 18,716,433 Net loss $ (14,840,964 ) (2,564,788 )

Debt

Debt	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Debt [Abstract]
Debt	7. Debt Master Lending and Credit Facility On June 25, 2021, the Company entered into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville, Kentucky (“FNBD”). The MLOCA provides for a $2,000,000 revolving secured credit facility (“Revolving Line”) to be drawn for the initial purchase of veterinary clinical practices (“Practices”) and a $8,000,000 closed end line of credit (“Closed End Line”) to be disbursed as individual loans (Term Loans) to paydown draws on the Revolving Line and to provide longer term financing of the purchase of Practices. Each draw on the Revolving Line shall be repaid with a Term Loan out of the Closed End Line within one hundred and twenty (120) days of the draw on the Revolving Line. Each draw on the Revolving Line and the Closed End Line shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Revolving Line or a Term Loan remains unpaid with FNBD. The Revolving Line has an interest rate equal to the New York Prime Rate plus 0.50% that shall never be less than 3.57%. Each Term Loan issued under the Closed End Line shall have a fixed interest rate of 3.98% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest rate will equal to the New York Prime Rate plus 0.65% that shall never be less than 3.57%. Each Practice to be acquired must have a minimum projected debt-service coverage ratio (“DSCR”) of 1.0x, defined as earnings before interest depreciation and amortization (“EBIDA”)/Annual Debt Service Requirement. The MLOCA terminates and the Revolving Line matures on June 25, 2023. Under the MLOCA the Term Loans to acquire a Practice shall not exceed 10 years. The first twelve months of the Term Loan may be interest only. Thereafter, the Loan will convert to an amortizing loan with monthly principal and interest payments. For Practice only Term Loans (“Practice Term Loans”), after the initial twelve-month interest only period, the balance will amortize over 9 years. For Loans made to purchase real property (“RE Term Loans”), after the initial twelve-month interest only period, the balance will amortize over a 19-year period. There is no prepayment penalty on payments on the Revolving Line. The Term Loans are subject to a refinance fee of 2% of the then outstanding principal balance of the Term Loan if paid within two years of entering into the Term Loan and 1% of the then outstanding principal balance of the Term Loan if paid within three to five years of entering into the Term Loan. The refinance fee is due only if the Term Loan is paid off by refinancing. Borrowing under the MLOCA are guaranteed by Kimball Carr, CEO & President of the Company. On August 18, 2022 the MLOCA was amended and restated to terminate the revolving feature on the Revolving Line and convert the line of credit to a closed end draw note (“Closed End Draw Note”) that mature on August 18, 2024. Each draw on the Closed End Draw Note shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Closed End Draw Note or a Term Loan remains unpaid with FNBD. The interest rate charge on all sums advance under the amended and restated MLOCA shall be 5.25% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest will be equal to the New York Prime Rate plus 0.65% that shall never be less than 4.75%. Each Practice to be acquired must have a minimum projected DSCR of 1.0x, defined as EBIDA/Annual Debt Service Requirement. The MLOCA terminates and the Closed End Draw Note matures on August 18, 2024. Notes payable to FNBD as of March 31, 2024 and December 31, 2023 consisted of the following: Original Acquisition Entered Maturity Interest March 31, December 31, Issuance $ 237,272 CAH 12/27/21 12/27/41 3.98 % $ 235,150 $ 237,272 $ 6,108 231,987 CAH 12/27/21 12/27/31 3.98 % 226,582 231,987 6,108 216,750 P&F 12/27/21 12/27/41 3.98 % 214,812 216,750 5,370 318,750 P&F 12/27/21 12/27/31 3.98 % 311,323 318,750 5,370 817,135 Pasco 1/14/22 1/14/32 3.98 % 804,374 817,135 3,085 478,098 Lytle 3/15/22 3/15/32 3.98 % 478,098 478,098 1,898 663,000 Lytle 3/15/22 3/15/42 3.98 % 663,000 663,000 11,875 425,000 Kern 3/22/22 3/22/42 3.98 % 425,000 425,000 7,855 1,275,000 Kern 3/22/22 3/22/32 3.98 % 1,275,000 1,275,000 4,688 246,500 Bartow 5/18/22 5/18/42 3.98 % 246,500 246,500 5,072 722,500 Bartow 5/18/22 5/18/32 3.98 % 722,500 722,500 2,754 382,500 Dietz 6/15/22 6/15/32 3.98 % 382,500 382,500 1,564 445,981 Aberdeen 7/19/22 7/29/32 3.98 % 445,981 445,981 1,786 1,020,000 All Breed 8/12/22 8/12/42 3.98 % 1,020,000 1,020,000 8,702 519,527 All Breed 8/12/22 8/12/32 3.98 % 519,527 519,527 3,159 225,923 All Breed 8/12/22 8/12/32 5.25 % 225,923 225,923 3,159 637,500 Williamsburg 12/8/22 12/8/32 5.25 % 637,500 637,500 2,556 850,000 Valley Vet 11/8/23 11/8/33 5.25 % 850,000 850,000 3,315 $ 9,713,423 $ 9,141,096 $ 9,309,286 $ 84,424 The Company amortized $1,543 and $2,082 of issuance cost in the aggregate during the three months ending March 31, 2024 and 2023, respectively, for the FNBD notes payable. FSB Commercial Loans On January 11, 2021, the Company entered into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC acquisition. The first commercial loan in the amount of $1,105,000 has a fixed interest rate of 4.35% and a maturity date of January 15, 2024. The commercial loan was modified in January 2021 to extend the maturity date to February 25, 2041. The fixed rate loan has monthly payments of $6,903 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $13,264 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $165 and $163 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The second commercial loan with FSB entered into on January 11, 2021 in the amount of $1,278,400 has a fixed interest rate of 4.35% and a maturity date of September 1, 2024. The commercial loan was modified in January 2021 to extend the maturity date to January 25, 2031. The fixed rate loan has monthly payments of $13,157 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $10,085 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $253 and $251 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The third commercial loan with FSB entered into on January 11, 2021 in the amount of $450,000 has a fixed interest rate of 5.05% and a maturity date of September 11, 2021. The commercial loan was modified on August 25, 2021 to extend the maturity date to February 25, 2023 and increase the principal amount to $469,914. The fixed rate loan has monthly payments of $27,164 and the interest rate remained at 5.05%. The commercial loan had issuance costs of $753 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $0 and $58 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. On October 31, 2022 the company entered into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered into on October 31, 2022, was in the amount of $2,086,921. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2025. The fixed rate loan has monthly payments of $23,138 except for a final monthly payment of $1,608,530. The commercial loan had issuance costs of $25,575 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $2,123 and $2,100 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The second loan with FSB that was entered into on October 31, 2022, was in the amount of $400,000. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2042. The fixed rate loan has monthly payments of $2,859. The commercial loan had issuance costs of $3,277 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $41 and $40 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The third loan with FSB that was entered into on October 31, 2022, was in the amount of $700,000. The loan has a fixed interest rate of 6.75% and a maturity date of April 1, 2023. The fixed rate loan has monthly payments of $6,903 except for a final monthly payment of $423,278. The commercial loan did not have any issuance costs that were capitalized. On December 16, 2022, the company entered into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into on December 16, 2022, was in the amount of $568,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has monthly payments of $4,772, except for a final payment of 593,039. The loan had issuance costs of $4,531 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $376 and $372 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The second loan with FSB that was entered into December 16, 2022, was in the amount of $640,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has twelve monthly payments of approximately $2,830, followed by monthly payments of $7,443. and the interest rate is 6.50%. The loan had issuance costs of $5,077 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The Company amortized $422 and $417 of issuance cost during the three months ended March 31, 2024 and 2023, respectively. The FSB commercial loans are guaranteed by Kimball Carr, Chief Executive Officer and President and Charles Stith Keiser, our Vice Chairman and Chief Operating Officer. Notes payable to FSB as of March 31, 2024 and December 31, 2023 consisted of the following: Original Acquisition Entered Maturity Interest March 31, December 31, Issuance Cost $ 1,105,000 KVC 1/25/21 2/25/41 4.35 % $ 987,082 $ 997,010 $ 13,264 1,278,400 KVC 1/25/21 1/25/31 4.35 % 931,696 960,849 10,085 469,914 KVC 1/25/21 2/25/23 5.05 % - - 753 2,086,921 Pony Express 10/31/22 10/31/25 5.97 % 1,861,227 1,902,452 25,575 400,000 Pony Express 10/31/22 10/31/42 5.97 % 384,624 387,433 3,277 568,000 Old 41 12/16/22 12/16/25 6.5 % 508,385 520,697 4,531 640,000 Old 41 12/16/22 12/16/25 6.5 % 619,660 623,861 5,077 375,000 Valley Vet 11/8/2023 11/8/2024 8.5 % 375,000 375,000 6,877 $ 7,623,235 $ 5,667,674 $ 5,767,302 $ 69,439 Notes payable as of March 31, 2024 and December 31, 2023 consisted of the following: March 31, December 31, 2024 2023 FNBD Notes Payable $ 9,141,096 $ 9,309,286 FSNB Notes Payable 5,667,674 5,767,302 Total notes payable 14,808,770 15,076,588 Unamortized debt issuance costs (116,540 ) (124,170 ) Notes payable, net of issuance cost 14,692,230 14,952,418 Less current portion (1,203,402 ) (1,469,043 ) Long-term portion $ 13,488,828 $ 13,483,375 Notes payable repayment requirements as of March 31, 2024, in the succeeding years are summarized as follows: Remainder of 2024 $ 1,203,402 2025 3,776,189 2026 1,008,110 2027 1,052,832 2028 1,098,387 Thereafter $ 6,669,850 Bridge Note In December 2021, the Company entered into two bridge loans in the aggregate amount of $2,500,000 with Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund as short term secured convertible notes (“Bridge Note”). The Bridge Note is convertible into the Company’s common stock, at the time of a successful initial public offering (“IPO”) at the noteholder’s option, at a 35% discount to the IPO price. The Bridge Note has a face value of $2,500,000 with an original issue discount (“OID”) of 12% and has a maturity date of January 24, 2023. The OID of $300,000 is being amortized over the life of the loan. If the Company has not issued the Company’s common stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission (“SEC”) and the listing of the common stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified financing”) by January 24, 2023 the conversion price will be set at a 40% discount to the IPO price. The Bridge Note was funded in two installments of net proceeds of $1,100,000 in December 2021 and the second installment January 2022. The bridge loans had issuance costs of $70,500 for the first installment and $54,000 for the second installment that is amortized straight line over the life of the loan. The Company amortized $0 and $62,758 of issuance cost during the three months ended March 31, 2024 and 2023. In conjunction with the Bridge Note the Company issued warrants on January 24, 2022 to Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund (collectively the “Bridge Lenders”). The warrants entitled the Bridge Lenders to purchase the Company’s Class A common stock, at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 50% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing, unless a Qualified Financing has not been completed by January 24, 2023 in which case the quantity of Class A common stock subject to purchase upon exercise of the warrants will be an amount equal to 75% of the face value of the Bridge Note divided by the per-share price in the Qualified Financing. If a Qualified Financing has not consummated or the Bridge Note has not been repaid in full on or before January 24, 2027, then the quantity of common stock subject to purchase upon exercise of the warrants will be an amount equal to 100% of the face value divided by the per-share price equal to the fair market value of one share of Class A common stock as mutually agreed by the Holder and the Company. The warrants are exercisable through the fifth anniversary of the issuance date. The warrants may be redeemed at the option of the Company at any time following a Qualified Financing if the Company’s common stock trade on a national securities exchange at a price equal to the purchase price of the Company’s common stock in the Qualified Financing multiplied by 2 for a period of ten consecutive trading days. On November 18, 2022, the Company entered into an Original Issue Discount Secured Convertible Note loan with Target Capital 1, LLC for $1,136,364. The note is issued at an original issue discount of 12% with an maturity date on the earlier of March 31, 2023 (“Initial Maturity Date”) or the Company’s sale of its common stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission and the listing of the common stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified Financing” or the “Maturity Date”). If the Company has filed its Form S-1 Registration Statement with the SEC on or prior to the Initial Maturity Date but the Qualified Financing has not closed by such date (“Automatic Extension”) then all principal and accrued interest under this Note shall become due and payable in cash on September 30, 2023 (the “Final Maturity Date”) or such earlier date as this note is required be repaid. The note bears an interest rate of 12% per annum by means of the original issue discount. Upon the occurrence of an Automatic Extension, this note shall commence to accrue interest at an interest rate of 12% percent per annum on the date of the commencement of the Automatic Extension until the note is converted or is paid in full. The Company may pay the full principal amount of this note, and all accrued but unpaid interest at any time prior to the Maturity Date without the prior written consent of the holder in the principal amount of $1,136,364, plus all accrued but unpaid interest, multiplied by 120%. In addition, and to the extent the Company is required to pay this note in cash at the on or after the Initial Maturity Date due to, upon the closing date of a Qualified Financing, the Company shall pay to the holder $1,136,364, plus all accrued unpaid interest, multiplied by 120%. Upon the occurrence and during the continuation of an Event of Default (as defined in the note), until the Event of Default is cured, or the note is repaid in full, Company will pay 20% of its total gross revenues (including that of all its subsidiaries) monthly, which shall be applied to payment of principal and interest under this this note. The conversion price (the “Conversion Price”) shall be equal to the price paid by the public in the Company’s Qualified Financing multiplied by 0.65 (or 0.60, from and after any Automatic Extension). In conjunction with the Original Issue Discount Secured Convertible Note with Target Capital 1, LLC the company issued the holder 412 shares of Class A common stock and equity classified warrants that entitle the holder to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 50% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing, unless a Qualified Financing has not been completed by March 31, 2023 in which case the quantity of Class A common stock subject to purchase upon exercise of the warrants will be an amount equal to 75% of the face value of the Bridge Note divided by the per-share price in the Qualified Financing. On November 18, 2022, the Company entered into an Original Issue Discount Secured Convertible Note with 622 Capital LLC for $568,182. The note is issued at an original issue discount of 12% with an maturity date on the earlier of January 24, 2023 (the “622 Initial Maturity Date”) or the Company’s sale of its common stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission and the listing of the common stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified Financing” or the “622 Maturity Date”). If the Company has filed its Form S-1 Registration Statement with the SEC on or prior to the 622 Initial Maturity Date but the Qualified Financing has not closed by such date (“Automatic Extension”) then all principal and accrued interest under this note shall become due and payable in cash on July 24, 2023 (the “622 Final Maturity Date”) or such earlier date as this note is required be repaid. The note bears an interest rate of 12% per annum by means of the original issue discount. Upon the occurrence of an Automatic Extension, this note shall commence to accrue interest at an interest rate of 12% percent per annum on the date of the commencement of the Automatic Extension until the note is converted or is paid in full. The Company may pay the full principal amount of this note and all accrued but unpaid interest at any time prior to the 622 Maturity Date without the prior written consent of the holder in the principal amount of $568,182, plus all accrued but unpaid interest, multiplied by 120%. In addition, and to the extent the Company is required to pay this note in cash at the on or after the 622 Initial Maturity Date due to, upon the closing date of Qualified Financing, the Company shall pay to the holder $568,182, plus all accrued unpaid interest, multiplied by 120%. Upon the occurrence and during the continuation of an Event of Default (as defined in the note), until the Event of Default is cured or the note is repaid in full, Company will pay 20% of its total gross revenues (including that of all its subsidiaries) monthly, which shall be applied to payment of principal and interest under this this note. The conversion price (the “Conversion Price”) shall be equal to the price paid by the public in the Company’s Qualified Financing multiplied by 0.65 (or 0.60, from and after any Automatic Extension). In conjunction with the Original Issue Discount Secured Convertible Note with 662 Capital LLC the company issued the holder equity classified warrants that entitle the holder to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 50% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing, unless a Qualified Financing has not been completed by March 31, 2023 in which case the quantity of Class A common stock subject to purchase upon exercise of the warrants will be an amount equal to 75% of the face value of the Bridge Note divided by the per-share price in the Qualified Financing. The warrants were deemed legally detachable from the Bridge Note and were fair valued using the Black Scholes Method to determine the relative fair values of the Bridge Note and the detachable warrants. The significant inputs for the Black Scholes calculation included the exercise price and common share price of $0.44, volatility rate of 27% and risk-free rate of 1.53% with a 5 year term. The proceeds received for the Bridge Note were allocated to the detached warrants based on the relative fair values. Pursuant to ASC 470 the relative fair value of the warrants attributable to a discount on debt is $429,284; this is amortized to interest expense on a straight-line basis over the term of the loan. A roll forward of the bridge note for the three months ended March 31, 2023 is below: Bridge notes, December 31, 2022 3,899,156 Amortization of original issue discount 116,656 Amortization of warrant discount 125,975 Amortization of debt issuance costs 62,758 Bridge notes, March 31, 2023 $ 4,204,545 On June 30, 2023, the Company entered into exchange agreements (the “Exchange Agreements”) with each of the Company’s Bridge Note lenders, pursuant to which the lenders exchanged their existing Bridge Notes for 29,896 shares, 352,771 shares, and 59,792 shares, respectively, of Convertible Series A preferred stock (442,458 shares of Convertible Series A Preferred stock in total) (the “Exchange”). The Exchange Agreements would have been rescinded, and the former Bridge Notes reinstated if the Company didn’t complete the initial public offering by September 1, 2023. Upon the IPO completing on August 31, 2023, the Company recognized the extinguishment of the Bridge Notes pursuant to ASC 470 and recognized a debt extinguishment loss of $16,105. The Company recognized a beneficial conversion feature of $2,567,866 for the issuance of the Series A preferred stock on the date of the IPO due to the $4 (Pre-Reverse Split) offering price related to the IPO being known as of that date. Convertible Debenture Between March 18 and December 28, 2021, the Company issued $2,102,500 in aggregate principal amount of 6.00% subordinated convertible promissory note (“Convertible Debenture”). During the year ending December 31, 2022 the Company issued $1,612,000 in aggregated principal amount of the 6.00% Convertible Debenture. In March 2023 the Company issued an additional $650,000 in aggregate principal amount of 6.00% Convertible Debenture to five (5) separate holders. The Convertible Debenture is convertible into the Company’s Class A common stock upon the Company’s offering for sale its shares in a public offering (“IPO”). At the holder’s election, the accrued interest and principal may be paid in cash or Class A common stock (such number of shares reflecting a twenty-five percent (25%) discount of the opening price per share of Class A common stock). The Convertible Debenture mature 5 years from the date of issuance to each holder. Prior to the maturity date, the holder is entitled to convert the Convertible Debenture into Class A common stock upon the Company’s IPO. Upon an IPO the accrued and unpaid interest is due and payable in cash on the first business day of the following month of March for any balance not elected to be converted into the Class A common stock. The Convertible Debenture incurred issuance cost of $40,000 that was amortized straight line over the life of the Convertible Debenture. The Company amortized $1,993 and $1,972 for the three months ending March 31, 2024 and 2023, respectively. Upon the Company’s IPO closing on August 31, 2023, the majority of Convertible Debenture holders elected to convert an aggregate of $4,014,500 of principal and $399,818 of accrued interest into 14,953 shares of Class A common stock at a conversion price of $30.00 per share. The Company recorded a beneficial conversion feature as of the date of the conversion of $1,569,395 based on the IPO price of $40 per share minus the principal and accrued interest of the Convertible Debenture balance converted into common stock. Four holders of the Convertible Debenture with an aggregate principal balance of $250,000 elected to be paid back in cash and one investor with a principal balance of $100,000 elected to be paid on February 28, 2024 including accrued interest through the date of payment at 6%. Loan Payable On May 30, 2023, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $1,050,000 with an unrelated third-party financial institution. Under the terms of the agreement, the Company must pay $57,346 each week for 26 weeks with the first payment being due June 6, 2023. The financing arrangement has an effective interest rate of 49%. The financing arrangement includes an original issuance discount (“OID”) of $441,000 and issuance costs of $50,000. The OID and issuance cost associated with the financing arrangement are presented in the balance sheets as a direct deduction from the carrying amount of the financing arrangement and is amortized using the effective interest method. On August 10, 2023, the Company amended the financing arrangement to borrow an additional $507,460 resulting in the weekly repayments increasing to $76,071 to be paid over 28 weeks. This amendment decreased the effective interest rate to 41%. The refinancing resulted in a loss on debt modification of $441,618. On November 28, 2023, the Company amended the financing arrangement to borrow an additional $531,071 resulting in the weekly payments to decrease to $56,800 to be paid over 40 weeks. This amendment increased the effective rate to 49%. The refinancing resulted in a loss on debt modification of $485,436. On January 18, 2024, the Company amended the financing arrangement to borrow an additional $549,185 resulting in the weekly payments to increase to $86,214 to be paid over 43 weeks. This amendment increased the effective interest rate to 52%. The refinancing resulted in a loss on debt modification of $728,278. During the three months ended March 31, 2024, the Company amortized $379,313 of OID and issuance cost included in interest expense on the statement of operations. During the three months ended March 31, 2024, the Company made $1,032,540 in payments on the loan payable. The outstanding balance of the loan payable as of December 31, 2023, is $2,809,820. The financing arrangement is secured by an interest in virtually all assets of the Company with a first security interest in accounts receivable. The financing arrangement is guaranteed by the Company’s CEO. Convertible Note Payable On March 26, Inspire Veterinary entered into a securities purchase agreement (the “Purchase Agreement”) with certain investor. Pursuant to the Purchase Agreement, Inspire Veterinary issued to investors Increasing OID Senior Note (“Convertible Note Payable”) for $250,000. The Convertible Note Payable has a maturity date of the earlier of December 26, 2024 or the consummation of a capital raise (the “Maturity Date”). The Convertible Note Payable contain an original issued discount (“OID”) which shall be: (i) fifteen percent (15%) if the Convertible Note Payable is satisfied and paid in full on or before the forty-fifth (45th) day after the Original Issue Date (as such term is defined in the Notes), (ii) twenty percent (20%) if the Convertible Note Payable is satisfied and paid in full after such 45th day but on or before the ninetieth (90th) day after the Original Issue Date, and (iii) thirty percent (30%) after such 90th day. The Convertible Note Payable can be prepaid at any time prior to the Maturity Date without any penalties. The Convertible Note Payable must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Convertible Note Payable until the Convertible Note Payable are repaid in full The Convertible Note Payable are convertible into shares of common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder at a fixed conversion price of $0.03 per share (the “Fixed Conversion Price”). If the Convertible Note Payable is not repaid by the Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Convertible Note Payable) of the Convertible Note Payable will increase by 20% (to a 50% OID -- $1,000,000 Face Value); (ii) the conversion price of the Convertible Note Payable will become convertible at the lower of (a) the Fixed Conversion Price or (b) 20% discount to a 3-Day volume-weighted average price (the “Default Conversion Price”).	6. Debt Master Lending and Credit Facility On June 25, 2021, the Company entered into a master line of credit loan agreement (“MLOCA”) with Wealth South a division of Farmers National Bank of Danville, Kentucky (“FNBD”). The MLOCA provides for a $2,000,000 revolving secured credit facility (“Revolving Line”) to be drawn for the initial purchase of veterinary clinical practices (“Practices”) and a $8,000,000 closed end line of credit (“Closed End Line”) to be disbursed as individual loans (Term Loans) to paydown draws on the Revolving Line and to provide longer term financing of the purchase of Practices. Each draw on the Revolving Line shall be repaid with a Term Loan out of the Closed End Line within one hundred and twenty (120) days of the draw on the Revolving Line. Each draw on the Revolving Line and the Closed End Line shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Revolving Line or a Term Loan remains unpaid with FNBD. The Revolving Line has an interest rate equal to the New York Prime Rate plus 0.50% that shall never be less than 3.57%. Each Term Loan issued under the Closed End Line shall have a fixed interest rate of 3.98% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest rate will equal to the New York Prime Rate plus 0.65% that shall never be less than 3.57%. Each Practice to be acquired must have a minimum projected debt-service coverage ratio (“DSCR”) of 1.0x, defined as earnings before interest depreciation and amortization (“EBIDA”)/Annual Debt Service Requirement. Under the MLOCA the Term Loans to acquire a Practice shall not exceed 10 years. The first twelve months of the Term Loan may be interest only. Thereafter, the Loan will convert to an amortizing loan with monthly principal and interest payments. For Practice only Term Loans (“Practice Term Loans”), after the initial twelve-month interest only period, the balance will amortize over 9 years. For Loans made to purchase real property (“RE Term Loans”), after the initial twelve-month interest only period, the balance will amortize over a 19-year period. There is no prepayment penalty on payments on the Revolving Line. The Term Loans are subject to a refinance fee of 2% of the then outstanding principal balance of the Term Loan if paid within two years of entering into the Term Loan and 1% of the then outstanding principal balance of the Term Loan if paid within three to five years of entering into the Term Loan. The refinance fee is due only if the Term Loan is paid off by refinancing. Borrowing under the MLOCA are guaranteed by Kimball Carr, CEO & President of the Company. On August 18, 2022 the MLOCA was amended and restated to terminate the revolving feature on the Revolving Line and convert the line of credit to a closed end draw note (“Closed End Draw Note”) that mature on August 18, 2024. Each draw on the Closed End Draw Note shall not exceed eighty-five (85%) percent of the purchase price of the Practice. The Company shall contribute and maintain equity of a minimum of fifteen (15%) percent of the initial purchase price of a Practice as long as any draw on the Closed End Draw Note or a Term Loan remains unpaid with FNBD. The interest rate charge on all sums advance under the amended and restated MLOCA shall be 5.25% for the first five years of the loan. Immediately following the fixed rate period, the rate of interest will be equal to the New York Prime Rate plus 0.65% that shall never be less than 4.75%. Each Practice to be acquired must have a minimum projected DSCR of 1.0x, defined as EBIDA/Annual Debt Service Requirement. The MLOCA terminates and the Closed End Draw Note matures on August 18, 2024. Notes payable to FNBD as of December 31, 2023 and 2022 consisted of the following: Original December 31, December 31, Issuance Principal Acquisition Entered Maturity Interest 2023 2022 Cost $ 237,272 CAH 12/27/2021 12/27/2041 3.98 % $ 228,785 $ 237,272 $ 6,108 231,987 CAH 12/27/2021 12/27/2031 3.98 % 10,161 231,987 6,108 216,750 P&F 12/27/2021 12/27/2041 3.98 % 208,997 216,750 5,370 318,750 P&F 12/27/2021 12/27/2031 3.98 % 288,761 318,750 5,370 817,135 Pasco 1/14/2022 1/14/2032 3.98 % 746,733 817,135 3,085 478,098 Lytle 3/15/2022 3/15/2032 3.98 % 444,593 478,098 1,898 663,000 Lytle 3/15/2022 3/15/2042 3.98 % 645,392 663,000 11,875 425,000 Kern 3/22/2022 3/22/2042 3.98 % 413,713 425,000 7,855 1,275,000 Kern 3/22/2022 3/22/2032 3.98 % 1,185,648 1,275,000 4,688 246,500 Bartow 5/18/2022 5/18/2042 3.98 % 241,429 246,500 5,072 722,500 Bartow 5/18/2022 5/18/2032 3.98 % 683,262 722,500 2,754 382,500 Dietz 6/15/2022 6/15/2032 3.98 % 364,708 382,500 1,564 445,981 Aberdeen 7/19/2022 7/29/2032 3.98 % 428,747 45,981 1,786 1,020,000 All Breed 8/12/2022 8/12/2042 3.98 % 1,008,039 1,020,000 8,702 519,527 All Breed 8/12/2022 8/12/2032 3.98 % 503,471 519,527 3,159 225,923 All Breed 8/12/2022 8/12/2032 5.25 % 219,347 225,923 3,159 637,500 Williamsburg 12/8/2022 12/8/2032 5.25 % 637,500 637,500 2,556 850,000 Valley Vet 11/8/2023 11/8/2033 5.25 % 850,000 - 3,315 $ 9,713,423 $ 9,309,286 $ 8,863,423 $ 84,424 The Company amortized $7,152 and $6,813 of issuance cost in the aggregate during the years ended December, 2023 and 2022, respectively, for the FNBD notes payable. FSB Commercial Loans On January 11, 2021, the Company entered into three separate commercial loans with First Southern National Bank (“FSB”) as part of the Kauai Veterinary Clinic, LLC acquisition. The first commercial loan in the amount of $1,105,000 has a fixed interest rate of 4.35% and a maturity date of January 15, 2024. The commercial loan was modified in January 2021 to extend the maturity date to February 25, 2041. The fixed rate loan has monthly payments of $6,903 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $13,264 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The second commercial loan with FSB entered into on January 11, 2021 in the amount of $1,278,400 has a fixed interest rate of 4.35% and a maturity date of September 1, 2024. The commercial loan was modified in January 2021 to extend the maturity date to January 25, 2031. The fixed rate loan has monthly payments of $13,157 and the interest rate remained at 4.35%. The commercial loan had issuance costs of $10,085 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. The third commercial loan with FSB entered into on January 11, 2021 in the amount of $450,000 has a fixed interest rate of 5.05% and a maturity date of September 11, 2021. The commercial loan was modified on August 25, 2021 to extend the maturity date to February 25, 2023 and increase the principal amount to $469,914. The fixed rate loan has monthly payments of $27,164 and the interest rate remained at 5.05%. The commercial loan had issuance costs of $753 for the year ended December 31, 2021 that was capitalized and is being amortized straight line over the life of the loan. On October 31, 2022 the Company entered into three separate commercial loans with FSB as part of the Pony Express Practice acquisition. The first loan with FSB that was entered into on October 31, 2022, was in the amount of $2,086,921. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2025. The fixed rate loan has monthly payments of $23,138 except for a final monthly payment of $1,608,530. The commercial loan had issuance costs of $25,575 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The second loan with FSB that was entered into on October 31, 2022, was in the amount of $400,000. The loan has a fixed interest rate of 5.97% and a maturity date of October 31, 2042. The fixed rate loan has monthly payments of $2,859. The commercial loan had issuance costs of $3,277 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The third loan with FSB that was entered into on October 31, 2022, was in the amount of $700,000. The loan has a fixed interest rate of 6.75% and a maturity date of April 1, 2023. The fixed rate loan has monthly payments of $6,903 except for a final monthly payment of $423,278. The commercial loan did not have any issuance costs that were capitalized. On December 16, 2022, the Company entered into two separate commercial loans with FSB as part of the Old 41 Practice acquisition. The first loan with FSB that was entered into on December 16, 2022, was in the amount of $568,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has monthly payments of $4,772, except for a final payment of 593,039. The loan had issuance costs of $4,531 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. The second loan with FSB that was entered into December 16, 2022, was in the amount of $640,000. The loan has a fixed interest rate of 6.50% and a maturity date of December 16, 2025. The fixed rate loan has twelve monthly payments of approximately $2,830, followed by monthly payments of $7,443. and the interest rate is 6.50%. The loan had issuance costs of $5,077 for the year ended December 31, 2022, that was capitalized and is being amortized straight line over the life of the loan. On November 8, 2023, the Company entered into a commercial loan with FSB as part of the Valley Vet acquisition. The loan with FSB was entered into on November 8, 2023, in the amount of $375,000. The loan has a fixed rate of 8.5% and a maturity date of November 8, 2024. The fixed rate loan has monthly payments of $3,255, except one final payment of the outstanding principal balance on the note, including any accrued and unpaid interest. The loan had issuance costs of $6,877 for the year ended December 31, 2023, that was capitalized and is being amortized straight line over the life of the loan. The FSB commercial loans are guaranteed by Kimball Carr, the Company’s Chief Executive Officer and President and Charles Stith Keiser, the Company’s Vice Chairman and Chief Operating Officer. Notes payable to FSB as of December 31, 2023 and 2022 consisted of the following: Original December 31, December 31, Issuance Principal Acquisition Entered Maturity Interest 2023 2022 Cost $ 1,105,000 KVC 1/25/2021 2/25/2041 4.35 % $ 997,010 $ 1,035,558 $ 13,264 1,278,400 KVC 1/25/2021 1/25/2031 4.35 % 960,849 1,074,251 10,085 469,914 KVC 1/25/2021 2/25/2023 5.05 % - 53,964 753 2,086,921 Pony Express 10/31/2022 10/31/2025 5.97 % 1,902,452 2,061,346 25,575 400,000 Pony Express 10/31/2022 10/31/2042 5.97 % 387,433 398,258 3,277 700,000 Pony Express 10/31/2022 8/16/2023 7.17 % - 700,000 - 568,000 Old 41 12/16/2022 12/16/2025 6.50 % 520,697 568,000 4,531 640,000 Old 41 12/16/2022 12/16/2025 6.50 % 623,861 640,000 5,077 375,000 Valley Vet 11/8/2023 11/8/2024 8.50 % 375,000 - 6,877 $ 7,623,235 $ 5,767,302 $ 6,531,377 $ 69,439 The Company amortized $14,611 and $ 3,635 of issuance cost in the aggregate for the years ended December 31, 2023 and 2022, respectively, for the FSB notes payable. Notes payable as of December 31, 2023 and 2022 consisted of the following: December 31, December 31, 2023 2022 FNBD Notes Payable $ 9,309,286 $ 8,863,423 FSB Notes Payable 5,767,302 6,531,377 Car loan - 6,653 Total notes payable 15,076,588 15,401,453 Unamortized debt issuance costs (124,170 ) (135,240 ) Notes payable, net of issuance cost 14,952,418 15,266,213 Less current portion (1,469,043 ) (1,549,861 ) Long-term portion $ 13,483,375 $ 13,716,353 Notes payable repayment requirements as of December 31, 2023, in the succeeding years are summarized as follows: 2024 $ 1,469,043 2025 3,776,189 2026 1,008,110 2027 1,052,832 2028 1,098,387 Thereafter $ 6,672,027 Bridge Note In December 2021, the Company entered into two bridge loans in the aggregate of $2,500,000 with Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund as short term secured convertible notes (“Bridge Note”). The Bridge Note was convertible into the Company’s common stock, at the time of a successful initial public offering (“IPO”) at the noteholder’s option, at a 35% discount to the IPO price. The Bridge Note had a face value of $2,500,000 with an original issue discount (“OID”) of 12% and had a maturity date of January 24, 2023. The OID of $300,000 was amortized over the life of the loan. If the Company had not issued the Company’s common stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission (“SEC”) and the listing of the common stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified financing”) by January 24, 2023 the conversion price will be set at a 40% discount to the IPO price. The Bridge Note was funded in two installments of net proceeds of $1,100,000 in December 2021 and the second installment January 2022. The Bridge Loan had issuance costs of $70,500 for the first installment and $54,000 for the second installment that is amortized straight line over the life of the loan. The Company amortized $0 In conjunction with the Bridge Note the Company issued warrants on January 24, 2022 to Target Capital 1, LLC and Dragon Dynamic Catalytic Bridge SAC Fund (collectively the “Bridge Lenders”). The warrants entitled the Bridge Lenders to purchase the Company’s Class A common stock, at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 50% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing, unless a Qualified Financing had not been completed by January 24, 2023 in which case the quantity of Class A common stock subject to purchase upon exercise of the warrants will be an amount equal to 75% of the face value of the Bridge Note divided by the per-share price in the Qualified Financing. If a Qualified Financing has not consummated or the Bridge Note had not been repaid in full on or before January 24, 2027, then the quantity of common stock subject to purchase upon exercise of the warrants will be an amount equal to 100% of the face value divided by the per-share price equal to the fair market value of one share of Class A common stock as mutually agreed by the Holder and the Company. The warrants were exercisable through the fifth anniversary of the issuance date. The warrants could be redeemed at the option of the Company at any time following a Qualified Financing if the Company’s common stock trade on a national securities exchange at a price equal to the purchase price of the Company’s common stock in the Qualified Financing multiplied by 2 for a period of ten consecutive trading days On November 18, 2022, the Company entered into an Original Issue Discount Secured Convertible Note loan (“bridge loan”) with Target Capital 1, LLC for $1,136,364. The note is issued at an original issue discount of 12% with an maturity date on the earlier of March 31, 2023 (“Initial Maturity Date”) or the Company’s sale of its Common Stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission and the listing of the Common Stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified Financing” or the “Maturity Date”). The note bears an interest rate of 12% per annum by means of the original issue discount. Upon the occurrence of an Automatic Extension, this note shall commence to accrue interest at an interest rate of 12% percent per annum on the date of the commencement of the Automatic Extension until the note is converted or is paid in full. The Company may pay the full principal amount of this note, and all accrued but unpaid interest at any time prior to the Maturity Date without the prior written consent of the Holder in the principal amount of $1,136,364, plus all accrued but unpaid interest, multiplied by 120%. In addition, and to the extent the Company is required to pay this note in cash at the on or after the Initial Maturity Date due to, upon the closing date of a Qualified Financing, the Company shall pay to the Holder $1,136,364, plus all accrued unpaid interest, multiplied by 120%. Upon the occurrence and during the continuation of an Event of Default, until the Event of Default is cured, or the Note is repaid in full, Company will pay 20% of its total gross revenues (including that of all its subsidiaries) monthly, which shall be applied to payment of principal and interest under this this note. The conversion price (the “Conversion Price”) shall be equal to the price paid by the public in the Company’s Qualified Financing multiplied by 0.65 (or 0.60, from and after any Automatic Extension). In conjunction with the Original Issue Discount Secured Convertible Note with Target Capital 1, LLC the company issued the holder 41,167 shares of Class A Common Stock and equity classified warrants that entitle the holder to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 75% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing. On November 18, 2022, the Company entered into an Original Issue Discount Secured Convertible Note with 622 Capital LLC for $568,182. The note is issued at an original issue discount of 12% with an maturity date on the earlier of January 24, 2023 (“Initial Maturity Date”) or the Company’s sale of its Common Stock in an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission and the listing of the Common Stock on a “national securities exchange” as defined in Section 6 of the Securities Exchange Act of 1934, as amended (“Qualified Financing” or the “Maturity Date”). If the Company has filed its Form S-1 Registration Statement with the SEC on or prior to the Initial Maturity Date but the Qualified Financing has not closed by such date (“Automatic Extension”) then all principal and accrued interest under this Note shall become due and payable in cash on July 24, 2023 (the “Final Maturity Date”) or such earlier date as this Note is required be repaid. The note bears an interest rate of 12% per annum by means of the original issue discount. Upon the occurrence of an Automatic Extension, this note shall commence to accrue interest at an interest rate of 12% percent per annum on the date of the commencement of the Automatic Extension until the note is converted or is paid in full. The Company may pay the full principal amount of this note and all accrued but unpaid interest at any time prior to the Maturity Date without the prior written consent of the Holder in the principal amount of $568,182, plus all accrued but unpaid interest, multiplied by 120%. In addition, and to the extent the Company is required to pay this note in cash at the on or after the Initial Maturity Date due to, upon the closing date of Qualified Financing, the Company shall pay to the Holder $568,182, plus all accrued unpaid interest, multiplied by 120%. Upon the occurrence and during the continuation of an Event of Default, until the Event of Default is cured or the Note is repaid in full, Company will pay 20% of its total gross revenues (including that of all its subsidiaries) monthly, which shall be applied to payment of principal and interest under this this note. The conversion price (the “Conversion Price”) shall be equal to the price paid by the public in the Company’s Qualified Financing multiplied by 0.65 (or 0.60, from and after any Automatic Extension). In conjunction with the Original Issue Discount Secured Convertible Note with 662 Capital LLC the company issued the holder equity classified warrants that entitle the holder to purchase the Company’s common stock at a purchase price equal to the per share price in an IPO. The quantity of the Company’s common stock of subject to purchase upon exercise of the warrants is equal to 75% of the face value of the Bridge Note, divided by the per-share price in the Qualified Financing. The warrants were deemed legally detachable from the Bridge Note and were fair valued using the Black Scholes Method to determine the relative fair values of the Bridge Note and the detachable warrants. The significant inputs for the Black Scholes calculation included the exercise price and common share price of $0.44, volatility rate of 27% and risk-free rate of 1.53% with a 5-year term. The proceeds received for the Bridge Note were allocated to the detached warrants based on the relative fair values. Pursuant to ASC 470 the relative fair value of the warrants attributable to a discount on debt is $429,284; this is amortized to interest expense on a straight-line basis over the term of the loan. On June 30, 2023, the Company entered into exchange agreements (the “Exchange Agreements”) with each of the Company’s Bridge Note lenders, pursuant to which the lenders exchanged their existing Bridge Notes for 29,896 shares, 352,771 shares, and 59,792 shares, respectively, of Convertible Series A preferred stock (442,458 shares of Convertible Series A Preferred stock in total) (the “Exchange”). The Exchange Agreements will be deemed rescinded and the former Bridge Notes will be deemed reinstated if the Company doesn’t complete an initial public offering by September 1, 2023. Upon the IPO completing on August 31, 2023, the Company recognized the extinguishment of the Bridge Notes pursuant to ASC 470 and recognized a debt extinguishment loss of $16,105. In connection with the Exchange, the Company also issued warrants to purchase additional shares of Class A common stock. The New Warrants were issued in exchange for the existing warrants held by the former Bridge Note lenders. See Note 8 for further information on the Series A preferred stock and the Warrants issued. A roll forward of the bridge note from January 1, 2022 to December 31, 2023 is below: Bridge notes, December 31, 2021 1,031,917 Issued for cash 2,600,000 Amortization of original issue discount 386,245 Warrant discount (429,284 ) Amortization of warrant discount 303,309 Debt issuance costs (164,000 ) Amortization of debt issuance costs 170,969 Bridge notes, December 31, 2022 3,899,156 Amortization of original issue discount 116,656 Amortization of warrant discount 125,975 Amortization of debt issuance costs 62,758 Extinguishment of bridge notes in exchange for Series A preferred stock upon IPO on August 31, 2023 (4,204,545 ) Bridge notes, December 31, 2023 $ - Convertible Debenture Between March 18 and December 28, 2021, the Company issued $2,102,500 in aggregate principal amount of 6.00% subordinated convertible promissory note (“Convertible Debenture”). During the year ending December 31, 2022 the Company issued $1,612,000 in aggregated principal amount of the 6.00% Convertible Debenture. In March 2023 the Company issued an additional $650,000 in aggregate principal amount of 6.00% Convertible Debenture notes to five (5) separate holders. The Convertible Debenture is convertible into the Company’s Class A Common Stock upon the Company’s offering for sale its shares in a public offering (“IPO”). At the holder’s election, the accrued interest and principal may be paid in cash or Class A Common Stock (such number of shares reflecting a twenty-five percent (25%) discount of the opening price per share of Class A Common Stock). The Convertible Debenture mature 5 years from the date of issuance to each holder. Prior to the maturity date, the holder is entitled to convert the Convertible Note into Class A Common Stock upon the Company’s IPO. Upon an IPO the accrued and unpaid interest is due and payable in cash on the first business day of the following month of March for any balance not elected to be converted into the Class A Common Stock. The Convertible Debenture principal balance was $100,000 and $3,714,500 as of December 31, 2023 and 2022. The Convertible Debenture incurred issuance cost of $40,000 that is amortized straight line over the life of the Convertible Debenture. The Company amortized $7,996 for the years ended December 31, 2023 and 2022. Upon the Company’s IPO closing on August 31, 2023, the majority of Convertible Debenture holders elected to convert an aggregate of $4,014,500 of principal and $399,818 of accrued interest into 1,495,295 shares of Class A common stock at a conversion price of $3.00 per share. The Company recorded a beneficial conversion feature as of the date of the conversion of $1,569,395 based on the PO price of $4 per share minus the principal and accrued interest of the Convertible Debenture balance converted into common stock. Four holders of the Convertible Debenture with an aggregate principal balance of $250,000 elected to be paid back in cash and one investor with a principal balance of $100,000 elected to be paid on February 28, 2024 including accrued interest through the date of payment at 6%. Loan Payable On May 30, 2023, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $1,050,000 with an unrelated third-party financial institution. Under the terms of the agreement, the Company must pay $57,346 each week for 26 weeks with the first payment being due June 6, 2023. The financing arrangement has an effective interest rate of 49%. The financing arrangement includes an original issuance discount (“OID”) of $441,000 and issuance costs of $50,000. The OID and issuance cost associated with the financing arrangement are presented in the balance sheets as a direct deduction from the carrying amount of the financing arrangement and is amortized using the effective interest method. On August 10, 2023, the Company amended the financing arrangement to borrow an additional $507,460 resulting in the weekly repayments increasing to $76,071 to be paid over 28 weeks. This amendment decreased the effective interest rate to 41%. The refinancing resulted in a loss on debt modification of $441,618. On November 28, 2023, the Company amended the financing arrangement to borrow an additional $531,071 resulting in the weekly payments to decrease to $56,800 to be paid over 40 weeks. This amendment increased the effective rate to 49%. The refinancing resulted in a loss on debt modification of $485,436. During the year ended December 31, 2023, the Company amortized $671,719 of OID and issuance cost included in interest expense on the statement of operations. During the year ended December 31, 2023, the Company made $1,923,474 in payments on the loan payable. The outstanding balance of the loan payable as of December 31, 2023, is $2,063,058. The financing arrangement is secured by an interest in virtually all assets of the Company with a first security interest in accounts receivable. The financing arrangement is guaranteed by the Company’s CEO..

Related Party Transactions

Related Party Transactions	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions Blue Heron The Company entered into a consulting agreement with Blue Heron Consulting (“BHC”) on June 24, 2021, pursuant to which BHC will consult with the Company on an on-going basis in connection with the Company’s acquisition of veterinary practices throughout the United States and will serve as the Company’s business and financial advisor with respect to its acquisition strategy and in connection with specific acquisition targets. The Company’s director and Chief Operating Officer Charles Stith Keiser is the Chief Operating Officer of BHC, and the Company’s director Dr. Charles “Chuck” Keiser is the Chief Visionary Officer of BHC. During the fourth quarter of 2023 management terminated the service agreement with Blue Heron, however, still uses Blue Heron on an ad-hoc basis for services and has incurred $68,027 and $229,614 in expenses for the three months ended March 31, 2024 and 2023, respectively. These expenses are recorded as a component of “General and administrative expenses” in the accompanying condensed consolidated statement of operations. Under the Consulting Agreement, BHC is entitled to a monthly fee for on-going services including: ● the preparation of valuation packages of potential acquisitions (including the gathering of pertinent information, financial and background data, completion of deal packets and financial projection worksheets used by the Company to calculate practice values); ● the institution of turnover protocols and procedures of hospitals immediately post-purchase; systems reporting; the formulation of individual hospital goals and targets; ● on-going monthly support of hospital units (including medical and operational coaching, business growth projections, establishment of financial targets and margin improvements, growth milestones) and recruiting support. Upon termination, all accrued, but not yet paid fees and expenses, whether invoiced or not, must be paid to BHC. Star Circle Advisory The Company entered into a consulting agreement with Star Circle Advisory Group, LLC (“Star Circle”) on August 2, 2022 to serve as financial consultant, on a non-exclusive basis, to assist with arranging bridge financing and the initial public offering of the Company. Star Circle is owned and controlled by Kimball Carr, Chairman, Chief Executive Officer and President, Peter Lau, Interim Chief Financial Officer and Director, James Coleman, Director, and Richard Marten, Director. Star Circle is entitled to a monthly fee of $33,000, payable monthly. Each party is responsible for its own ordinary office and personnel expenses; however, Star Circle is entitled, with prior written consent from the Company, for reimbursement for required extraordinary expenses including air travel, lodging, and Company filing fees. The consulting agreement will terminate on August 1, 2024, unless terminated earlier by mutual agreement of the parties or by either party upon 30 days written notice. During the fourth quarter of 2023, management terminated service agreements with Star Circle Advisory and has incurred $0 and $99,000 in expenses for the three months ended March 31, 2024 and 2023, respectively. These expenses are recorded as a component of “General and administrative expenses” in the accompanying condensed consolidated statement of operations. CEO Warrant On January 1, 2023, the board of directors issued 500 shares of Class A common stock issuable upon cashless exercise of a warrant granted to Kimball Carr, Chief Executive Officer (“CEO”) and Chairman of the board of directors, in consideration for his personal guaranty of the Company loans. The warrant expires on January 1, 2028. The Warrant is fully paid and nonassessable shares of Class A common stock at a purchase price per share equal to the price per share of the common stock sold through an initial public offering pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission on a national securities exchange. The warrants were measured at fair value using the Black Scholes Method to determine the fair value of warrants issued to the CEO. The significant inputs for the Black Scholes calculation included the exercise price and common share price of $1.73, volatility rate of 27.13% and risk-free rate of 3.94% with a 5-year term. The warrants were valued at $2,701 at the time of issuance and the entire amount was recorded as an expense in General and administrative expenses in the accompanying unaudited condensed consolidated statement of operations for the three months ended March 31, 2023.	7. Related Party Transactions Blue Heron The Company entered into a consulting agreement with Blue Heron Consulting (“BHC”) on June 24, 2021, pursuant to which BHC will consult with the Company on an on-going basis in connection with the Company’s acquisition of veterinary practices throughout the United States and will serve as the Company’s business and financial advisor with respect to its acquisition strategy and in connection with specific acquisition targets. The Company’s director and Chief Operating Officer Charles Stith Keiser is the Chief Operating Officer of BHC, and the Company’s director Dr. Charles “Chuck” Keiser is the Chief Visionary Officer of BHC. The Company has incurred $907,866 and $983,355 in expenses for the years ended December 31, 2023, and 2022, respectively. These expenses are recorded as a component of “General and administrative expenses” in the accompanying consolidated statement of operations. Under the Consulting Agreement, BHC is entitled to a monthly fee for on-going services including: ● the preparation of valuation packages of potential acquisitions (including the gathering of pertinent information, financial and background data, completion of deal packets and financial projection worksheets used by the Company to calculate practice values); ● the institution of turnover protocols and procedures of hospitals immediately post-purchase; systems reporting; the formulation of individual hospital goals and targets; ● on-going monthly support of hospital units (including medical and operational coaching, business growth projections, establishment of financial targets and margin improvements, growth milestones) and recruiting support. The Consulting Agreement may be terminated at any time without cause and without penalty upon thirty days’ notice to the other party. Upon termination, all accrued, but not yet paid fees and expenses, whether invoiced or not, must be paid to BHC. Star Circle Advisory The Company entered into a consulting agreement with Star Circle Advisory Group, LLC (“Star Circle”) on August 2, 2022, to serve as financial consultant, on a non-exclusive basis, to assist with arranging bridge financing and the initial public offering of the Company. Star Circle is owned and controlled by Kimball Carr, Chairman and Chief Executive Officer (“CEO”), Peter Lau, former Interim Chief Financial Officer and Director, James Coleman, Director, and Richard Marten, Director. Star Circle is entitled to a monthly fee of $33,000, payable monthly. Each party is responsible for its own ordinary office and personnel expenses; however, Star Circle is entitled, with prior written consent from the Company, for reimbursement for required extraordinary expenses including air travel, lodging, and Company filing fees. The consulting agreement will terminate on August 1, 2024, unless terminated earlier by mutual agreement of the parties or by either party upon 30 days written notice. The consulting agreement may also be extended by mutual agreement. Prior to the formal agreement between the Company and Star Circle, Star Circle provided the same services under a verbal agreement that was memorialized by the consulting agreement. The Company has incurred $284,900 and $450,000 in expenses for the years ended December 31, 2023 and 2022. These expenses are recorded as a component of “General and administrative expenses” in the accompanying consolidated statement of operations. The Agreement with Star Circle Advisory was terminated on September 18, 2023. Chief Executive Officer’s Warrant On January 1, 2023, the board of directors issued 50,000 warrants of Class A common stock issuable upon cashless exercise of a warrant granted to Kimball Carr, CEO and Chairman of the board of directors, in consideration for his personal guaranty of the Company loans. The warrant expires on January 1, 2028. The Warrant is fully paid and nonassessable shares of Class A common stock at a purchase price per share equal of $4. The warrants were measured at fair value using the Black Scholes Method to determine the fair value of warrants issued to the CEO. The significant inputs for the Black Scholes calculation included the exercise price and common share price of $1.73, volatility rate of 27.13% and risk-free rate of 3.94% with a 5-year term. The warrants were valued at $2,701 at the time of issuance and the entire amount was recorded as an expense in General and administrative expenses in the accompanying consolidated statement of operations for the years ended December 31, 2023.

Stockholders' Equity

Stockholders' Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Stockholders Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity The Company is authorized to issue is 71,000,000 shares, of which 1,000,000 shares are designated as Class A common stock, with a par value of $0.0001 per share, 20.000,000 Each outstanding share of Class A common stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class A common stock is entitled to one (1) vote for each share of Class A common stock held by such holder. Each outstanding share of Class B common stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class B common stock is entitled to twenty-five (25) votes for each share of Class B common stock held by such holder. Each Class B common stock is convertible to 1/100 th All shares of Class A common stock and Class B common stock (collectively “common stock”) will be identical and will entitle the holders thereof to the same rights and privileges, except as otherwise provided above. On November 15, 2022, the companies amended the consulting agreement with Alchemy Advisory, LLC until June 30, 2023. The contract amendment stipulates an additional fee of $40,000 as well as 83 restricted shares of the Company’s Class A common stock. The Company recorded the $72,084 fair value of the common stock with $0 and $36,042 expensed during the three months ended March 31, 2024 and 2023, respectively. The Company will amortize the cost of the common stock issued over the life of the agreement. On November 15, 2022, the Company entered into a consulting agreement with 662 Capital LLC until June 30, 2023. The contract stipulates the Company will issue 417 restricted shares of the Company’s Class A common stock for services rendered. The Company recorded the $144,168 fair value of the common stock with $0 and $72,804 expensed during the three months ended March 31, 2024 and 2023, respectively. The Company will amortize the cost of the common stock issued over the life of the agreement. Convertible Series A Preferred Stock On June 30, 2023, the Company amended its articles of incorporation by the filing of a certificate of designation for the Series A Preferred Stock. One million shares of the Series A Preferred Stock are authorized under the Series A Certificate of Designation, with each having a stated value of $1,000.00 per share, with a par value of $0.0001. The Series A Preferred Stock earns a dividend rate equal to 12% of the stated rate per annum, which such dividend may be payable either in cash or in-kind at the sole option of the Company. Holders of shares of the Series A Preferred Stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A Preferred Stock are also entitled to convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to the stated value divided by a conversion price. The conversion price is equal to 60% of the dollar volume-weighted average price for shares for the Company’s Class A common stock for the three trading days immediately preceding the date of the conversion. However, the conversion price can never be less than 50% of the per-share price for shares of Class A common stock during the Company’s initial public offering. For any conversion during the Company’s initial three days of market trading, the conversion price will be equal to 60% of the price for the Company’s underwritten initial public offering. On November 7, 2023, the Company amended its article of incorporation to increase the total authorized preferred stock by 2,000,000 shares. The conversion price of the convertible series A preferred stock to be no less than $1.00 per share, as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction conducted after the date of the series A preferred stock amendment. The holders of the Series A Preferred Stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class. On June 30, 2023, the Company issued 442.458 shares of Series A Preferred Stock to the holders of the Bridge Notes in exchange for the Bridge Notes (the “Exchange”). In connection with the Exchange, the Company also issued warrants (the “New Warrants”) to purchase additional shares of Class A common stock. The New Warrants were issued in exchange for the existing warrants held by the former Bridge Note holders. The exercise price of the shares to be issued pursuant to the New Warrants is the price of the shares of Class A common stock to be issued in this offering. The number of shares to be issued upon exercise of the New Warrants is equal to the quotient of 75% of the outstanding Series A Preferred Stock value divided by the exercise price. Also, in connection with the Exchange, the Company entered into new registration rights agreements (the “New Registration Rights Agreements”) with each of holders, pursuant to which the Company has agreed to register the public resale of the shares of Class A common stock issuable upon conversion of the Series A Preferred Stock and upon exercise of the under the New Warrants. The New Registration Rights Agreements supersede in their entirety the prior registration rights agreements with the former senior secured lenders. If Company did not close the initial public offering on or before September 1, 2023, the Exchange Agreements would have been deemed rescinded, and the former Bridge Notes would have been deemed reinstated. As the offering was outside the control of the Company the Company did not recognize the full extinguishment of the Bridge Notes until the IPO was completed on August 31, 2023. The Company recognized a beneficial conversion feature of $2,567,866 for the issuance of the Series A Preferred Stock on the date of the IPO due to the $4 (pre-Reverse Split) offering price related to the IPO being known as of that date.	8. Stockholders’ Equity The Company is authorized to issue is 170,000,000 shares, of which 100,000,000 shares are designated as Class A common stock, with a par value of $0.0001 per share (the “Class A Common Stock”), 20,000,000 shares are designated as Class B common stock, with a par value of $0.0001 per share (the “Class B Common Stock”), and 50,000,000 shares are designated as Preferred Stock, with a par value of $0.0001 per share (the “Preferred Stock”). Each outstanding share of Class A Common Stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class A Common Stock is entitled to one (1) vote for each share of Class A Common Stock held by such holder. Each outstanding share of Class B Common Stock is entitled to vote on each matter on which the stockholders of the Company is entitled to vote, and each holder of Class B Common Stock is entitled to twenty-five (25) votes for each share of Class B Common Stock held by such holder. All shares of Class A Common Stock and Class B Common Stock (collectively “Common Stock”) will be identical and will entitle the holders thereof to the same rights and privileges, except as otherwise provided above. On November 15, 2022, the Company amended the consulting agreement with Alchemy Advisory, LLC until June 30, 2023. The contract amendment stipulates an additional fee of $40,000 as well as 83,334 restricted shares of the Company’s Class A Common Stock. The Company recorded the $144,168 fair value of the common stock with $108,126 and $36,042 expensed during the years ended December 31, 2023 and 2022, respectively. The Company amortizes the cost of the common stock issued over the life of the agreement. On November 15, 2022, the Company entered into a consulting agreement with 662 Capital LLC. The contract stipulates the Company will issue 41,667 restricted shares of the Company’s Class A Common Stock for services rendered. The Company recorded the $72,084 fair value of the common stock with $54,063 and $18,021 expensed during the years ended December 31, 2023 and 2022, respectively. The Company amortizes the cost of the common stock issued over the life of the agreement. Convertible Series A preferred stock On June 30, 2023, the Company amended its articles of incorporation by the filing of a certificate of designation for the Series A preferred stock. One million shares of the Series A Preferred stock are authorized under the Series A Certificate of Designation, with each such having a stated value of $10.00 per share, with a par value of $0.0001. The Series A preferred stock earns a dividend rate equal to 12% of the stated rate per annum, which such dividend may be payable either in cash or in-kind at the sole option of the Company. Holders of shares of the Series A preferred stock are entitled to a liquidation preference in the event of any dissolution, liquidation or winding up of the Company equal to the stated value plus any accrued and unpaid dividends on such stock. Holders of shares of Series A preferred stock are also entitled to convert such shares at any time and from time, at the option of such holder, into a number of shares of Class A common stock equal to the stated value divided by a conversion price. The conversion price is equal to 60% of the dollar volume-weighted average price for shares for the Company’s Class A common stock for the three On November 7, 2023, the Company amended its article of incorporation to increase the total authorized preferred stock by 2,000,000 shares and modified the conversion price of the convertible series A preferred stock to be no less than $0.25 per share, as adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction conducted after the date of the series A preferred stock amendment. The holders of the Series A preferred stock have the right to vote on all matters submitted to a vote of shareholders on an as-if-converted basis together with the holders of shares of the Company’s Class A and Class B common stock, voting together as a single class. On June 30, 2023, the Company issued 442,458 shares of Series A preferred stock to the holders of the Bridge Notes in exchange for the Bridge Notes (the “Exchange”). In connection with the Exchange, the Company also issued warrants (the “New Warrants”) to purchase additional shares of Class A common stock. The New Warrants were issued in exchange for the existing warrants held by the former Bridge Note holders. The exercise price of the shares to be issued pursuant to the New Warrants is the price of the shares of Class A common stock to be issued in this offering. The number of shares to be issued upon exercise of the New Warrants is equal to the quotient of 75% of the outstanding Series A preferred stock value divided by the exercise price. Also, in connection with the Exchange, the Company entered into new registration rights agreements (the “New Registration Rights Agreements”) with each of holders, pursuant to which the Company has agreed to register the public resale of the shares of Class A common stock issuable upon conversion of the Series A preferred stock and upon exercise of the under the New Warrants. The New Registration Rights Agreements supersede in their entirety the prior registration rights agreements with the former senior secured lenders. If the Company does not close this offering on or before September 1, 2023, the Exchange Agreements will be deemed rescinded, and the former Bridge Notes will be deemed reinstated. As the offering was outside the control of the Company the Company did not recognize the full extinguishment of the Bridge Notes until the IPO was completed on August 31, 2023. The Company recognized a beneficial conversion feature of $2,567,866 for the issuance of the Series A preferred stock on the date of the IPO due to the $4 offering price related to the IPO being known as of that date.

Retirement Plan

Retirement Plan	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Retirement Plan [Abstract]
Retirement Plan	10. Retirement Plan During the year ending December 31, 2022, the Company implemented a qualified 401(K) retirement plan. The Company offers eligible domestic full-time employees participation in certain 401K plans. The plans provide for a discretionary annual company contribution. In addition, employees may contribute a portion of their salary to the plans, which certain of the 401K plans, is partially matched by the Company. The plans may be amended or terminated at any time. The Company contributed and expensed approximately $40,264 and $4,995 during the three months ending March 31, 2024 and 2023, respectively.	9. Retirement Plan The Company, through its acquisition of KVC sponsors a Savings Incentive Match Plan for former KVC Employees (SIMPLE IRA). The SIMPLE IRA plan provides for voluntary employee contributions up to statutory IRA limitations. KVC makes a dollar-for-dollar matching contribution equal to the elective deferral of each participant up to a maximum of 3% of the participants compensation. The participant’s interest in the balance of their SIMPLE IRA is immediately vested and non-forfeitable. The Company contributed and expensed $0 and $2,648 during the years ended December 31, 2023 and 2022, to the SIMPLE IRA plan. During the year ending December 31, 2022, the Company implemented a qualified 401(K) retirement plan. The Company offers eligible domestic full-time employees participation in certain 401K plans. The plans provide for a discretionary annual company contribution. In addition, employees may contribute a portion of their salary to the plans, which certain of the 401K plans, is partially matched by the Company. The plans may be amended or terminated at any time. The Company contributed and expensed approximately $124,166 and $50,704 during the years ended December 31, 2023 and 2022, respectively.

Income Taxes

Income Taxes	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Income Taxes [Abstract]
Income Taxes	11. Income Taxes The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. As of March 31, 2024 and December 31, 2023, no	10. Income Taxes The Company estimated NOL carry-forwards for Federal and State income tax purposes of $14,924,318 as of December 31, 2023, and $6,348,656 as of December 31, 2022. No Year ended December 31, 2023 2022 Deferred tax assets: Net Operating Loss Carryforwards $ 3,684,694 $ 1,731,713 Accrued Expenses 112,936 11,197 Stock Based Compensation 98,625 - Charitable Contribution Carryforward 621 412 ROU Asset (400,605 ) (204,479 ) Lease Liability 410,405 204,982 R&D Sec 174 1,830 - Total deferred tax assets 3,908,505 1,743,825 Deferred tax liabilities: Amortization/Depreciation 89,165 134,382 Total deferred tax liabilities 89,165 134,382 Valuation allowance (3,819,340 ) (1,609,443 ) Net deferred Tax Assets (Liabilities) $ 0 - The differences between the total calculated income tax (benefit) provision and the expected income tax computed using the U.S. federal income tax rate are as follows: 2023 2022 Tax benefit at statutory tax rate (2,872,031 ) (1,021,920 ) State benefit, net of federal benefit (210,273 ) (291,977 ) Beneficial conversion feature 868,825 - Other permanent differences 3,713 (13,535 ) Valuation allowance 2,209,897 1,308,517 Other (131 ) (11,179 ) $ (0.00 ) $ (30,094 ) Income tax benefit consists of the following for the years ending December 31, 2023 and 2022: December 31 December 31 Current income benefit expense Federal $ - $ - State - (30,094 ) $ - $ -

Leases

Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Leases	12. Leases Accounting for Leases as Lessee The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), operating lease liabilities, and operating lease liabilities, non-current. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company has operating leases for real estate. The Company has certain intercompany leases between its subsidiaries, and these transactions and balances have been eliminated in consolidation and are not reflected in the tables and information presented below. The components of lease expense included on the Company’s unaudited condensed statements of operations were as follows: For the Three Months Operating lease expense: Expense Classification 2024 2023 Amortization of ROU asset General and administrative $ 53,831 28,875 Accretion of operating lease liability General and administrative 10,541 7,385 Total operating lease expense $ 64,372 36,260 Other lease expense General and administrative (2,026 ) 11,708 Total $ 62,346 47,968 Other information related to leases is as follows: As of As of 2024 2023 Weighted-average remaining lease term: Operating leases (in years) 9.35 9.29 Weighted-average Discount rate: Operating leases 7.04 % 7.083 % Amounts relating to leases were presented on the unaudited condensed Balance Sheets as of March 31, 2024 and December 31, 2023 in the following line items: As of As of Balance Sheet Classification 2024 2023 Assets: Operating lease assets Right-of-use assets $ 1,562,367 $ 1,616,198 Liabilities: Operating lease liabilities Operating lease liabilities $ 133,113 141,691 Operating lease liabilities Operating lease liabilities, non-current 1,482,514 1,514,044 Total lease liabilities $ 1,615,627 $ 1,655,735 The future minimum lease payments required under leases as of March 31, 2024, were as follows: Fiscal Year Operating Remainder of 2024 $ 181,811 2025 230,198 2026 231,959 2027 233,619 2028 238,078 Thereafter 1,100,287 Undiscounted cash flows 2,215,952 Less: imputed interest (600,325 ) Lease liability $ 1,615,627	11. Leases Accounting for Leases as Lessee The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use assets (“ROU”), operating lease liabilities, and operating lease liabilities, non-current. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. None of the leases entered into have an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future payments. Incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in economic environments where the leased asset is located. The ROU assets also include any prepaid lease payments made and initial direct costs incurred and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease, which is recognized when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company has operating leases for real estate. The Company has certain intercompany leases between its subsidiaries, and these transactions and balances have been eliminated in consolidation and are not reflected in the tables and information presented below. The components of lease expense included on the Company’s consolidated statements of operations were as follows: For the Year Ended Expense Classification 2023 2022 Operating lease expense: Amortization of ROU asset General and administrative $ 132,138 $ 52,863 Accretion of Operating lease liability General and administrative 25,667 10,695 Total operating lease expense $ 157,805 $ 63,558 Other lease expense General and administrative 28,012 8,723 Total $ 185,817 $ 72,281 Other information related to leases is as follows: As of December 31, 2023 2022 Remaining lease term: Operating leases (in years) 9.29 8.43 Discount rate: Operating leases 7.03 % 4.08 % Amounts relating to leases were presented on the consolidated balance sheets as of December 31, 2023 and 2022 in the following line items: As of December 31, Balance Sheet Classification 2023 2022 Assets: Operating lease assets Right-of-use assets $ 1,616,198 $ 746,973 Liabilities: Operating lease liabilities Operating lease liabilities 141,691 91,152 Operating lease liabilities Operating lease liabilities, non-current 1,514,044 666,179 Total lease liabilities $ 1,655,735 $ 757,331 The future minimum lease payments required under leases as of December 31, 2023, were as follows: Fiscal Year Operating 2024 $ 249,808 2025 230,198 2026 231,959 2027 233,619 2028 238,078 Thereafter 1,100,287 Undiscounted cash flows 2,283,949 Less: imputed interest (628,214 ) Lease liability $ 1,655,735

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies As of March 31, 2024, substantially all of the Company’s assets were pledged as collateral for the Company’s credit facilities. On November 30, 2023, the Company entered into a common stock purchase agreement with a 3 rd Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor, and the Investor is obligated to purchase, shares of Class A common stock in an amount up to $30 million. Such sales of Class A common stock by the Company, if any, will be subject to certain limitations, and may occur from time-to-time in the Company’s sole discretion, over the period commencing once certain customary conditions are satisfied, including the filing and effectiveness of a resale registration statement with the U.S. Securities and Exchange Commission (the “Commission”) with respect to the shares to be sold to the Investor under the Purchase Agreement and ending on the first day of the month following the 24-month anniversary of the date on which the resale registration statement is declared effective by the Commission. The Investor has no right to require the Company to sell any shares of Class A common stock to the Investor, but the Investor is obligated to purchase shares of Class A common stock pursuant to a valid purchase notice delivered by the Company, subject to certain conditions and limitations. Purchase Price The shares of Class A common stock to be issued by the Company and purchased by the Investor will be sold at a purchase price equal to 95% of the lowest daily volume-weighted average price of the Class A common stock on the Nasdaq Capital Market (or any eligible substitute exchange) during the three consecutive trading days immediately following the trading date on which a valid purchase notice is delivered to the Investor by the Company. Such purchase price will be adjusted for reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction by the Company with respect to its Class A common stock. Actual sales of shares of Class A common stock to the Investor will depend on a variety of factors to be determined by the Company from time-to-time, including, among other things, market conditions, the trading price of the Company’s Class A common stock, and the working capital needs, if any, of the Company. The net proceeds from sales, if any, under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Class A common stock to the Investor. the Company expects that any proceeds received by the Company from such sales to the Investor will be used for working capital and general corporate purposes. Purchase Limits Pursuant to the Purchase Agreement, the Company may not require the Investor to purchase, and the Investor will have no obligation to purchase, shares of Class A common stock in excess of a number equal to the lowest of (i) 100% of the average daily trading volume of the Class A common stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable) for the five consecutive trading days immediately prior to the trading date on which a valid purchase notice is delivered to the Investor, (ii) a 30% discount to the daily trading volume in the Class A common stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable), and (iii) $2 million divided by the volume-weighted average price for the Class A common stock on the trading day immediately prior to the trading date on which a valid purchase notice is delivered to the Investor. Consistent with certain applicable Nasdaq rules, the Company may not issue to the Investor more than 12,143 shares of its Class A common stock (the “Exchange Cap”) under the Purchase Agreement, which number of shares is equal to 19.99% of the shares of the Company’s Class A common stock issued and outstanding immediately prior to the execution of the Purchase Agreement, unless the Company obtains stockholder approval to issue shares of its Class A common stock in excess of such limit in accordance with applicable rules of Nasdaq or any other applicable national stock exchange. Fees As consideration for the Investor’s irrevocable commitment to purchase shares of Class A Common Stock, upon execution of the Purchase Agreement, the Company became obligated to issue to the Investor a number of shares of Class A Common Stock equal to $600,000 divided by the average daily volume-weighted average price for the Class A Common Stock on the Nasdaq Capital Market during the five consecutive trading days ending on the trading date immediately prior to the Company’s filing of an initial registration statement pursuant to the Registration Rights Agreement described below. In certain circumstances, the Company may become obligated to pay to the Investor a cash fee equal to $600,000 in lieu of issuing such shares of Class A Common Stock, under the terms and subject to the conditions described more fully in the Purchase Agreement. Certain Representations, Warranties and Covenants The Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of each of the Company and the Investor. Pursuant to the Purchase Agreement, the Investor has agreed not to enter into or effect, in any manner whatsoever, directly or indirectly, any short sales of the Company’s Class A Common Stock or hedging transaction which establishes a net short position with respect to the Class A Common Stock. In addition, the Company has covenanted, among other things, through the 24-month anniversary of the signing of the Purchase Agreement, to not effect or enter into any agreement to issue any shares of Class A Common Stock or securities convertible into or exercisable or exchangeable into shares of Class A Common Stock except in limited circumstances. The Company has the right to terminate the Purchase Agreement at any time following the satisfaction of certain conditions precedent relating to the initial sale of shares to the Investor, subject to the Company paying all documented fees and amounts to the Investor’s legal counsel and, if the agreement is terminated prior to effectiveness of the resale registration statement, the Company paying the $600,000 cash commitment fee to the Investor or, if the agreement is terminated after such effectiveness, the Company issuing all commitment shares of Class A Common Stock to the Investor. The Purchase Agreement will automatically terminate on (i) the 24-month anniversary of the effective date of the initial resale registration statement filed with the Commission, (ii) the date when the Investor purchases the Total Commitment, (iii) the date when the shares of Class A Common Stock are no longer listed on the Nasdaq Capital Market or another eligible national stock exchange, or (iv) when the Company is subject to a voluntary or involuntary bankruptcy or insolvency proceeding. In addition, the Investor may terminate the Purchase Agreement upon (i) the occurrence of an event constituting a material adverse effect (as defined in the Purchase Agreement), (ii) the occurrence of a change of control transaction of the Company, (iii) the failure by the Company to file a registration statement by the applicable deadline set forth in the Registration Rights Agreement, (iv) the lapse of the effectiveness, or unavailability of, a registration statement filed by the Company pursuant to the Registration Rights Agreement in certain other circumstances set forth in the Purchase Agreement, (v) the suspension of trading of the Class A Common Stock for a period of three (3) consecutive trading days, or (vi) the material breach of the Purchase Agreement by the Company, which breach is not cured within the 10 trading days after receipt of notice of such breach. On December 28, 2023, the Company amended the agreement to provide that, if the number of commitment shares required to be issued by the Company to the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder) pursuant to the Purchase Agreement would result in the beneficial ownership by the Investor of more than 4.99% of the outstanding shares of Class A common stock of the Company, then the Company shall be obligated to deliver to the Investor: (i) the number of shares of Class A common stock that, after giving effect to the issuance thereof to the Investor, would result in the Investor and its affiliates beneficially owning one (1) share less than 4.99% of the outstanding shares of Class A common stock of the Company, and (ii) a warrant to purchase shares of Class A common stock (such warrant, the “Warrant” and the shares issuable upon exercise thereof, the “Warrant Shares”), granting the Investor the right to purchase, at an exercise price of $0.01 per Warrant Share, up to that number of Warrant Shares equal to the difference between (x) the number of shares that would be required to be issued to the Investor as commitment shares but-for the 4.99% ownership limitation, and (y) the number of shares of Class A common stock to be issued to the Investor as commitment shares. The amendment further provide that, if the issuance of the total number of commitment shares of Class A common stock and Warrant Shares by the Company to the Investor would cause the beneficial ownership of the Investor and its affiliates to exceed 19.99% of the outstanding shares of Class A common stock of the Company, and the Company has not obtained stockholder approval for the issuance of such shares of Class A common stock in an amount in excess of the 19.99% ownership threshold in accordance with the applicable rules of The Nasdaq Capital Market on or before May 24, 2024, then the Company shall be obligated to pay to the Investor an amount in cash equal to $600,000 minus the value of the shares of Class A common stock issuable to the Investor as commitment shares and the value of the Warrant Shares issuable upon exercise of the Warrant. On February 14, 2024, the Company issued 12,143 shares of Class A Common stock, per share to an Investor. In addition, the Company, on February 13, 2024, issued a prefunded warrant to purchase up to 16,549 shares of Class A common stock of the Company to the Investor. The Company issued the shares and the warrant in fulfilment to its obligation to issue “commitment shares” to the Investor upon its entry into the purchase agreement. The Company issued the shares and warrant to the Investor exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933. The Company did not receive any proceeds with respect to the issuance of the Commitment Shares or the Warrant and does not expect to receive any material proceeds from the Investor’s exercise, if any, of Warrant for the purchase of Warrant shares. Holdback Agreement As part of the Valley Veterinary Services, Inc. acquisition in November 2023, a portion of the purchase price in the amount of $200,000 is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheet. The Holdback Agreement dictates that $80,000 is contingent upon both former owners (now employees of the Company) still being employed by the Company as of November 8, 2025 and the Valley Vet Practice’s gross revenue exceeding 105% of the target gross revenue. The remaining $120,000 is contingent upon both former owners (now employees of the Company) still being employed by the Company as of November 8, 2025 and the Valley Vet Practice’s gross revenue exceeding 110% of the target gross revenue. As the contingent consideration arrangement in which the Holdback amounts are automatically forfeited if the employment of the former owners (now employees of the Company) terminates is accounted for as compensation for post combination services. The Company will recognize the contingent consideration from the Holdback Agreement when probable.	12. Commitments and Contingencies As of December 31, 2023, substantially all of the Company’s assets were pledged as collateral for the Company’s credit facilities. Common Stock Purchase Agreement On November 30, 2023, the Company entered into a common stock purchase agreement with a 3 rd Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to the Investor, and the Investor is obligated to purchase, shares of Class A Common Stock in an amount up to $30 million. Such sales of Class A Common Stock by the Company, if any, will be subject to certain limitations, and may occur from time-to-time in the Company’s sole discretion, over the period commencing once certain customary conditions are satisfied, including the filing and effectiveness of a resale registration statement with the U.S. Securities and Exchange Commission (the “Commission”) with respect to the shares to be sold to the Investor under the Purchase Agreement and ending on the first day of the month following the 24-month anniversary of the date on which the resale registration statement is declared effective by the Commission. The Investor has no right to require the Company to sell any shares of Class A Common Stock to the Investor, but the Investor is obligated to purchase shares of Class A Common Stock pursuant to a valid purchase notice delivered by the Company, subject to certain conditions and limitations. Purchase Price The shares of Class A Common Stock to be issued by the Company and purchased by the Investor will be sold at a purchase price equal to 95% of the lowest daily volume-weighted average price of the Class A Common Stock on the Nasdaq Capital Market (or any eligible substitute exchange) during the three consecutive trading days immediately following the trading date on which a valid purchase notice is delivered to the Investor by the Company. Such purchase price will be adjusted for reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction by the Company with respect to its Class A Common Stock. Actual sales of shares of Class A Common Stock to the Investor will depend on a variety of factors to be determined by the Company from time-to-time, including, among other things, market conditions, the trading price of the Company’s Class A Common Stock, and the working capital needs, if any, of the Company. The net proceeds from sales, if any, under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of Class A Common Stock to the Investor. the Company expects that any proceeds received by the Company from such sales to the Investor will be used for working capital and general corporate purposes. Purchase Limits Pursuant to the Purchase Agreement, the Company may not require the Investor to purchase, and the Investor will have no obligation to purchase, shares of Class A Common Stock in excess of a number equal to the lowest of (i) 100% of the average daily trading volume of the Class A Common Stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable) for the five consecutive trading days immediately prior to the trading date on which a valid purchase notice is delivered to the Investor, (ii) a 30% discount to the daily trading volume in the Class A Common Stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable), and (iii) $2 million divided by the volume-weighted average price for the Class A Common Stock on the trading day immediately prior to the trading date on which a valid purchase notice is delivered to the Investor. Consistent with certain applicable Nasdaq rules, the Company may not issue to the Investor more than 1,214,293 shares of its Class A Common Stock (the “Exchange Cap”) under the Purchase Agreement, which number of shares is equal to 19.99% of the shares of the Company’s Class A Common Stock issued and outstanding immediately prior to the execution of the Purchase Agreement, unless the Company obtains stockholder approval to issue shares of its Class A Common Stock in excess of such limit in accordance with applicable rules of Nasdaq or any other applicable national stock exchange. Fees As consideration for the Investor’s irrevocable commitment to purchase shares of Class A Common Stock, upon execution of the Purchase Agreement, the Company became obligated to issue to the Investor a number of shares of Class A Common Stock equal to $600,000 divided by the average daily volume-weighted average price for the Class A Common Stock on the Nasdaq Capital Market during the five consecutive trading days ending on the trading date immediately prior to the Company’s filing of an initial registration statement pursuant to the Registration Rights Agreement described below. In certain circumstances, the Company may become obligated to pay to the Investor a cash fee equal to $600,000 in lieu of issuing such shares of Class A Common Stock, under the terms and subject to the conditions described more fully in the Purchase Agreement. Certain Representations, Warranties and Covenants The Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of each of the Company and the Investor. Pursuant to the Purchase Agreement, the Investor has agreed not to enter into or effect, in any manner whatsoever, directly or indirectly, any short sales of the Company’s Class A Common Stock or hedging transaction which establishes a net short position with respect to the Class A Common Stock. In addition, the Company has covenanted, among other things, through the 24-month anniversary of the signing of the Purchase Agreement, to not effect or enter into any agreement to issue any shares of Class A Common Stock or securities convertible into or exercisable or exchangeable into shares of Class A Common Stock except in limited circumstances. The Company has the right to terminate the Purchase Agreement at any time following the satisfaction of certain conditions precedent relating to the initial sale of shares to the Investor, subject to the Company paying all documented fees and amounts to the Investor’s legal counsel and, if the agreement is terminated prior to effectiveness of the resale registration statement, the Company paying the $600,000 cash commitment fee to the Investor or, if the agreement is terminated after such effectiveness, the Company issuing all commitment shares of Class A Common Stock to the Investor. The Purchase Agreement will automatically terminate on (i) the 24-month anniversary of the effective date of the initial resale registration statement filed with the Commission, (ii) the date when the Investor purchases the Total Commitment, (iii) the date when the shares of Class A Common Stock are no longer listed on the Nasdaq Capital Market or another eligible national stock exchange, or (iv) when the Company is subject to a voluntary or involuntary bankruptcy or insolvency proceeding. In addition, the Investor may terminate the Purchase Agreement upon (i) the occurrence of an event constituting a material adverse effect (as defined in the Purchase Agreement), (ii) the occurrence of a change of control transaction of the Company, (iii) the failure by the Company to file a registration statement by the applicable deadline set forth in the Registration Rights Agreement, (iv) the lapse of the effectiveness, or unavailability of, a registration statement filed by the Company pursuant to the Registration Rights Agreement in certain other circumstances set forth in the Purchase Agreement, (v) the suspension of trading of the Class A Common Stock for a period of three (3) consecutive trading days, or (vi) the material breach of the Purchase Agreement by the Company, which breach is not cured within the 10 trading days after receipt of notice of such breach. On December 28, 2023, the Company amended the agreement to provide that, if the number of commitment shares required to be issued by the Company to the Investor and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder) pursuant to the Purchase Agreement would result in the beneficial ownership by the Investor of more than 4.99% of the outstanding shares of Class A common stock of the Company, then the Company shall be obligated to deliver to the Investor: (i) the number of shares of Class A common stock that, after giving effect to the issuance thereof to the Investor, would result in the Investor and its affiliates beneficially owning one (1) share less than 4.99% of the outstanding shares of Class A common stock of the Company, and (ii) a warrant to purchase shares of Class A common stock (such warrant, the “Warrant” and the shares issuable upon exercise thereof, the “Warrant Shares”), granting the Investor the right to purchase, at an exercise price of $0.0001 per Warrant Share, up to that number of Warrant Shares equal to the difference between (x) the number of shares that would be required to be issued to the Investor as commitment shares but-for the 4.99% ownership limitation, and (y) the number of shares of Class A common stock to be issued to the Investor as commitment shares. The amendment further provide that, if the issuance of the total number of commitment shares of Class A common stock and Warrant Shares by the Company to the Investor would cause the beneficial ownership of the Investor and its affiliates to exceed 19.99% of the outstanding shares of Class A common stock of the Company, and the Company has not obtained stockholder approval for the issuance of such shares of Class A common stock in an amount in excess of the 19.99% ownership threshold in accordance with the applicable rules of The Nasdaq Capital Market on or before May 24, 2024, then the Company shall be obligated to pay to the Investor an amount in cash equal to $600,000 minus the value of the shares of Class A common stock issuable to the Investor as commitment shares and the value of the Warrant Shares issuable upon exercise of the Warrant. Also pursuant to the Agreement, the Company and the Investor amended the Registration Rights Agreement to extend the filing deadline by which the Company must file an initial registration statement with the U.S. Securities and Exchange Commission (the “Commission”) with respect to the resale by the Investor of the shares of Class A common stock of the Company issuable to the Investor pursuant to the Purchase Agreement, including the commitment shares and the Warrant Shares, to January 31, 2024. Holdback Agreement As part of the Valley Veterinary Services, Inc. acquisition in November 2023, a portion of the purchase price in the amount of $200,000 as part of the Holdback Agreement classified as restricted cash in the accompanying consolidated balance sheet. The Holdback Agreement dictates that $80,000 is contingent upon both former owners (now employees of the Company) still being employed by the Company as of November 8, 2025 and the Valley Vet Practice’s gross revenue exceeding 105% of the target gross revenue. The remaining $120,000 is contingent upon both former owners (now employees of the Company) still being employed by the Company as of November 8, 2025 and the Valley Vet Practice’s gross revenue exceeding 110% of the target gross revenue. As the contingent consideration arrangement in which the Holdback amounts are automatically forfeited if the employment of the former owners (now employees of the Company) terminates is accounted for as compensation for post combination services. The Company will recognize the contingent consideration from the Holdback Agreement when probable.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company had the following subsequent events: Refinancing Loan Payable On May 7, 2024, the Company amended the financing arrangement to borrow an additional $518,750 resulting in the weekly payments to increase to $90,229 to be paid over 48 weeks. This amendment decreased the effective interest rate to 49%. New Loan Payable On April 4, 2024, the Company entered into a new financing arrangement to borrow $400,000 with weekly payments of $21,600 to be paid over 28 weeks. This financing arrangement has an effective interest rate to 51%.	13. Subsequent Events The Company follows the guidance in FASB ASC 855-10 for the disclosure of subsequent events. The Company evaluated subsequent events through the date the financial statements were issued and determined the Company had the following subsequent events: Series A Preferred Stock Issuance On January 2, 2024, the Company entered into a subscription agreement (the “Subscription Agreement”) with Target Capital 1, LLC (“Target”), pursuant to which Target purchased 20,000 shares of Series A preferred stock for gross proceeds of $200,000. The issuance and sale of the Series A preferred stock to Target was consummated in a privately negotiated transaction exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended. “Best-Efforts” Offering of Class A Common Stock On January 26, 2024, the Company filed an amended registration statement on Form S-1/A to register the Company’s public offering and sale, on a reasonable best-efforts basis, of up to 26,581,605 shares of Class A Common Stock at an assumed offering price of $0.188 (the “Best-Efforts Offering”), for anticipated gross proceeds of approximately $5,000,000. On February 13, 2024, the Company closed the Best-Efforts Offering of shares of Class A common stock for gross proceeds of approximately $4,000,000, prior to deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for strategic acquisitions, the engagement of external, third-party marketing and business consultants, working capital and general corporate purposes. IR Agency Consulting Agreement On February 8, 2024, the Company entered into a consulting agreement with a provider of investor relations-related services (“IR Agency”). Pursuant to the IR Agency Consulting Agreement, the Company has engaged IR Agency, on a non-exclusive basis, to prepare marketing materials and leverage digital newsletters to build a digital community of potential investors in the Company. As consideration for its performance under the IR Agency Consulting Agreement, the Company will pay IR Agency a non-refundable fee of $1,250,000 in cash. IR Agency is not a registered broker-dealer or investment advisor and will not engage in any activities on behalf of the Company that would require it to be registered as a broker-dealer or investment advisor. In addition, IR Agency is being engaged by the Company as an independent contractor and not in an employer-employee or joint venturer relationship. The IR Agency Consulting Agreement has a term of six (6) months and may be terminated by written notice, with or without cause, by Inspire at any time. Consulting Agreement On February 8, 2024, the Company entered into a Consulting Agreement with unrelated third party pursuant to which the Company engaged to provide business consulting services in the veterinary medicine sector. As consideration for its performance under the Consulting Agreement, the Company will pay the consultant a fee of $500,000. The Consulting Agreement also provides that the Company will reimburse the consultant, from time to time, for all out-of-pocket expenses, including travel costs, actually and properly incurred in connection with providing the consulting engagement. Common Stock Purchase Agreement On February 14, 2024, the Company issued 1,214,293 shares of Class A Common stock, per share to an Investor. In addition, the Company, on February 13, 2024, issued a prefunded warrant to purchase up to 1,654,889 shares of Class A common stock of the Company to the Investor. The Company issued the shares and the warrant in fulfilment to its obligation to issue “commitment shares” to the Investor upon its entry into the purchase agreement. The Company issued the shares and warrant to the Investor exempt from registration pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933. The Company did not receive any proceeds with respect to the issuance of the Commitment Shares or the Warrant and does not expect to receive any material proceeds from the Investor’s exercise, if any, of Warrant for the purchase of Warrant shares. Consulting Payment On March 6, 2024, the Company entered into a Consulting Agreement with Charles “Chuck” Keiser, DVM, an experienced professional of veterinary medicine and the business of veterinary medicine, and a former member of the board of directors of the Company, pursuant to which the Company agreed to compensate Dr. Keiser for certain consulting services that he has provided to the Company relating to veterinary medicine business support and other related activities. As consideration for Dr. Keiser’s consulting services to the Company, the Company issued to Dr. Kesier $151,695.60 worth of restricted shares of Class A common stock of the Company, which resulted in the issuance of 1,865,875 shares of Class A common stock based on the closing price of $0.0813 per share on the last trading day immediately prior to the date of the Consulting Agreement, as quoted on The Nasdaq Capital Market. General Release On March 6, 2024, the Company entered into a General Release Agreement with Kenneth Seth Lundquist, DVM, Charles “Chuck” Keiser, DVM, and Don I. Williamson, Jr. DVM, and the Estate of Gregory Armstrong (each, a “Releasor” and collectively, the “Releasors”), pursuant to which the Company agreed to issue to each Releasor $5,000 worth of restricted shares of Class A common stock of the Company, which resulted in the issuance of 61,501 shares of Class A common stock to each Releasor, based on the closing price of $0.0813 per share on the last trading day immediately prior to the date of the General Release Agreement, as quoted on The Nasdaq Capital Market. Securities Purchase Agreement On March 26, Inspire Veterinary entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors. Pursuant to the Purchase Agreement, Inspire Veterinary issued to certain investors two Increasing OID Senior Notes (each a “Note” and collectively the “Notes”) each for $250,000. The Notes have a maturity date of the earlier of December 26, 2024 or the consummation of a capital raise (the “Maturity Date”). The Notes contain an original issue discount (“OID”) which shall be: (i) fifteen percent (15%) if the Notes are satisfied and paid in full on or before the forty-fifth (45th) day after the Original Issue Date (as such term is defined in the Notes), (ii) twenty percent (20%) if the Notes are satisfied and paid in full after such 45th day but on or before the ninetieth (90th) day after the Original Issue Date, and (iii) thirty percent (30%) after such 90th day. The Notes can be prepaid at any time prior to the Maturity Date without any penalties. The Notes must be repaid in full from any future capital raises (debt, equity or any other form of capital raise) of Inspire Veterinary. All of the funds raised must be used to repay the Notes until the Notes are repaid in full. The Notes are convertible into shares of common stock of Inspire Veterinary, in full or in part, at any time after issuance at the discretion of the noteholder at a fixed conversion price of $0.03 per share (the “Fixed Conversion Price”). If the Notes are not repaid by the Maturity Date the default provisions are as follow: (i) The Face Value (as such term is defined in the Notes) of the Notes will increase by 20% (to a 50% OID -- $1,000,000 Face Value); (ii) the conversion price of the Notes will become convertible at the lower of (a) the Fixed Conversion Price or (b) 20% discount to a 3-Day volume-weighted average price (the “Default Conversion Price”). Loan Payable On March 26, 2024, the Company entered into a Merchant Cash Advance Agreement for gross proceeds of $400,000 with an unrelated third-party financial institution. Under the terms of the agreement, the Company must pay $24,983 each week for 24 weeks with the first payment being due April 1, 2024.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Significant Accounting Policies and Basis of Presentation [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2023, which are included with the Company’s Annual Report on Form 10-K and related amendments filed with the United States Securities Exchange Commission (“SEC”). Furthermore, the Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the years ended December 31, 2023 and 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC. Since the date of those audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies, except as noted below. The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification(“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the Company’s financial position, results of operations, and cash flows. The December 31, 2023, condensed consolidated balance sheet was derived from audited financial statements, but does not include all GAAP disclosures. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. On October 20, 2022, the Company amended and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas the Class A common stock prior to the amendment had 25 votes per share is now designated Class B common stock and the Class B common stock prior the amendment had 1 vote per share is now designated Class A common stock. All information included in these unaudited condensed consolidated financial statements have been adjusted, on a retrospective basis to reflect the change in designation.	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). On October 20, 2022, the Company amended and restated the articles of incorporation to change the designation of the Class A common stock and the Class B common stock, whereas the Class A common stock prior to the amendment had 25 votes per share is now designated Class B common stock and the Class B common stock prior the amendment had 1 vote per share is now designated Class A common stock. All information included in these consolidated financial statements has been adjusted, on a retrospective basis to reflect the change in designation.
Going Concern	Going Concern These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of March 31, 2024, had an accumulated deficit of $24,849,319. For the three months ending March 31, 2024, the Company sustained a net loss of $3,421,792. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months from the date of issuance of these financial statements. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.	Going Concern These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of December 31, 2023, had an accumulated deficit of $21,215,257. For the year ending December 31, 2023, the Company sustained a net loss of $15,064,131. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these financial statements were issued. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is contingent upon its ability to obtain additional financing and to generate revenue and cash flow to meet its obligations on a timely basis. The Company will continue to seek to raise additional funding through debt or equity financing during the next twelve months from the date of issuance of these financial statements. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. There is no guarantee the Company will be successful in achieving these objectives.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable and Allowance for Expected Credit Losses	Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable consist of amounts due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current expected credit losses was $123,513 as of March 31, 2024 and December 31, 2023.	Accounts Receivable and Allowance for Expected Credit Losses Accounts receivable consist of amounts due from veterinary customers. The Company records an allowance for current expected credit losses for estimated losses inherent in its trade accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted for current market conditions, the financial condition of the customer, the amount of receivables in dispute, and the current receivables aging and payment patterns. The Company does not have any off-balance sheet credit exposure related to its customers. The allowance for current expected credit losses was $123,513 and $0 as of December 31, 2023 and 2022, respectively.
Basic and Diluted Net Loss Per Share	Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share. The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: March 31, 2024 2023 Warrants 28,540 - Convertible Series A Preferred Shares 27,047 - Total 55,587 -	Basic and Diluted Net Loss Per Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during each period. Diluted net loss per share of common shares includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, share options and warrants, which would result in the issuance of incremental shares of common shares. For diluted net loss per share, the weighted-average number of common shares is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. For all periods presented, basic and diluted net loss per share are the same, as any additional share equivalents would be anti-dilutive. The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: December 31, 2023 2022 Warrants 959,610 - Convertible Series A Preferred Shares 16,145,600 - Total 17,105,210 -
Emerging Growth Company Status	Emerging Growth Company Status The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.	Emerging Growth Company Status The Company is an Emerging Growth Company, as defined in Section 2(a) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act, until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. As of December 31, 2023 and 2022 the Company had no cash equivalents. Financial instruments that potentially subject the Company to a significant concentration of credit risk consist of cash. Cash is deposited in checking accounts at accredited financial institutions with high credit-quality and is insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000, which at times, may exceed federally insured limits. The excess amounts as of December 31, 2023 and 2022, were $114,080 and $43,094, respectively. Management believes that these financial institutions are financially sound, and, accordingly, minimal credit risk exists with respect to these high-quality financial institutions.
Restricted Cash		Restricted Cash Restricted Cash consisted of cash designated to settle a holdback agreement related to our acquisition of Valley Veterinary Services, Inc. to be settled by February 8, 2026 if specific contingencies are met (see note 12 for more information).
Due from Former Owners		Due from Former Owners The Company enters into asset purchase agreements related to the acquisitions of veterinary hospitals and as part of these agreements contractually obligates the former owners of the veterinary hospitals to reimburse the Company for any monies collected by the former owners for revenues earned subsequent to the closing date of the acquisition, less monies paid by the former owner on behalf of the Company for expenses incurred subsequent to the closing date of the acquisition. Any adjustments relating to pre-acquisition amounts will be reflected in goodwill.
Inventory		Inventory Inventory is recorded at the lower of cost or net realizable value. Cost is using the weighted average method. Inventory consists of inventoriable supplies used for veterinary care and services.
Leases		Leases The Company reviews all arrangements for potential leases, and at inception, determines whether a lease is an operating or finance lease. Lease assets and liabilities, which generally represent the present value of future minimum lease payments over the term of the lease, are recognized as of the commencement date. Leases with an initial lease term of twelve months or less are classified as short-term leases and are not recognized in the balance sheets unless the lease contains a purchase option that is reasonably certain to be exercised. Lease term, discount rate, variable lease costs and future minimum lease payment determinations require the use of judgment and are based on the facts and circumstances related to the specific lease. Lease terms are generally based on their initial non-cancellable terms, unless there is a renewal option that is reasonably certain to be exercised. Various factors, including economic incentives, intent, past history and business needs are considered to determine if a renewal option is reasonably certain to be exercised. The implicit rate in a lease agreement is used when it can be determined to value the lease obligation. Otherwise, the Company’s incremental borrowing rate, which is based on information available as of the lease commencement date, including applicable lease terms and the current economic environment, is used to determine the value of the lease obligation.
Property and Equipment		Property and Equipment Property and equipment are recorded at cost, less accumulated depreciation. Depreciation of property and equipment is determined using the straight line method over the estimated useful lives of the related assets up to the salvage value. Expenditures for repairs and maintenance are charged to expense as incurred, and expenditures for betterments and major Improvements are capitalized and depreciated over the remaining useful lives of the assets. The carrying amount of the assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal, with resulting gains or losses included in operations. Estimated useful lives are as follows for major classes of property and equipment: Computers and equipment 3 – 7 years Furniture and fixtures 5 – 7 years Automobile 5 – 7 years Leasehold improvements 5 – 15 years Buildings 5 – 15 years
Acquisitions		Acquisitions The Company enters into acquisitions primarily with existing veterinary hospitals throughout the United States. When we acquire a business or assets that are determined to meet the definition of a business, we allocate the purchase consideration paid to acquire the business to the assets and liabilities acquired based on estimated fair values at the acquisition date, with the excess of purchase price over the estimated fair value of the net assets acquired recorded as goodwill. If during the measurement period (a period not to exceed 12 months from the acquisition date) we receive additional information that existed as of the acquisition date but at the time of the original allocation described above was unknown to us, we make the appropriate adjustments to the purchase price allocation in the reporting period that the amounts are determined.
Goodwill		Goodwill Goodwill represents the excess of the cost of an acquired business over the fair value assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include significant changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than it’s carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value. The Company has recorded Goodwill in connection with business acquisitions during the years ended December 31, 2023 and 2022 (see Note 5). During the years ended December 31, 2023 and 2022, the Company recorded no impairment of Goodwill.
Intangible Assets		Intangible Assets Intangible assets consist of client list, trademark and non-compete intangibles that result from the acquisition of veterinary hospitals or practices. Client list intangible assets represent the value of the long-term client relationship from the veterinary hospitals and practices. Trademark intangible assets represent the value associated with the brand names in place at the date of the acquisition. Non-compete intangible assets represent the value associated with non-compete agreements for former employees and owners in place at the date of the acquisition. The client lists and trademarks’ are included in intangible assets reported in the balance sheet which are being amortized over a 5-year term based on the estimated economic useful life of the client list and trademark. The non-compete intangible asset included in other intangibles, net is amortized over a 2-year term based on the estimated useful life of the asset. The amortization of the intangible asset is computed using the straight-line method. The intangibles are evaluated for impairment on an annual basis or more frequently whenever events or circumstances occur indicating that the carrying amount may not be recoverable.
Revenue Recognition		Revenue Recognition The Company recognizes service revenue from veterinary care services once the service is completed, as this is when the customer has the ability to direct the use of and obtain the benefits of the service. Payment terms are typically at the point of sale but may also occur upon completion of the service. The Company’s service contracts are primarily with veterinary customers. Product revenue is recognized when control passes, which occurs at a point in time when the customer completes a transaction at our animal hospitals or clinics and receives the product. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations are the delivery of veterinary services at the estimated net realizable amount for those services and goods. The Company’s accounting methodologies and processes include an evaluation of the historical collection and consideration of whether contractual allowances are necessary based on historical experience. Revenue is reported net of sales discounts and excludes sales taxes.
Cost of service revenue (exclusive of depreciation and amortization)		Cost of service revenue (exclusive of depreciation and amortization) Cost of service revenue consists of cost directly related to the animal services provided at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, laboratory costs, pet supply costs, third-party veterinarian contractors, office rent, utilities, supplies, and other cost arising as a result of the services being performed, excluding depreciation and amortization.
Cost of product revenue (exclusive of depreciation and amortization)		Cost of product revenue (exclusive of depreciation and amortization) Cost of product revenue consists of cost directly related to the product sales at the Company’s veterinary clinics and animal hospitals, which primarily includes personnel-related compensation costs of the employees at the Company’s veterinary clinics or animal hospitals, purchase price of the medication we dispense, and purchase price of product sold, excluding depreciation and amortization.
General and administrative expenses		General and administrative expenses General and administrative expenses include personnel-related compensation costs for corporate employees, such as management, accounting, legal, acquisition related and non-recurring expenses, insurance and other expenses used to operate the business.
Depreciation and Amortization Expense		Depreciation and Amortization Expense Depreciation and amortization expenses mainly relate to the assets used in generating revenue.
Convertible Instruments		Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company recognized a beneficial conversion feature of $1,569,395 during the year ended December 31, 2023. The Company records a discount to convertible notes and convertible preferred stock for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note, if applicable. Debt discounts under these arrangements are amortized to noncash interest expense using the effective interest rate method over the term of the related debt to their date of maturity. If a security or instrument becomes convertible only upon the occurrence of a future event outside the control of the Company, or, is convertible from inception, but contains conversion terms that change upon the occurrence of a future event, then any contingent beneficial conversion feature is measured and recognized when the triggering event occurs and contingency has been resolved.
Beneficial Conversion Feature of Convertible Debt		Beneficial Conversion Feature of Convertible Debt The Company accounts for convertible debt in accordance with the guidelines established by FASB ASC 470-20, “Debt with Conversion and Other Options”. The Beneficial Conversion Feature (“BCF”) of convertible debt is normally characterized as the convertible portion or feature of certain debt that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of convertible debt when issued, and also records the estimated fair value. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the event is resolved.
Debt Issuance Costs		Debt Issuance Costs Debt issuance costs are specifically identifiable costs associated with issuance of a new debt instrument. Debt issuance costs are reported on the consolidated balance sheet as a direct deduction from the face amount of the related debt. Debt issuance costs are amortized to interest expense over the term of the related debt.
Advertising Costs		Advertising Costs The Company expenses advertising costs as they are incurred. Advertising expenses were $107,766 and $28,469 for the years ending December 31, 2023 and 2022, respectively. These costs are included in “General and administrative expenses” in the accompanying consolidated statements of operations.
Stock Warrants		Stock Warrants Certain warrants that were granted by the Company for lenders through convertible bridge loans transactions (see also Note 6 Debt - Bridge Note) are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price and thus, are considered as indexed to the Company’s own stock. In addition, the warrants must require physical settlement and may not provide any guarantee of value or return. We present the allocated value for the warrants within additional paid-in capital in our consolidated balance sheet. The value assigned to the warrants was determined based on a relative fair value allocation between the warrants and related debt. The fair value of the warrants was determined using a Black Scholes valuation and applying a discount for the lack of marketability for the warrants.
Stock-Based Compensation		Stock-Based Compensation The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the consolidated financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods, which typically conform to the performance period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees.
Income Tax		Income Tax The Company and its U.S. subsidiaries file a consolidated federal income tax return and is taxed as a C-Corporation, whereby it is subject to federal and state income taxes. The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 requires an asset and liability approach for financial accounting and reporting for income taxes and established for all the entities a minimum threshold for financial statement recognition of the benefit of tax positions and requires certain expanded disclosures. The provision for income taxes is based upon income or loss after adjustment for those permanent items that are not considered in the determination of taxable income. Deferred income taxes represent the tax effects of differences between the financial reporting and tax basis of the Company’s assets and liabilities at the enacted tax rates in effect for the years in which the differences are expected to reverse. The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all the deferred tax assets will not be realized. Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In management’s opinion, adequate provisions for income taxes have been made. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.
Recently Issued Accounting Pronouncements		Recently Issued Accounting Pronouncements In September 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instrument (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 was effective for the Company beginning January 1, 2023. The adoption of ASU 2016-13 did not have a material impact on the Company’s financial position, results of operations and cash flows. The FASB and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2023. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.

Significant Accounting Polici_2

Significant Accounting Policies and Basis of Presentation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Significant Accounting Policies and Basis of Presentation [Abstract]
Schedule of Diluted Net Loss Per Share Antidilutive	The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: March 31, 2024 2023 Warrants 28,540 - Convertible Series A Preferred Shares 27,047 - Total 55,587 -	The following outstanding potentially dilutive Common Shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: December 31, 2023 2022 Warrants 959,610 - Convertible Series A Preferred Shares 16,145,600 - Total 17,105,210 -
Schedule of Estimated Useful Lives		Estimated useful lives are as follows for major classes of property and equipment: Computers and equipment 3 – 7 years Furniture and fixtures 5 – 7 years Automobile 5 – 7 years Leasehold improvements 5 – 15 years Buildings 5 – 15 years

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	As of March 31, 2024, and December 31, 2023, property and equipment, net, consisted of the following: March 31, December 31, 2024 2023 Land $ 1,983,810 $ 1,839,596 Computers and equipment 1,425,774 1,425,774 Furniture and fixtures 143,874 143,874 Automobile 101,269 101,269 Leasehold improvements 656,255 499,310 Buildings 4,607,874 4,607,874 8,918,856 8,761,911 Less - accumulated depreciation (952,135 ) (812,767 ) Property and Equipment, net $ 7,966,721 $ 7,949,144	As of December 31, 2023 and 2022, property and equipment, net, consisted of the following: December 31, December 31, 2023 2022 Land $ 1,983,810 $ 1,839,596 Buildings 4,607,874 4,162,088 Computers and equipment 1,425,774 1,321,708 Furniture and fixtures 143,874 143,874 Automobile 101,269 69,083 Leasehold improvements 499,310 95,991 8,761,911 7,632,340 Less - accumulated depreciation (812,767 ) (309,290 ) Property and Equipment, net $ 7,949,144 $ 7,323,050

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Goodwill and Intangible Assets [Abstract]
Schedule of Intangible Assets	The following summarizes the Companies’ intangibles assets as of March 31, 2024 and December 31, 2023: March 31, December 31, 2024 2023 Client List $ 2,071,000 $ 2,071,000 Noncompete Agreement 398,300 398,300 Trademark 1,117,200 1,117,200 Other Intangible Assets 45,836 45,836 Accumulated amortization (1,327,322 ) (1,119,308 ) $ 2,305,014 $ 2,513,028	The following summarizes the Company’s intangibles assets not including goodwill as of December 31, 2023 and 2022: December 31, December 31, 2023 2022 Client List $ 2,071,000 $ 1,851,000 Noncompete Agreement 398,300 354,300 Trademark 1,117,200 852,700 Other Intangible Assets 45,836 41,819 Accumulated amortization (1,119,308 ) (370,245 ) $ 2,513,028 $ 2,729,574
Schedule of Future Amortization Expense of Intangible Assets	Expected future amortization expense of intangible assets as of March 31, 2024, is as follows: Remainder of 2024 578,763 2025 664,166 2026 600,139 2027 379,382 2028 82,564 $ 2,305,014	Expected future amortization expense of intangible assets as of December 31, 2023 is as follows: 2024 $ 786,776 2025 664,166 2026 600,139 2027 379,382 2028 82,564 $ 2,513,028
Schedule of Carrying Amount of Goodwill		The following table shows the changes in the carrying amount of goodwill for the years ended December 31, 2023 and 2022:: Goodwill as of December 31, 2021 $ 1,610,843 Acquisitions 6,003,710 Goodwill as of December 31, 2022 7,614,553 Acquisitions 533,037 Goodwill as of December 31, 2023 $ 8,147,590

Business Acquisitions (Tables)

Business Acquisitions (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Business Acquisitions [Abstract]
Schedule of Assets and Liabilities Assumed	Due to the timing of the acquisition, the Company’s purchase accounting related to the valuation of the inventory, fixed assets, intangible assets, goodwill and liabilities assumed is not yet complete and subject to revision. Consideration: Cash paid prior to the time of closing $ 1,390,000 Convertible Note Payable 400,000 Acquisition costs included in general and administrative 39,535 Recognized amounts of identifiable assets acquired Inventory 74,405 Building 445,786 Land 144,214 Furniture, fixtures & equipment 64,058 Trademark (5-year life) 264,500 Non-compete agreement (2-year life) 44,000 Client list (5-year life) 220,000 Total identifiable net assets assumed 1,256,963 Goodwill 533,037 Total $ 1,790,000	The final purchase price allocation amounts are as follows: Consideration: Cash paid prior to the time of closing $ 850,000 Note Payable 164,000 Acquisition costs included in general and administrative 25,315 Recognized amounts of identifiable assets acquired Inventory 35,000 Furniture, fixtures & equipment 144,904 Trademark (5-year life) 97,600 Non-compete agreement (2-year life) 25,500 Client list (5-year life) 157,000 Total identifiable net assets assumed 460,004 Goodwill 553,996 Total $ 1,014,000 Consideration: Cash paid prior to the time of closing $ 1,342,469 Note Payable 100,000 Acquisition costs included in general and administrative 43,605 Recognized amounts of identifiable assets acquired Inventory 28,894 Buildings 660,000 Land 120,000 Furniture, fixtures & equipment 22,991 Tradename – trademarks (5-year life) 40,300 Non-compete agreement (2-year life) 23,200 Client list (5-year life) 116,000 Total identifiable net assets assumed 1,011,385 Goodwill 431,084 Total $ 1,442,469 Consideration: Cash paid prior to the time of closing $ 2,000,000 Acquisition costs included in general and administrative 34,812 Recognized amounts of identifiable assets acquired Inventory 25,000 Buildings 425,156 Land 74,844 Furniture, fixtures & equipment 176,862 Tradename – Trademarks (5-year life) 57,800 Non-compete agreement (2-year life) 38,600 Client list (5-year life) 249,000 Total identifiable net assets assumed 1,047,262 Goodwill 952,738 Total $ 2,000,000 Consideration: Cash paid prior to the time of closing $ 1,305,000 Notes Payable 100,000 Acquisition costs included in general and administrative 14,960 Recognized amounts of identifiable assets acquired Inventory 15,000 Buildings 230,000 Land 60,000 Furniture, fixtures & equipment 171,984 Tradename – Trademarks (5-year life) 49,800 Non-compete agreement (2-year life) 13,900 Client list (5-year life) 90,000 Total identifiable net assets assumed 630,684 Goodwill 774,316 Total $ 1,405,000 Consideration: Cash paid prior to the time of closing $ 450,000 Notes Payable 50,000 Acquisition costs included in general and administrative 20,193 Recognized amounts of identifiable assets acquired Inventory 21,000 Furniture, fixtures & equipment 59,151 Tradename – trademarks (5-year life) 37,800 Non-compete agreement (2-year life) 12,200 Customer Lists (5-year life) 32,000 Total identifiable net assets assumed 162,151 Goodwill 337,849 Total $ 500,000 Consideration: Cash paid prior to the time of closing $ 524,683 Convertible Notes Payable 50,000 Acquisition costs included in general and administrative 17,762 Recognized amounts of identifiable assets acquired Inventory 20,000 Furniture, fixtures & equipment 145,982 Trademark (5-year life) 18,600 Non-compete agreement (2-year life) 9,700 Client list (5-year life) 25,000 Total identifiable net assets assumed 219,282 Goodwill 355,401 Total $ 574,683 Consideration: Cash paid prior to the time of closing $ 2,077,000 Convertible Notes Payable 75,000 Acquisition costs included in general and administrative 15,000 Recognized amounts of identifiable assets acquired Inventory 45,000 Building 1,045,000 Land 155,000 Furniture, fixtures & equipment 170,013 Trademark (5-year life) 63,600 Non-compete agreement (2-year life) 31,800 Client list (5-year life) 196,000 Total identifiable net assets assumed 1,706,413 Goodwill 445,587 Total $ 2,152,000 Consideration: Cash paid prior to the time of closing $ 2,908,652 Convertible Note Payable 200,000 Acquisition costs included in general and administrative 6,077 Recognized amounts of identifiable assets acquired Inventory 44,000 Building 234,221 Land 265,779 Furniture, fixtures & equipment 253,072 Trademark (5-year life) 276,900 Non-compete agreement (2-year life) 120,400 Client list (5-year life) 556,000 Total identifiable net assets assumed 1,760,372 Goodwill 1,348,280 Total $ 3,108,652 Consideration: Cash paid prior to the time of closing $ 750,000 Convertible Note Payable 100,000 Acquisition costs included in general and administrative 19,196 Recognized amounts of identifiable assets acquired Inventory 61,196 Building - Land - Furniture, fixtures & equipment 28,202 Trademark (5-year life) 79,500 Non-compete agreement (2-year life) 56,300 Client list (5-year life) 190,000 Total identifiable net assets assumed 415,198 Goodwill 434,802 Total $ 850,000 Consideration: Cash paid prior to the time of closing $ 1,415,000 Convertible Note Payable 50,000 Acquisition costs included in general and administrative 12,820 Recognized amounts of identifiable assets acquired Inventory 15,804 Building 570,000 Land 300,000 Furniture, fixtures & equipment 103,239 Trademark (5-year life) 44,900 Non-compete agreement (2-year life) 17,400 Client list (5-year life) 44,000 Total identifiable net assets assumed 1,095,343 Goodwill 369,657 Total $ 1,465,000 Consideration: Cash paid prior to the time of closing $ 1,390,000 Consideration paid in Common Stock 400,000 Acquisition costs included in general and administrative 39,535 Recognized amounts of identifiable assets acquired Inventory 74,405 Building 445,786 Land 144,214 Furniture, fixtures & equipment 64,058 Trademark (5-year life) 264,500 Non-compete agreement (2-year life) 44,000 Client list (5-year life) 220,000 Total identifiable net assets assumed 1,256,963 Goodwill 533,037 Total $ 1,790,000
Schedule of Unaudited Pro Forma Consolidated Results of Operation	The unaudited pro forma consolidated results of operations, assuming the acquisitions had occurred on January 1, 2023, are as follows: For the Revenue $ 4,723,308 Net Income (Loss) (1,488,111 )	The unaudited pro forma consolidated results of revenue and net loss, assuming the acquisitions had occurred on January 1, 2023 and 2022, are as follows: Year Ended Year Ended December 31, December 31, Revenue $ 18,438,565 $ 18,716,433 Net loss $ (14,840,964 ) (2,564,788 )

Debt (Tables)

Debt (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Debt (Tables) [Line Items]
Schedule of Notes Payable	Notes payable as of March 31, 2024 and December 31, 2023 consisted of the following: March 31, December 31, 2024 2023 FNBD Notes Payable $ 9,141,096 $ 9,309,286 FSNB Notes Payable 5,667,674 5,767,302 Total notes payable 14,808,770 15,076,588 Unamortized debt issuance costs (116,540 ) (124,170 ) Notes payable, net of issuance cost 14,692,230 14,952,418 Less current portion (1,203,402 ) (1,469,043 ) Long-term portion $ 13,488,828 $ 13,483,375	Notes payable as of December 31, 2023 and 2022 consisted of the following: December 31, December 31, 2023 2022 FNBD Notes Payable $ 9,309,286 $ 8,863,423 FSB Notes Payable 5,767,302 6,531,377 Car loan - 6,653 Total notes payable 15,076,588 15,401,453 Unamortized debt issuance costs (124,170 ) (135,240 ) Notes payable, net of issuance cost 14,952,418 15,266,213 Less current portion (1,469,043 ) (1,549,861 ) Long-term portion $ 13,483,375 $ 13,716,353
Schedule of Notes Payable Repayment Requirements	Notes payable repayment requirements as of March 31, 2024, in the succeeding years are summarized as follows: Remainder of 2024 $ 1,203,402 2025 3,776,189 2026 1,008,110 2027 1,052,832 2028 1,098,387 Thereafter $ 6,669,850	Notes payable repayment requirements as of December 31, 2023, in the succeeding years are summarized as follows: 2024 $ 1,469,043 2025 3,776,189 2026 1,008,110 2027 1,052,832 2028 1,098,387 Thereafter $ 6,672,027
Schedule of Bridge Note	A roll forward of the bridge note for the three months ended March 31, 2023 is below: Bridge notes, December 31, 2022 3,899,156 Amortization of original issue discount 116,656 Amortization of warrant discount 125,975 Amortization of debt issuance costs 62,758 Bridge notes, March 31, 2023 $ 4,204,545	A roll forward of the bridge note from January 1, 2022 to December 31, 2023 is below: Bridge notes, December 31, 2021 1,031,917 Issued for cash 2,600,000 Amortization of original issue discount 386,245 Warrant discount (429,284 ) Amortization of warrant discount 303,309 Debt issuance costs (164,000 ) Amortization of debt issuance costs 170,969 Bridge notes, December 31, 2022 3,899,156 Amortization of original issue discount 116,656 Amortization of warrant discount 125,975 Amortization of debt issuance costs 62,758 Extinguishment of bridge notes in exchange for Series A preferred stock upon IPO on August 31, 2023 (4,204,545 ) Bridge notes, December 31, 2023 $ -
Wealth South A Division Of Farmers National Bank Of Danville [Member]
Debt (Tables) [Line Items]
Schedule of Notes Payable to FNBD	Notes payable to FNBD as of March 31, 2024 and December 31, 2023 consisted of the following: Original Acquisition Entered Maturity Interest March 31, December 31, Issuance $ 237,272 CAH 12/27/21 12/27/41 3.98 % $ 235,150 $ 237,272 $ 6,108 231,987 CAH 12/27/21 12/27/31 3.98 % 226,582 231,987 6,108 216,750 P&F 12/27/21 12/27/41 3.98 % 214,812 216,750 5,370 318,750 P&F 12/27/21 12/27/31 3.98 % 311,323 318,750 5,370 817,135 Pasco 1/14/22 1/14/32 3.98 % 804,374 817,135 3,085 478,098 Lytle 3/15/22 3/15/32 3.98 % 478,098 478,098 1,898 663,000 Lytle 3/15/22 3/15/42 3.98 % 663,000 663,000 11,875 425,000 Kern 3/22/22 3/22/42 3.98 % 425,000 425,000 7,855 1,275,000 Kern 3/22/22 3/22/32 3.98 % 1,275,000 1,275,000 4,688 246,500 Bartow 5/18/22 5/18/42 3.98 % 246,500 246,500 5,072 722,500 Bartow 5/18/22 5/18/32 3.98 % 722,500 722,500 2,754 382,500 Dietz 6/15/22 6/15/32 3.98 % 382,500 382,500 1,564 445,981 Aberdeen 7/19/22 7/29/32 3.98 % 445,981 445,981 1,786 1,020,000 All Breed 8/12/22 8/12/42 3.98 % 1,020,000 1,020,000 8,702 519,527 All Breed 8/12/22 8/12/32 3.98 % 519,527 519,527 3,159 225,923 All Breed 8/12/22 8/12/32 5.25 % 225,923 225,923 3,159 637,500 Williamsburg 12/8/22 12/8/32 5.25 % 637,500 637,500 2,556 850,000 Valley Vet 11/8/23 11/8/33 5.25 % 850,000 850,000 3,315 $ 9,713,423 $ 9,141,096 $ 9,309,286 $ 84,424	Notes payable to FNBD as of December 31, 2023 and 2022 consisted of the following: Original December 31, December 31, Issuance Principal Acquisition Entered Maturity Interest 2023 2022 Cost $ 237,272 CAH 12/27/2021 12/27/2041 3.98 % $ 228,785 $ 237,272 $ 6,108 231,987 CAH 12/27/2021 12/27/2031 3.98 % 10,161 231,987 6,108 216,750 P&F 12/27/2021 12/27/2041 3.98 % 208,997 216,750 5,370 318,750 P&F 12/27/2021 12/27/2031 3.98 % 288,761 318,750 5,370 817,135 Pasco 1/14/2022 1/14/2032 3.98 % 746,733 817,135 3,085 478,098 Lytle 3/15/2022 3/15/2032 3.98 % 444,593 478,098 1,898 663,000 Lytle 3/15/2022 3/15/2042 3.98 % 645,392 663,000 11,875 425,000 Kern 3/22/2022 3/22/2042 3.98 % 413,713 425,000 7,855 1,275,000 Kern 3/22/2022 3/22/2032 3.98 % 1,185,648 1,275,000 4,688 246,500 Bartow 5/18/2022 5/18/2042 3.98 % 241,429 246,500 5,072 722,500 Bartow 5/18/2022 5/18/2032 3.98 % 683,262 722,500 2,754 382,500 Dietz 6/15/2022 6/15/2032 3.98 % 364,708 382,500 1,564 445,981 Aberdeen 7/19/2022 7/29/2032 3.98 % 428,747 45,981 1,786 1,020,000 All Breed 8/12/2022 8/12/2042 3.98 % 1,008,039 1,020,000 8,702 519,527 All Breed 8/12/2022 8/12/2032 3.98 % 503,471 519,527 3,159 225,923 All Breed 8/12/2022 8/12/2032 5.25 % 219,347 225,923 3,159 637,500 Williamsburg 12/8/2022 12/8/2032 5.25 % 637,500 637,500 2,556 850,000 Valley Vet 11/8/2023 11/8/2033 5.25 % 850,000 - 3,315 $ 9,713,423 $ 9,309,286 $ 8,863,423 $ 84,424
First South National Bank [Member]
Debt (Tables) [Line Items]
Schedule of Notes Payable to FSB	Notes payable to FSB as of March 31, 2024 and December 31, 2023 consisted of the following: Original Acquisition Entered Maturity Interest March 31, December 31, Issuance Cost $ 1,105,000 KVC 1/25/21 2/25/41 4.35 % $ 987,082 $ 997,010 $ 13,264 1,278,400 KVC 1/25/21 1/25/31 4.35 % 931,696 960,849 10,085 469,914 KVC 1/25/21 2/25/23 5.05 % - - 753 2,086,921 Pony Express 10/31/22 10/31/25 5.97 % 1,861,227 1,902,452 25,575 400,000 Pony Express 10/31/22 10/31/42 5.97 % 384,624 387,433 3,277 568,000 Old 41 12/16/22 12/16/25 6.5 % 508,385 520,697 4,531 640,000 Old 41 12/16/22 12/16/25 6.5 % 619,660 623,861 5,077 375,000 Valley Vet 11/8/2023 11/8/2024 8.5 % 375,000 375,000 6,877 $ 7,623,235 $ 5,667,674 $ 5,767,302 $ 69,439	Notes payable to FSB as of December 31, 2023 and 2022 consisted of the following: Original December 31, December 31, Issuance Principal Acquisition Entered Maturity Interest 2023 2022 Cost $ 1,105,000 KVC 1/25/2021 2/25/2041 4.35 % $ 997,010 $ 1,035,558 $ 13,264 1,278,400 KVC 1/25/2021 1/25/2031 4.35 % 960,849 1,074,251 10,085 469,914 KVC 1/25/2021 2/25/2023 5.05 % - 53,964 753 2,086,921 Pony Express 10/31/2022 10/31/2025 5.97 % 1,902,452 2,061,346 25,575 400,000 Pony Express 10/31/2022 10/31/2042 5.97 % 387,433 398,258 3,277 700,000 Pony Express 10/31/2022 8/16/2023 7.17 % - 700,000 - 568,000 Old 41 12/16/2022 12/16/2025 6.50 % 520,697 568,000 4,531 640,000 Old 41 12/16/2022 12/16/2025 6.50 % 623,861 640,000 5,077 375,000 Valley Vet 11/8/2023 11/8/2024 8.50 % 375,000 - 6,877 $ 7,623,235 $ 5,767,302 $ 6,531,377 $ 69,439

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Deferred Tax Assets and Liabilities	The Company’s deferred tax assets and liabilities as of December 31, 2023 and 2022 are as follows: Year ended December 31, 2023 2022 Deferred tax assets: Net Operating Loss Carryforwards $ 3,684,694 $ 1,731,713 Accrued Expenses 112,936 11,197 Stock Based Compensation 98,625 - Charitable Contribution Carryforward 621 412 ROU Asset (400,605 ) (204,479 ) Lease Liability 410,405 204,982 R&D Sec 174 1,830 - Total deferred tax assets 3,908,505 1,743,825 Deferred tax liabilities: Amortization/Depreciation 89,165 134,382 Total deferred tax liabilities 89,165 134,382 Valuation allowance (3,819,340 ) (1,609,443 ) Net deferred Tax Assets (Liabilities) $ 0 -
Schedule of U.S Federal Income Tax Rate	The differences between the total calculated income tax (benefit) provision and the expected income tax computed using the U.S. federal income tax rate are as follows: 2023 2022 Tax benefit at statutory tax rate (2,872,031 ) (1,021,920 ) State benefit, net of federal benefit (210,273 ) (291,977 ) Beneficial conversion feature 868,825 - Other permanent differences 3,713 (13,535 ) Valuation allowance 2,209,897 1,308,517 Other (131 ) (11,179 ) $ (0.00 ) $ (30,094 )
Schedule of Income Tax Benefit	Income tax benefit consists of the following for the years ending December 31, 2023 and 2022: December 31 December 31 Current income benefit expense Federal $ - $ - State - (30,094 ) $ - $ -

Leases (Tables)

Leases (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Leases [Abstract]
Schedule of Lease Expense Included on the Company’s Unaudited Consolidated Statements of Operations	The components of lease expense included on the Company’s unaudited condensed statements of operations were as follows: For the Three Months Operating lease expense: Expense Classification 2024 2023 Amortization of ROU asset General and administrative $ 53,831 28,875 Accretion of operating lease liability General and administrative 10,541 7,385 Total operating lease expense $ 64,372 36,260 Other lease expense General and administrative (2,026 ) 11,708 Total $ 62,346 47,968 As of As of 2024 2023 Weighted-average remaining lease term: Operating leases (in years) 9.35 9.29 Weighted-average Discount rate: Operating leases 7.04 % 7.083 %	The components of lease expense included on the Company’s consolidated statements of operations were as follows: For the Year Ended Expense Classification 2023 2022 Operating lease expense: Amortization of ROU asset General and administrative $ 132,138 $ 52,863 Accretion of Operating lease liability General and administrative 25,667 10,695 Total operating lease expense $ 157,805 $ 63,558 Other lease expense General and administrative 28,012 8,723 Total $ 185,817 $ 72,281 As of December 31, 2023 2022 Remaining lease term: Operating leases (in years) 9.29 8.43 Discount rate: Operating leases 7.03 % 4.08 %
Schedule of Leases Were Presented on the Unaudited Condensed Balance Sheets	Amounts relating to leases were presented on the unaudited condensed Balance Sheets as of March 31, 2024 and December 31, 2023 in the following line items: As of As of Balance Sheet Classification 2024 2023 Assets: Operating lease assets Right-of-use assets $ 1,562,367 $ 1,616,198 Liabilities: Operating lease liabilities Operating lease liabilities $ 133,113 141,691 Operating lease liabilities Operating lease liabilities, non-current 1,482,514 1,514,044 Total lease liabilities $ 1,615,627 $ 1,655,735	Amounts relating to leases were presented on the consolidated balance sheets as of December 31, 2023 and 2022 in the following line items: As of December 31, Balance Sheet Classification 2023 2022 Assets: Operating lease assets Right-of-use assets $ 1,616,198 $ 746,973 Liabilities: Operating lease liabilities Operating lease liabilities 141,691 91,152 Operating lease liabilities Operating lease liabilities, non-current 1,514,044 666,179 Total lease liabilities $ 1,655,735 $ 757,331
Schedule of Future Minimum Lease Payments	The future minimum lease payments required under leases as of March 31, 2024, were as follows: Fiscal Year Operating Remainder of 2024 $ 181,811 2025 230,198 2026 231,959 2027 233,619 2028 238,078 Thereafter 1,100,287 Undiscounted cash flows 2,215,952 Less: imputed interest (600,325 ) Lease liability $ 1,615,627	The future minimum lease payments required under leases as of December 31, 2023, were as follows: Fiscal Year Operating 2024 $ 249,808 2025 230,198 2026 231,959 2027 233,619 2028 238,078 Thereafter 1,100,287 Undiscounted cash flows 2,283,949 Less: imputed interest (628,214 ) Lease liability $ 1,655,735

Description of Business (Detail

Description of Business (Details) - IPO [Member]	Aug. 31, 2023 USD ($) $ / shares shares
Description of Business [Line Items]
Net proceeds	$ 5,400,000
Underwriting discounts and commissions	512,000
Offering expenses	$ 448,429
Class A Common Stock [Member]
Description of Business [Line Items]
IPO shares (in Shares) | shares	16,000
IPO Price (in Dollars per share) | $ / shares	$ 400

Retrospective Adjustments (Deta

Retrospective Adjustments (Details)	3 Months Ended
	Mar. 31, 2024
Retrospective Adjustments [Abstract]
Description of reverse stock split	On May 8, 2024, the Company effected a 100-for-1 reverse stock split (“Reverse Split”) of the Company’s authorized and outstanding shares of Class A common stock

Significant Accounting Polici_3

Significant Accounting Policies and Basis of Presentation (Details) - USD ($)		3 Months Ended		12 Months Ended
	Oct. 20, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Significant Accounting Policies and Basis of Presentation [Line Items]
Accumulated deficit		$ (24,849,319)		$ (21,215,257)	$ (6,243,448)
Net income loss		(3,421,792)	$ (1,538,949)	(14,792,886)	(4,911,926)
Allowance for current credit losses		123,513		123,513	0
Net loss sustained		$ (3,636,312)	$ (1,538,949)	(15,064,131)	(4,911,926)
Federal deposit insurance corporation				250,000
Excess amount				$ 114,080	43,094
Useful life				2 years
Advertising expenses				$ 107,766	$ 28,469
Convertible Notes Payable [Member]
Significant Accounting Policies and Basis of Presentation [Line Items]
Beneficial conversion feature				$ 1,569,395
Trademarks [Member]
Significant Accounting Policies and Basis of Presentation [Line Items]
Useful life		5 years		5 years
Class A Common Stock [Member]
Significant Accounting Policies and Basis of Presentation [Line Items]
Voting rights	25 votes
Voting rights	25 votes	one (1) vote for each share		one (1) vote for each share
Class B Common Stock [Member]
Significant Accounting Policies and Basis of Presentation [Line Items]
Voting rights	1
Voting rights	1	twenty-five (25) votes for each share		twenty-five (25) votes for each share

Significant Accounting Polici_4

Significant Accounting Policies and Basis of Presentation (Details) - Schedule of Diluted Net Loss Per Share Antidilutive - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Diluted Net Loss Per Share Antidilutive [Abstract]
Warrants	28,540		959,610
Convertible Series A Preferred Shares	27,047		16,145,600
Total	55,587		17,105,210

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment [Abstract]
Depreciation expense	$ 139,368	$ 118,368	$ 503,477	$ 263,387

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 8,918,856	$ 8,761,911	$ 7,632,340
Less - accumulated depreciation	(952,135)	(812,767)	(309,290)
Property and Equipment, net	7,966,721	7,949,144	7,323,050
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	1,983,810	1,839,596
Computers and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	1,425,774	1,425,774	1,321,708
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	143,874	143,874	143,874
Automobile [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	101,269	101,269	69,083
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	656,255	499,310	95,991
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 4,607,874	$ 4,607,874	$ 4,162,088

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets [Abstract]
Amortization expenses	$ 208,014	$ 180,124	$ 749,062	$ 332,240

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
Accumulated amortization	$ (1,327,322)	$ (1,119,308)	$ (370,245)
Intangibles assets, Net	2,305,014	2,513,028	2,729,574
Client List [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	2,071,000	2,071,000	1,851,000
Noncompete Agreement [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	398,300	398,300	354,300
Trademark [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	1,117,200	1,117,200	852,700
Other Intangible Assets [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	$ 45,836	$ 45,836	$ 41,819

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets (Details) - Schedule of Future Amortization Expense of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Expected Future Amortization Expense of Intangible Assets [Abstract]
Remainder of 2024	$ 578,763
2025	664,166	$ 786,776
2026	600,139	664,166
2027	379,382	600,139
2028	82,564	379,382
Total	$ 2,305,014	$ 2,513,028	$ 2,729,574

Business Acquisitions (Details)

Business Acquisitions (Details) - Part 1 - USD ($)								3 Months Ended			12 Months Ended
	Nov. 08, 2023	Jun. 30, 2022	Jun. 15, 2022	May 18, 2022	Mar. 22, 2022	Mar. 15, 2022	Jan. 14, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2023
Business Acquisitions [Line Items]
Exchange payment	$ 800,000
Official closing price	400,000										$ 400,000
Share issued (in Shares)											1,865,875
Holdback agreement paid	200,000
Real estate purchase agreement exchange	$ 590,000
Adjustment of amortization expense									$ 4,954
Combined acquisitions											$ 1,014,000
Advanced Veterinary Care of Pasco [Member]
Business Acquisitions [Line Items]
Combined acquisitions							$ 1,014,000
Conversion price discount											25%
Furniture, fixtures & equipment										$ 74,904
Lytle Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions											$ 1,442,469
Conversion price discount						25%
Furniture, fixtures & equipment										46,563
Consideration transferred, total						$ 662,469
Sale in exchange						$ 780,000
Southern Kern Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions					$ 1,700,000
Furniture, fixtures & equipment					2,000,000					76,862
Consideration transferred, total					1,500,000
Sale in exchange					$ 500,000
Bartow Animal Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions				$ 1,405,000
Conversion price discount				25%
Furniture, fixtures & equipment										$ 96,984
Consideration transferred, total				$ 1,055,000
Sale in exchange				$ 350,000
Dietz Family Pet Hospital [Member]
Business Acquisitions [Line Items]
Combined acquisitions											$ 500,000
Conversion price discount											25%
Furniture, fixtures & equipment		$ 15,849
Consideration transferred, total			$ 500,000
Valley Veterinary Hospital [Member]
Business Acquisitions [Line Items]
Combined acquisitions								$ 1,790,000			$ 1,790,000
Advanced Veterinary Care of Pasco [Member]
Business Acquisitions [Line Items]
Maturity date								Jan. 01, 2023			Sep. 09, 2027
Convertible note											$ 164,000
Interest											6%
Lytle Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Maturity date						Sep. 09, 2027
Financed loan provided						$ 1,141,098
Convertible note						$ 100,000
Interest						6%
Bartow Animal Clinic [Member]
Business Acquisitions [Line Items]
Maturity date				Sep. 09, 2027
Financed loan provided				$ 969,000
Convertible note				$ 100,000
Interest				6%
Dietz Family Pet Hospital [Member]
Business Acquisitions [Line Items]
Maturity date			Sep. 09, 2027
Financed loan provided			$ 382,500
Convertible note			$ 50,000
Interest											6%
Class A Common Stock [Member]
Business Acquisitions [Line Items]
Share issued (in Shares)	1
Class A Common Stock [Member] | Valley Veterinary Hospital [Member]
Business Acquisitions [Line Items]
Share issued (in Shares)	1
Advanced Veterinary Care of Pasco [Member]
Business Acquisitions [Line Items]
Financed loan provided											$ 817,135

Business Acquisitions (Detail_2

Business Acquisitions (Details) - Part 2 - USD ($)								12 Months Ended
	Dec. 31, 2023	Dec. 09, 2022	Oct. 31, 2022	Aug. 12, 2022	Jul. 29, 2022	Jun. 30, 2022	Jun. 15, 2022	Dec. 31, 2023
Business Acquisitions [Line Items]
Combined acquisitions								$ 1,014,000
Dietz Family Pet Hospital [Member]
Business Acquisitions [Line Items]
Combined acquisitions								$ 500,000
Furniture, fixtures & equipment						$ 15,849
Consideration transferred, total							$ 500,000
Conversion price discount	25%							25%
Aberdeen Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions					$ 574,683
Furniture, fixtures & equipment					30,882
Consideration transferred, total					$ 574,683
Conversion price discount	25%							25%
All Breed Pet Care veterinary clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions				$ 2,122,000
Furniture, fixtures & equipment						70,013
Consideration transferred, total				952,000
Conversion price discount	25%							25%
Sale in exchange				$ 1,200,000
Measurement period adjustments						$ 20,000
Pony Express Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions	$ 3,108,652
Consideration transferred, total			$ 2,608,652
Conversion price discount	25%							25%
Sale in exchange			$ 500,000
Williamsburg Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Combined acquisitions		$ 850,000
Consideration transferred, total		$ 850,000
Conversion price discount	25%							25%
Aberdeen Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Financed loan provided	$ 445,981							$ 445,981
Maturity date								Sep. 09, 2027
Convertible note								$ 50,000
Interest	6%							6%
All Breed Pet Care veterinary clinic [Member]
Business Acquisitions [Line Items]
Financed loan provided	$ 1,765,450							$ 1,765,450
Maturity date								Sep. 09, 2027
Convertible note								$ 75,000
Interest	6%							6%
Pony Express Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Financed loan provided	$ 2,853,314							$ 2,853,314
Maturity date	Sep. 09, 2027
Convertible note	$ 200,000
Interest	6%							6%
Williamsburg Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Financed loan provided	$ 637,500							$ 637,500
Maturity date	Sep. 09, 2027
Convertible note	$ 100,000
Interest	6%							6%

Business Acquisitions (Detail_3

Business Acquisitions (Details) - Part 4 - USD ($)				12 Months Ended
	Dec. 31, 2023	Nov. 08, 2023	Dec. 16, 2022	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2024
Business Acquisitions [Line Items]
Combined acquisitions				$ 1,014,000
Exchange payment		$ 800,000
Official closing price		400,000		$ 400,000
Share issued (in Shares)	1,865,875			1,865,875
Holdback agreement paid		200,000
Real estate purchase agreement exchange		$ 590,000
Amortization expense				$ 23,220	$ 111,045
Old 41 Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Consideration transferred, total			$ 665,000
Sale in exchange			$ 800,000
Conversion price discount	25%			25%
Combined acquisitions	$ 1,465,000
Old 41 Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Maturity date	Sep. 09, 2027
Convertible note	$ 50,000
Interest	6%			6%
Valley Veterinary Hospital [Member]
Business Acquisitions [Line Items]
Combined acquisitions	$ 1,790,000			$ 1,790,000		$ 1,790,000
Convertible Notes Payable [Member] | Old 41 Veterinary Clinic [Member]
Business Acquisitions [Line Items]
Financed loan provided	$ 1,208,000			$ 1,208,000
Class A Ordinary Share [Member]
Business Acquisitions [Line Items]
Share issued (in Shares)		1
Class A Ordinary Share [Member] | Valley Veterinary Hospital [Member]
Business Acquisitions [Line Items]
Share issued (in Shares)		1

Business Acquisitions (Detail_4

Business Acquisitions (Details) - Schedule of Assets and Liabilities Assumed - Advanced Veterinary Care of Pasco [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Consideration:
Cash paid prior to the time of closing	$ 1,390,000	$ 850,000
Note Payable	400,000	164,000
Acquisition costs included in general and administrative	39,535	25,315
Recognized amounts of identifiable assets acquired
Inventory	74,405	35,000
Building	445,786
Land	144,214
Furniture, fixtures & equipment	64,058	144,904
Trademark (5-year life)	264,500	97,600
Non-compete agreement (2-year life)	44,000	25,500
Client list (5-year life)	220,000	157,000
Total identifiable net assets assumed	1,256,963	460,004
Goodwill	533,037	553,996
Total	$ 1,790,000	$ 1,014,000

Business Acquisitions (Detail_5

Business Acquisitions (Details) - Schedule of Assets and Liabilities Assumed (Parentheticals)	Mar. 31, 2024	Dec. 31, 2023
Trademark [Member]
Business Acquisitions (Details) - Schedule of Assets and Liabilities Assumed (Parentheticals) [Line Items]
Useful lives	5 years	5 years
Non-compete agreement [Member]
Business Acquisitions (Details) - Schedule of Assets and Liabilities Assumed (Parentheticals) [Line Items]
Useful lives	2 years
Client List [Member]
Business Acquisitions (Details) - Schedule of Assets and Liabilities Assumed (Parentheticals) [Line Items]
Useful lives	5 years

Business Acquisitions (Detail_6

Business Acquisitions (Details) - Schedule of Unaudited Pro Forma Consolidated Results of Operation - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Unaudited Pro Forma Consolidated Results of Operation [Abstract]
Revenue	$ 4,723,308	$ 18,438,565	$ 18,716,433
Net Income (Loss)	$ (1,488,111)	$ (14,840,964)	$ (2,564,788)

Debt (Details) - Part-1

Debt (Details) - Part-1 - USD ($)			3 Months Ended		12 Months Ended
	Aug. 18, 2022	Jun. 25, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2023
Debt [Line Items]
Fixed interest rate							8.50%
Initial purchase percentage	15%
Aggregate issuance cost			$ 15,825	$ 70,212	$ 128,583	$ 189,414
Farmers National Bank Of Danville [Member]
Debt [Line Items]
Debt-service coverage ratio		1
Revolving Secured Credit Facility [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Secured credit facility		$ 2,000,000
Closed end line		120 days
Purchase price percentage		85%
Initial purchase price		15%
Interest rate		0.50%
Revolving Secured Credit Facility [Member] | Minimum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
New york prime rate		3.57%
Closed End Line of Credit [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Loan amount		$ 8,000,000
Purchase price percentage		85%
Closed End Line of Credit [Member] | Minimum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
New york prime rate		3.57%
Closed End Line of Credit [Member] | Within Two Years Of Entering Into The Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Outstanding principal rate			2%
Closed End Line of Credit [Member] | After Three Years From The Date Of Entering Into Term Loan And With Five Years Of Entering Into The Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Outstanding principal rate			1%
Closed End Line of Credit [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amended date	Aug. 18, 2022
Aggregate issuance cost			$ 1,543	$ 2,082
Closed End Line of Credit [Member] | First Five Years [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Fixed interest rate		3.98%
Closed End Line of Credit [Member] | First Five Years [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Interest rate	5.25%
Closed End Line of Credit [Member] | After Five Years [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Interest rate		0.65%
Closed End Line of Credit [Member] | After Five Years [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Purchase price percentage	85%
Interest rate	0.65%
Closed End Line of Credit [Member] | After Five Years [Member] | Amendment Agreement [Member] | Maximum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
New york prime rate	4.75%
Term Loans To Acquire A Practise [Member] | Maximum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Exceed term			10 years		10 years
Practice Only Term Loans [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amortize period term			9 years		9 years
Real Estate Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amortize period term			19 years		19 years

Debt (Details) - Part-2

Debt (Details) - Part-2

Feb. 25, 2023 USD ($)

Dec. 16, 2022 USD ($)

Oct. 31, 2022 USD ($)

Sep. 25, 2021 USD ($)

Jun. 25, 2021 USD ($)

Jan. 11, 2021 USD ($)

Mar. 31, 2024 USD ($)

Nov. 08, 2023

Mar. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Sep. 11, 2021

Debt [Line Items]

Fixed interest rate

8.50%

Commercial Loan Two [Member]

Debt [Line Items]

Fixed interest rate

4.35%

Farmers National Bank Of Danville [Member]

Debt [Line Items]

Debt-service coverage ratio

1

First South National Bank [Member] | Commercial Loan Two [Member]

Debt [Line Items]

Loan amount

$ 1,278,400

Fixed interest rate

4.35%

Amended date

Jan. 25, 2031

Fixed rate loan monthly payments

$ 13,157

Commercial loan issuance costs

$ 253

$ 251

$ 10,085

First South National Bank [Member] | Commercial Loans Three [Member]

Debt [Line Items]

Loan amount

450,000

Revolving Credit Facility [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

Secured credit facility

$ 2,000,000

Closed end line

120 days

Purchase price percentage

85%

Interest rate

0.50%

Revolving Credit Facility [Member] | Minimum [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

New york prime rate

3.57%

Closed End Line Of Credit Facility [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

Loan amount

$ 8,000,000

Purchase price percentage

85%

Closed End Line Of Credit Facility [Member] | Minimum [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

New york prime rate

3.57%

Closed End Line Of Credit Facility [Member] | First Five Years [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

Fixed interest rate

3.98%

Closed End Line Of Credit Facility [Member] | After Five Years [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

Interest rate

0.65%

Revolving Credit Facility And Closed End Line Of Credit Facility [Member] | Farmers National Bank Of Danville [Member]

Debt [Line Items]

Initial purchase price

15%

Acquisition Of Kuai Veterinary Clinic [Member] | Farmers National Bank Of Danville [Member] | Commercial Loans One [Member]

Debt [Line Items]

Loan amount

$ 1,105,000

Fixed interest rate

4.35%

Amended date

Feb. 25, 2041

Acquisition Of Kuai Veterinary Clinic [Member] | First South National Bank [Member] | Commercial Loans One [Member]

Debt [Line Items]

Fixed interest rate

4.35%

Fixed rate loan monthly payments

$ 6,903

Commercial loan issuance costs

165

163

13,264

Acquisition Of Kuai Veterinary Clinic [Member] | First South National Bank [Member] | Commercial Loans Three [Member]

Debt [Line Items]

Loan amount

$ 469,914

Fixed interest rate

5.05%

5.05%

Amended date

Feb. 25, 2023

Fixed rate loan monthly payments

$ 27,164

Commercial loan issuance costs

0

58

753

Acquisition Of Kuai Veterinary Clinic [Member] | First South National Bank [Member] | Commercial Loan Three [Member]

Debt [Line Items]

Loan amount

$ 469,914

Fixed interest rate

5.05%

5.05%

Amended date

Feb. 25, 2023

Fixed rate loan monthly payments

$ 27,164

Commercial loan issuance costs

$ 753

Pony Express Practice Acquistion [Member] | First South National Bank [Member] | Commercial Loans One [Member]

Debt [Line Items]

Loan amount

$ 2,086,921

Fixed interest rate

5.97%

Amended date

Oct. 31, 2025

Fixed rate loan monthly payments

$ 23,138

Final monthly payment

1,608,530

Pony Express Practice Acquistion [Member] | First Southern National Bank [Member] | Commercial Loans One [Member]

Debt [Line Items]

Commercial loan issuance costs

2,123

2,100

$ 25,575

Pony Express Practice Acquistion [Member] | First Southern National Bank [Member] | Commercial Loan Two [Member]

Debt [Line Items]

Loan amount

$ 400,000

Fixed interest rate

5.97%

Amended date

Oct. 31, 2042

Fixed rate loan monthly payments

$ 2,859

Commercial loan issuance costs

41

40

3,277

Pony Express Practice Acquistion [Member] | First Southern National Bank [Member] | Commercial Loans Three [Member]

Debt [Line Items]

Loan amount

$ 700,000

Fixed interest rate

6.75%

Amended date

Apr. 01, 2023

Fixed rate loan monthly payments

$ 6,903

Final monthly payment

423,278

Pony Express Practice Acquistion [Member] | First Southern National Bank [Member] | Commercial Loan Three [Member]

Debt [Line Items]

Commercial loan issuance costs

$ 0

Old Fourty One Practise Acquistion [Member] | First Southern National Bank [Member]

Debt [Line Items]

Loan amount

$ 568,000

Fixed interest rate

6.50%

Old Fourty One Practise Acquistion [Member] | First Southern National Bank [Member] | Commercial Loans One [Member]

Debt [Line Items]

Loan amount

$ 640,000

Fixed interest rate

6.50%

Amended date

Dec. 16, 2025

Fixed rate loan monthly payments

$ 4,772

Commercial loan issuance costs

376

372

4,531

Final monthly payment

$ 593,039

Old Fourty One Practise Acquistion [Member] | First Southern National Bank [Member] | Commercial Loan Two [Member]

Debt [Line Items]

Commercial loan issuance costs

$ 422

$ 417

$ 5,077

Old Fourty One Practise Acquistion [Member] | First Southern National Bank [Member] | Commercial Loan Two [Member] | Original Issue Discount Secured Convertible Note loan [Member]

Debt [Line Items]

Fixed interest rate

6.50%

Old Fourty One Practise Acquistion [Member] | First Southern National Bank [Member] | Commercial Loans Two [Member]

Debt [Line Items]

Amended date

Dec. 16, 2025

Old Fourty One Practise Acquistion [Member] | Upto Twelve Months [Member] | First Southern National Bank [Member] | Commercial Loan Two [Member]

Debt [Line Items]

Fixed rate loan monthly payments

$ 2,830

Old Fourty One Practise Acquistion [Member] | After Twelve Months [Member] | First Southern National Bank [Member] | Commercial Loan Two [Member]

Debt [Line Items]

Fixed rate loan monthly payments

$ 7,443

Debt (Details) - Part-3

Debt (Details) - Part-3				1 Months Ended	3 Months Ended		12 Months Ended
	Aug. 31, 2023 USD ($)	Jun. 30, 2023 shares	Nov. 18, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt [Line Items]
Net proceeds								$ 12,253,585
Aggregate issuance cost					$ 15,825	$ 70,212	$ 128,583	189,414
Qualified financing multiplied period					2		2
Multiplier to conversion price			0.65
Automatic extension price			0.6
Gain loss on extinguishment of debt					$ (728,278)		$ (16,105)
Bridge Note [Member]
Debt [Line Items]
Warrants outstanding term					5 years
Fair value of warrant					$ 429,284
Dragon Dynamic Catalytic Bridge SAC [Member]
Debt [Line Items]
Loan amount				$ 2,500,000
Measurement Input, Share Price [Member] | Bridge Note [Member]
Debt [Line Items]
Warrant exercise price					0.44
Measurement Input, Price Volatility [Member] | Bridge Note [Member]
Debt [Line Items]
Volatility rate					27%
Risk-Free Rate [Member] | Bridge Note [Member]
Debt [Line Items]
Volatility rate					1.53%
Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Interest rate per annum			12%
Bridge Loans [Member]
Debt [Line Items]
Aggregate issuance cost						$ 62,758	$ 62,758	$ 170,969
Gain loss on extinguishment of debt	$ 16,105
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member]
Debt [Line Items]
Conversion share price					$ 2,567,866
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | IPO [Member]
Debt [Line Items]
Conversion share price					$ 4
Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Loan amount			$ 1,136,364
Maturity date			Mar. 31, 2023
Percentage of face value						50%
Debt instrument percentage of discount			12%
Interest rate per annum			12%		12%		12%
Percentage of gross revenue			20%
Multiplier to conversion price			0.65
Automatic extension price			0.6
Stock issued during period shares (in Shares) | shares			41,167		412
Capital, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Percentage of face value						50%
622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Loan amount			$ 568,182
Interest rate per annum			12%		12%
Percentage of gross revenue			20%
Debt instrument initial maturity date			Jan. 24, 2023
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares) | shares		442,458
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender One [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares) | shares		29,896
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender Two [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares) | shares		352,771
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender Three [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares) | shares		59,792
Initial Maturity Date [Member] | Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt					$ 1,136,364		$ 1,136,364
Percentage price			120%
Initial Maturity Date [Member] | 622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt					568,182
Percentage price			120%
Initial Maturity Date [Member] | Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt			$ 1,136,364
Percentage price			120%
Initial Maturity Date [Member] | 622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt			$ 568,182
Percentage price			120%
Short Term Secured Convertible Notes [Member] | Dragon Dynamic Catalytic Bridge SAC [Member]
Debt [Line Items]
Loan amount				$ 2,500,000
Original issue discount rate				12%
Maturity date				Jan. 24, 2023
Original issue discount amount				$ 300,000
Conversion price rate				40%
Net proceeds				$ 1,100,000
Issuance costs				70,500
Debt issuance costs gross two				$ 54,000
Aggregate issuance cost					$ 0	$ 62,758
Percentage of face value					50%
Share price triggering warrant redemption					10 days
Short Term Secured Convertible Notes [Member] | Dragon Dynamic Catalytic Bridge SAC [Member] | Bridge Note [Member]
Debt [Line Items]
Percentage of face value					75%
Short Term Secured Convertible Notes [Member] | IPO [Member] | Dragon Dynamic Catalytic Bridge SAC [Member]
Debt [Line Items]
IPO discount rate				35%
Term Loans To Acquire A Practise [Member] | Maximum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Exceed term					10 years		10 years
Practice Only Term Loans [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amortize period term					9 years		9 years
Real Estate Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amortize period term					19 years		19 years
Class A Common Stock [Member] | Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Percentage of face value						75%
Class A Common Stock [Member] | Capital, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Percentage of face value						75%
Class A Common Stock [Member] | Short Term Secured Convertible Notes [Member] | Dragon Dynamic Catalytic Bridge SAC [Member] | Bridge Note [Member]
Debt [Line Items]
Percentage of face value					100%

Debt (Details) - Part-4

Debt (Details) - Part-4 - USD ($)					1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2024	Aug. 31, 2023	Dec. 28, 2021	Mar. 18, 2021	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Debt [Line Items]
Issuance of convertible debentures						$ 500,000
Percentage of accrued interest	6%
Convertible Notes Payable [Member]
Debt [Line Items]
Conversion share price								$ 1,569,395
Convertible Debentures [Member]
Debt [Line Items]
Issuance of convertible debentures			$ 2,102,500	$ 2,102,500	$ 650,000				$ 1,612,000
Subordinated convertible percentage			6%	6%	6%				6%
Discount price percentage						25%		25%
Exceed term					5 years	5 years	5 years
Debenture issuance cost						$ 40,000		$ 40,000
Amortized					$ 1,972	$ 1,993	$ 1,972
Principal balance paid		$ 250,000
Investor principal balance	$ 100,000	100,000
Convertible Debenture Principal Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debenture convert amount		4,014,500
Convertible Debenture Interest Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debenture convert amount		$ 399,818
Convertible Debenture Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)		14,953
Price per share (in Dollars per share)		$ 30
Closed End Line Of Credit Facility [Member] | Within Two Years Of Entering Into The Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Outstanding principal rate								2%
Closed End Line Of Credit Facility [Member] | After Three Years From The Date Of Entering Into Term Loan And With Five Years Of Entering Into The Term Loan [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Outstanding principal rate								1%
IPO [Member]
Debt [Line Items]
Price per share (in Dollars per share)		40
IPO [Member] | Convertible Notes Payable [Member]
Debt [Line Items]
Price per share (in Dollars per share)		$ 4
Conversion share price		$ 1,569,395

Debt (Details) - Part-5

Debt (Details) - Part-5 - USD ($)							3 Months Ended		12 Months Ended
	Jan. 18, 2024	Nov. 28, 2023	Aug. 10, 2023	May 30, 2023	Aug. 18, 2022	Jun. 25, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 26, 2024
Debt [Line Items]
Gross proceeds debt								$ 650,000	$ 650,000	$ 1,612,000
Loss on debt	$ 728,278		$ 441,618
Financing arrangement		$ 531,071
Payments to decrease		$ 56,800
OID and issuance cost									379,313
Convertible note payable											$ 250,000
Convertible note payable percentage							15%
Conversion price per share (in Dollars per share)							$ 0.03
Convertible note payable increase percentage							20%
Face value							$ 1,000,000
Fixed conversion price percentage							20%
Initial purchase percentage					15%
Aggregate issuance cost							$ 15,825	$ 70,212	128,583	189,414
Loans Payable [Member]
Debt [Line Items]
Increased the effective rate		49%	41%	49%
Loss on Reacquired Debt [Member]
Debt [Line Items]
Loss on debt		$ 485,436
Convertible Notes Payable [Member]
Debt [Line Items]
Convertible note payable percentage							20%
Loans Payable [Member]
Debt [Line Items]
Gross proceeds debt	549,185		$ 507,460	$ 1,050,000
Fixed rate loan monthly payments	$ 86,214		$ 76,071	$ 57,346
Due payments period				Jun. 06, 2023
Increased the effective rate	52%
Original issuance discount				$ 441,000
Debenture issuance cost				$ 50,000
Loan payable									1,032,540
Loan payable							$ 2,809,820		2,063,058
OID [Member]
Debt [Line Items]
Convertible note payable percentage							30%
Convertible note payable increase percentage							50%
Closed End Line Of Credit Facility [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Purchase price percentage						85%
Closed End Line Of Credit Facility [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Amended date					Aug. 18, 2022
Aggregate issuance cost									$ 7,152	$ 6,813
Closed End Line Of Credit Facility [Member] | After Five Years [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Interest rate						0.65%
Closed End Line Of Credit Facility [Member] | After Five Years [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Purchase price percentage					85%
Interest rate					0.65%
Closed End Line Of Credit Facility [Member] | After Five Years [Member] | Amendment Agreement [Member] | Maximum [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
New york prime rate					4.75%
Closed End Line Of Credit Facility [Member] | First Five Years [Member] | Amendment Agreement [Member] | Farmers National Bank Of Danville [Member]
Debt [Line Items]
Interest rate					5.25%

Debt (Details) - Part-6

Debt (Details) - Part-6 - Acquisition Of Kuai Veterinary Clinic [Member] - Commercial Loan One [Member] - USD ($)	Jan. 11, 2021	Dec. 31, 2023
Farmers National Bank Of Danville [Member]
Debt [Line Items]
Loan amount	$ 1,105,000
Fixed interest rate	4.35%
Amended date		Feb. 25, 2041
First South National Bank [Member]
Debt [Line Items]
Fixed interest rate	4.35%
Fixed rate loan monthly payments	$ 6,903
Commercial loan issuance costs	$ 13,264

Debt (Details) - Part-7

Debt (Details) - Part-7 - Commercial Loan Two [Member] - USD ($)	Jan. 11, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Sep. 11, 2021
Debt [Line Items]
Fixed interest rate	4.35%
First South National Bank [Member]
Debt [Line Items]
Loan amount	$ 1,278,400
Fixed interest rate	4.35%
Amended date	Jan. 25, 2031
Fixed rate loan monthly payments	$ 13,157
Commercial loan issuance costs		$ 253	$ 251	$ 10,085
Amendment Agreement [Member]
Debt [Line Items]
Fixed interest rate	4.35%
Amendment Agreement [Member] | First South National Bank [Member]
Debt [Line Items]
Loan amount	$ 1,278,400				$ 450,000
Amended date	Jan. 25, 2031
Fixed rate loan monthly payments	$ 13,157
Commercial loan issuance costs				$ 10,085

Debt (Details) - Part-8

Debt (Details) - Part-8 - First South National Bank [Member] - USD ($)	Feb. 25, 2023	Jan. 11, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2021	Sep. 11, 2021
Commercial Loan Two [Member]
Debt [Line Items]
Loan amount		$ 1,278,400
Fixed interest rate		4.35%
Amended date		Jan. 25, 2031
Fixed rate loan monthly payments		$ 13,157
Commercial loan issuance costs			$ 253	$ 251	$ 10,085
Amendment Agreement [Member] | Commercial Loan Two [Member]
Debt [Line Items]
Loan amount		$ 1,278,400				$ 450,000
Amended date		Jan. 25, 2031
Fixed rate loan monthly payments		$ 13,157
Commercial loan issuance costs					10,085
Acquisition Of Kuai Veterinary Clinic [Member] | Commercial Loan Three [Member]
Debt [Line Items]
Loan amount	$ 469,914
Fixed interest rate	5.05%					5.05%
Amended date						Feb. 25, 2023
Fixed rate loan monthly payments	$ 27,164
Commercial loan issuance costs					$ 753

Debt (Details) - Part-10

Debt (Details) - Part-10 - Pony Express Practice Acquistion [Member]	Oct. 31, 2022 USD ($)
First South National Bank [Member] | Commercial Loan One [Member]
Debt [Line Items]
Loan amount	$ 2,086,921
Fixed interest rate	5.97%
Amended date	Oct. 31, 2025
Fixed rate loan monthly payments	$ 23,138
Final monthly payment	1,608,530
First South National Bank [Member]
Debt [Line Items]
Commercial loan issuance costs	$ 25,575

Debt (Details) - Part-11

Debt (Details) - Part-11 - Pony Express Practice Acquistion [Member] - First South National Bank [Member] - Commercial Loan Two [Member] - USD ($)	Oct. 31, 2022	Dec. 31, 2022
Debt [Line Items]
Loan amount	$ 400,000
Fixed interest rate	5.97%
Amended date	Oct. 31, 2042
Fixed rate loan monthly payments	$ 2,859
Commercial loan issuance costs		$ 3,277

Debt (Details) - Part-12

Debt (Details) - Part-12 - Pony Express Practice Acquistion [Member] - First South National Bank [Member] - Commercial Loan Three [Member]	Oct. 31, 2022 USD ($)
Debt [Line Items]
Loan amount	$ 700,000
Fixed interest rate	6.75%
Amended date	Apr. 01, 2023
Fixed rate loan monthly payments	$ 6,903
Final monthly payment	423,278
Commercial loan issuance costs	$ 0

Debt (Details) - Part-13

Debt (Details) - Part-13 - USD ($)		3 Months Ended		12 Months Ended
	Dec. 16, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Nov. 08, 2023	Jan. 11, 2021
Debt [Line Items]
Fixed interest rate						8.50%
Loan with bank						$ 375,000
Fixed rate loan						$ 3,255
Loan issuance costs					$ 260,611
Aggregate issuance cost		$ 15,825	$ 70,212	128,583	189,414
Commercial Loan Two [Member]
Debt [Line Items]
Fixed interest rate							4.35%
First South National Bank [Member]
Debt [Line Items]
Loan issuance costs				6,877
Aggregate issuance cost				$ 14,611	3,635
Old Fourty One Practise Acquistion [Member] | First South National Bank [Member] | Commercial Loan One [Member]
Debt [Line Items]
Loan amount	$ 568,000
Fixed interest rate	6.50%
Amended date	Dec. 16, 2025
Fixed rate loan monthly payments	$ 4,772
Final monthly payment	593,039
Commercial loan issuance costs	4,531
Old Fourty One Practise Acquistion [Member] | First South National Bank [Member] | Commercial Loan Two [Member]
Debt [Line Items]
Loan amount	$ 640,000
Fixed interest rate	6.50%
Amended date	Dec. 16, 2025
Commercial loan issuance costs					$ 5,077
Old Fourty One Practise Acquistion [Member] | First South National Bank [Member] | Commercial Loan Two [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fixed interest rate	6.50%
Old Fourty One Practise Acquistion [Member] | Upto Twelve Months [Member] | First South National Bank [Member] | Commercial Loan Two [Member]
Debt [Line Items]
Fixed rate loan monthly payments	$ 2,830
Old Fourty One Practise Acquistion [Member] | After Twelve Months [Member] | First South National Bank [Member] | Commercial Loan Two [Member]
Debt [Line Items]
Fixed rate loan monthly payments	$ 7,443

Debt (Details) - Part-14

Debt (Details) - Part-14 - Dragon Dynamic Catalyic Bridge SAP And Taget Capital One LLC [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt [Line Items]
Loan amount			$ 2,500,000
Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
Loan amount			$ 2,500,000
Original issue discount rate			12%
Maturity date	Jan. 24, 2023
Original issue discount amount	$ 300,000
Conversion price rate	40%
Net proceeds			$ 1,100,000
Issuance costs			70,500
Debt issuance costs gross two			$ 54,000
Aggregate issuance cost		$ 123,727
IPO [Member] | Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
IPO discount rate			35%

Debt (Details) - Part-15

Debt (Details) - Part-15	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2024
Debt [Line Items]
Qualified financing multiplied period	2	2
Dragon Dynamic Catalyic Bridge SAP And Taget Capital One LLC [Member] | Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
Share price triggering warrant redemption	10 years
Dragon Dynamic Catalyic Bridge SAP And Taget Capital One LLC [Member] | If Qualified Financing Is Completed On Or Before Twenty Fourth Of January Two Thousand And Twenty Three [Member] | Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
Percentage of face value	50%
Dragon Dynamic Catalyic Bridge SAP And Taget Capital One LLC [Member] | If Qualified Financing Is Completed On Or Before Twenty Fourth Of January Two Thousand And Twenty Seven [Member] | Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
Percentage of face value	75%
Dragon Dynamic Catalyic Bridge SAP And Taget Capital One LLC [Member] | Non Consummation Of Qualified Financing Or Non Repayment Of Loan [Member] | Short Term Secured Convertible Debt One [Member]
Debt [Line Items]
Percentage of face value	100%

Debt (Details) - Part-16

Debt (Details) - Part-16 - Original Issue Discount Secured Convertible Note loan [Member] - USD ($)		3 Months Ended
	Nov. 18, 2022	Mar. 31, 2024	Dec. 31, 2023
Target Capital 1, LLC [Member]
Debt [Line Items]
Loan amount	$ 1,136,364
Debt instrument percentage of discount	12%
Maturity date	Mar. 31, 2023
Interest rate per annum	12%	12%	12%
Percentage of gross revenue	20%
Multiplier to conversion price	0.65
Automatic extension price	0.6
Stock issued during period shares (in Shares)	41,167	412
Exercise warrants percentage	75%
Lender 622 Capital LLC [Member]
Debt [Line Items]
Loan amount	$ 568,182
Interest rate per annum	12%		12%
Percentage of gross revenue	20%
Exercise warrants percentage	75%
Before Debt Initial Maturity Date [Member] | Target Capital 1, LLC [Member]
Debt [Line Items]
Fair value amount of debt		$ 1,136,364	$ 1,136,364
Percentage price	120%
Before Debt Initial Maturity Date [Member] | Lender 622 Capital LLC [Member]
Debt [Line Items]
Fair value amount of debt			$ 568,182
Percentage price	120%
After Debt Initial Maturity Date [Member] | Target Capital 1, LLC [Member]
Debt [Line Items]
Fair value amount of debt	$ 1,136,364
Percentage price	120%
After Debt Initial Maturity Date [Member] | Lender 622 Capital LLC [Member]
Debt [Line Items]
Fair value amount of debt	$ 568,182
Percentage price	120%

Debt (Details) - Part-17

Debt (Details) - Part-17 - USD ($)					3 Months Ended		12 Months Ended
	Aug. 31, 2023	Jun. 30, 2023	Jan. 01, 2023	Nov. 18, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Debt [Line Items]
Multiplier to conversion price				0.65
Automatic extension price				0.6
Risk-free rate			3.94%
Gain loss on extinguishment of debt					$ (728,278)		$ (16,105)
Bridge Note Detachable Warrants [Member]
Debt [Line Items]
Warrants outstanding term							5 years
Fair value of warrant							$ 429,284
Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Interest rate per annum				12%
Bridge Loans [Member]
Debt [Line Items]
Gain loss on extinguishment of debt	$ 16,105
Lender 622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Loan amount				$ 568,182
Interest rate per annum				12%			12%
Debt instrument initial maturity date				Jan. 24, 2023
Percentage of gross revenue				20%
Exercise warrants percentage				75%
Bridge Note Detachable Warrants [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Interest rate per annum				12%
Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Loan amount				$ 1,136,364
Interest rate per annum				12%	12%		12%
Percentage of gross revenue				20%
Multiplier to conversion price				0.65
Automatic extension price				0.6
Exercise warrants percentage				75%
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)		442,458
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender One [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)		29,896
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender Two [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)		352,771
Conversion of Bridge Loan to Convertible Series A Preferred Stock [Member] | Lender Three [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)		59,792
Measurement Input, Share Price [Member] | Bridge Note Detachable Warrants [Member]
Debt [Line Items]
Warrant exercise price							0.44
Measurement Input, Price Volatility [Member] | Bridge Note Detachable Warrants [Member]
Debt [Line Items]
Volatility rate percentage							27%
Measurement Input, Risk Free Interest Rate [Member] | Bridge Note Detachable Warrants [Member]
Debt [Line Items]
Risk-free rate							1.53%
Before Debt Initial Maturity Date [Member] | Lender 622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt							$ 568,182
Percentage price				120%
Before Debt Initial Maturity Date [Member] | Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt					$ 1,136,364		$ 1,136,364
Percentage price				120%
After Debt Initial Maturity Date [Member] | Lender 622 Capital LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt				$ 568,182
Percentage price				120%
After Debt Initial Maturity Date [Member] | Target Capital 1, LLC [Member] | Original Issue Discount Secured Convertible Note loan [Member]
Debt [Line Items]
Fair value amount of debt				$ 1,136,364
Percentage price				120%

Debt (Details) - Part-18

Debt (Details) - Part-18 - USD ($)									1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 28, 2024	Jan. 18, 2024	Nov. 28, 2023	Aug. 31, 2023	Aug. 10, 2023	May 30, 2023	Dec. 28, 2021	Mar. 18, 2021	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Debt [Line Items]
Issuance of convertible debentures										$ 500,000
Aggregate issuance cost										15,825	70,212	$ 128,583	$ 189,414
Percentage of accrued interest	6%
Gross proceeds debt											650,000	650,000	1,612,000
Loss on debt		$ 728,278			$ 441,618
Financing arrangement			$ 531,071
Payments to decrease			$ 56,800
Amortized issuance cost												671,719
Payments on loan payable										$ 1,032,540		1,923,474
Convertible Notes Payable [Member]
Debt [Line Items]
Conversion share price												$ 1,569,395
Loans Payable [Member]
Debt [Line Items]
Increased the effective rate			49%		41%	49%
Loss on Reacquired Debt [Member]
Debt [Line Items]
Loss on debt			$ 485,436
Convertible Debentures [Member]
Debt [Line Items]
Issuance of convertible debentures							$ 2,102,500	$ 2,102,500	$ 650,000				$ 1,612,000
Subordinated convertible percentage							6%	6%	6%				6%
Discount price percentage										25%		25%
Exceed term									5 years	5 years	5 years
Convertible debenture												$ 100,000	$ 3,714,500
Debenture issuance cost										$ 40,000		40,000
Aggregate issuance cost												7,996
Principal balance paid				$ 250,000
Investor principal balance	$ 100,000			100,000
Loans Payable [Member]
Debt [Line Items]
Debenture issuance cost						$ 50,000
Gross proceeds debt		549,185			$ 507,460	1,050,000
Fixed rate loan monthly payments		$ 86,214			$ 76,071	$ 57,346
Due payments period						Jun. 06, 2023
Increased the effective rate		52%
Original issuance discount						$ 441,000
Loan payable										$ 2,809,820		$ 2,063,058
Convertible Debenture Principal Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debenture convert amount				4,014,500
Convertible Debenture Interest Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debenture convert amount				$ 399,818
Convertible Debenture Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)				14,953
Price per share (in Dollars per share)				$ 30
Class A Common Stock [Member] | Convertible Debenture Conversion to Class A Common Stock [Member]
Debt [Line Items]
Debt conversion shares issued (in Shares)				1,495,295
Price per share (in Dollars per share)				$ 3
Forecast [Member]
Debt [Line Items]
Percentage of accrued interest	6%
IPO [Member]
Debt [Line Items]
Price per share (in Dollars per share)				40
IPO [Member] | Convertible Notes Payable [Member]
Debt [Line Items]
Price per share (in Dollars per share)				$ 4
Conversion share price				$ 1,569,395

Debt (Details) - Schedule of No

Debt (Details) - Schedule of Notes Payable to FNBD - FNDB [Member] - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 9,713,423
Notes Payable	9,141,096	$ 9,309,286
Issuance Cost	84,424
Notes Payable One [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	237,272
Notes Payable	235,150	237,272
Issuance Cost	$ 6,108
Acquisition	CAH
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2041
Interest	3.98%
Notes Payable Two [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 231,987
Notes Payable	226,582	231,987
Issuance Cost	$ 6,108
Acquisition	CAH
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2031
Interest	3.98%
Notes Payable Three [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 216,750
Notes Payable	214,812	216,750
Issuance Cost	$ 5,370
Acquisition	P&F
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2041
Interest	3.98%
Notes Payable Four [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 318,750
Notes Payable	311,323	318,750
Issuance Cost	$ 5,370
Acquisition	P&F
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2031
Interest	3.98%
Notes Payable Five [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 817,135
Notes Payable	804,374	817,135
Issuance Cost	$ 3,085
Acquisition	Pasco
Entered	Jan. 14, 2022
Maturity	Jan. 14, 2032
Interest	3.98%
Notes Payable Six [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 478,098
Notes Payable	478,098	478,098
Issuance Cost	$ 1,898
Acquisition	Lytle
Entered	Mar. 15, 2022
Maturity	Mar. 15, 2032
Interest	3.98%
Notes Payable Seven [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 663,000
Notes Payable	663,000	663,000
Issuance Cost	$ 11,875
Acquisition	Lytle
Entered	Mar. 15, 2022
Maturity	Mar. 15, 2042
Interest	3.98%
Notes Payable Eight [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 425,000
Notes Payable	425,000	425,000
Issuance Cost	$ 7,855
Acquisition	Kern
Entered	Mar. 22, 2022
Maturity	Mar. 22, 2042
Interest	3.98%
Notes Payable Nine [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 1,275,000
Notes Payable	1,275,000	1,275,000
Issuance Cost	$ 4,688
Acquisition	Kern
Entered	Mar. 22, 2022
Maturity	Mar. 22, 2032
Interest	3.98%
Notes Payable Ten [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 246,500
Notes Payable	246,500	246,500
Issuance Cost	$ 5,072
Acquisition	Bartow
Entered	May 18, 2022
Maturity	May 18, 2042
Interest	3.98%
Notes Payable Eleven [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 722,500
Notes Payable	722,500	722,500
Issuance Cost	$ 2,754
Acquisition	Bartow
Entered	May 18, 2022
Maturity	May 18, 2032
Interest	3.98%
Notes Payable Twelve [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 382,500
Notes Payable	382,500	382,500
Issuance Cost	$ 1,564
Acquisition	Dietz
Entered	Jun. 15, 2022
Maturity	Jun. 15, 2032
Interest	3.98%
Notes Payable Thirteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 445,981
Notes Payable	445,981	445,981
Issuance Cost	$ 1,786
Acquisition	Aberdeen
Entered	Jul. 19, 2022
Maturity	Jul. 29, 2032
Interest	3.98%
Notes Payable Fourteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 1,020,000
Notes Payable	1,020,000	1,020,000
Issuance Cost	$ 8,702
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2042
Interest	3.98%
Notes Payable Fifteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 519,527
Notes Payable	519,527	519,527
Issuance Cost	$ 3,159
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2032
Interest	3.98%
Notes Payable Sixteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 225,923
Notes Payable	225,923	225,923
Issuance Cost	$ 3,159
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2032
Interest	5.25%
Notes Payable Seventeen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 637,500
Notes Payable	637,500	637,500
Issuance Cost	$ 2,556
Acquisition	Williamsburg
Entered	Dec. 08, 2022
Maturity	Dec. 08, 2032
Interest	5.25%
Notes Payable Eighteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 850,000
Notes Payable	850,000	$ 850,000
Issuance Cost	$ 3,315
Acquisition	Valley Vet
Entered	Nov. 08, 2023
Maturity	Nov. 08, 2033
Interest	5.25%

Debt (Details) - Schedule of _2

Debt (Details) - Schedule of Notes Payable to FSB - First South National Bank [Member] - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Notes Payable Nineteen [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 1,105,000
Notes Payable	987,082	$ 997,010
Issuance Cost	$ 13,264
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Feb. 25, 2041
Interest	4.35%
Notes Payable Twenty [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 1,278,400
Notes Payable	931,696	960,849
Issuance Cost	$ 10,085
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Jan. 25, 2031
Interest	4.35%
Notes Payable Twenty One [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 469,914
Notes Payable
Issuance Cost	$ 753
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Feb. 25, 2023
Interest	5.05%
Notes Payable Twenty Two [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 2,086,921
Notes Payable	1,861,227	1,902,452
Issuance Cost	$ 25,575
Acquisition	Pony Express
Entered	Oct. 31, 2022
Maturity	Oct. 31, 2025
Interest	5.97%
Notes Payable Twenty Three [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 400,000
Notes Payable	384,624	387,433
Issuance Cost	$ 3,277
Acquisition	Pony Express
Entered	Oct. 31, 2022
Maturity	Oct. 31, 2042
Interest	5.97%
Notes Payable Twenty Four [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 568,000
Notes Payable	508,385	520,697
Issuance Cost	$ 4,531
Acquisition	Old 41
Entered	Dec. 16, 2022
Maturity	Dec. 16, 2025
Interest	6.50%
Notes Payable Twenty Five [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 640,000
Notes Payable	619,660	623,861
Issuance Cost	$ 5,077
Acquisition	Old 41
Entered	Dec. 16, 2022
Maturity	Dec. 16, 2025
Interest	6.50%
Notes Payable Twenty Six [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 375,000
Notes Payable	375,000	375,000
Issuance Cost	$ 6,877
Acquisition	Valley Vet
Entered	Nov. 08, 2023
Maturity	Nov. 08, 2024
Interest	8.50%
First South National Bank [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 7,623,235
Notes Payable	5,667,674	$ 5,767,302
Issuance Cost	$ 69,439

Debt (Details) - Schedule of _3

Debt (Details) - Schedule of Notes Payable - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Notes Payable [Abstract]
FNBD Notes Payable	$ 9,141,096	$ 9,309,286	$ 8,863,423
FSNB Notes Payable	5,667,674	5,767,302	6,531,377
Total notes payable	14,808,770	15,076,588	15,401,453
Unamortized debt issuance costs	(116,540)	(124,170)	(135,240)
Notes payable, net of issuance cost	14,692,230	14,952,418	15,266,213
Less current portion	(1,203,402)	(1,469,043)	(1,549,861)
Long-term portion	$ 13,488,828	$ 13,483,375	$ 13,716,353

Debt (Details) - Schedule of _4

Debt (Details) - Schedule of Notes Payable Repayment Requirements - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Tabular Form of Maturities of Notes Payable [Abstract]
Remainder of 2024	$ 1,203,402	$ 1,469,043
2025	3,776,189	3,776,189
2026	1,008,110	1,008,110
2027	1,052,832	1,052,832
2028	1,098,387	1,098,387
Thereafter	$ 6,669,850	$ 6,672,027

Debt (Details) - Schedule of Br

Debt (Details) - Schedule of Bridge Note - Bridge note [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Bridge Notes [Line Items]
Bridge notes beginning balance	$ 3,899,156	$ 3,899,156	$ 1,031,917
Amortization of original issue discount	116,656	116,656	386,245
Amortization of warrant discount	125,975	125,975	303,309
Amortization of debt issuance costs	62,758	62,758	170,969
Bridge notes ending balance	$ 4,204,545		$ 3,899,156

Related Party Transactions (Det

Related Party Transactions (Details)		3 Months Ended		12 Months Ended
	Jan. 01, 2023 $ / shares shares	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transactions [Line Items]
Incurred expenses		$ 68,027	$ 229,614
Volatility rate	27.13%
Percentage of risk-free rate	3.94%
Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Warrants of Class A common stock issuable (in Shares) | shares	500
Warrant expires	Jan. 01, 2028
Year term	5 years
General and administrative expenses		2,701		$ 2,701
Consulting Agreement [Member] | Star Circle Advisory Group, LLC [Member]
Related Party Transactions [Line Items]
Payable amount		33,000		33,000
Incurred expenses				284,900	$ 450,000
Consulting Agreement [Member] | Blue Heron Consulting [Member]
Related Party Transactions [Line Items]
Incurred expenses				$ 907,866	$ 983,355
Service Agreements [Member]
Related Party Transactions [Line Items]
Incurred expenses		$ 0	$ 99,000
Warrant [Member]
Related Party Transactions [Line Items]
Common share price per share (in Dollars per share) | $ / shares	$ 1.73
Class A Common Stock [Member] | Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Warrants of Class A common stock issuable (in Shares) | shares	50,000
Measurement Input, Share Price [Member] | Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Purchase price per share	1.73
Measurement Input, Share Price [Member] | Class A Common Stock [Member] | Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Purchase price per share	4
Measurement Input, Price Volatility [Member] | Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Purchase price per share	27.13
Measurement Input, Risk Free Interest Rate [Member] | Kimball Carr, Chief Executive Officer (CEO) and Chairman of the board of directors [Member]
Related Party Transactions [Line Items]
Purchase price per share	3.94

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)					3 Months Ended	12 Months Ended
	Nov. 07, 2023	Jun. 30, 2023	Nov. 15, 2022	Oct. 20, 2022	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Stockholders Equity [Line Items]
Authorized to issue shares					71,000,000	170,000,000
Preferred stock, shares authorized					50,000,000	50,000,000
Preferred stock, par value (in Dollars per share)					$ 0.0001	$ 0.0001
Price per share (in Dollars per share)						$ 0.0813
Preferred stock, convertible, conversion price (in Dollars per share)					$ 1
Percentage of shares to be issued upon exercise of the new warrants					75%	75%
Fair value of common stock (in Dollars)						$ 144,168
Common stock expense (in Dollars)						$ 108,126	$ 36,042
Preferred stock authorized	2,000,000
Preferred stock per share (in Dollars per share)	$ 0.25
Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, shares authorized	2,000,000
Equal To Volume Weighted Average Price [Member]
Stockholders Equity [Line Items]
Percentage of conversion price					60%	60%
Number of trading days						3 years
Equal To Per Share Price Of IPO [Member]
Stockholders Equity [Line Items]
Percentage of conversion price					50%	50%
Equal To Price Of Underwritten Initial Public Offering [Member]
Stockholders Equity [Line Items]
Percentage of conversion price					60%	60%
Number of trading days						3 days
Alchemy Advisory, LLC [Member]
Stockholders Equity [Line Items]
Stock or unit option plan expense (in Dollars)			$ 40,000
Fair value expenses (in Dollars)					$ 0			$ 36,042
Alchemy Advisory, LLC [Member] | Common Stock [Member]
Stockholders Equity [Line Items]
Fair value of the common stock (in Dollars)			72,084
Six Hundred And Sixty Two Capital LLC [Member]
Stockholders Equity [Line Items]
Fair value of the common stock (in Dollars)					144,168
Fair value expenses (in Dollars)					$ 0			$ 72,804
Equity securities restricted (in Dollars)						$ 72,084
Restricted stock or unit expense (in Dollars)						$ 54,063	$ 18,021
Alchemy Advisory, Llc [Member]
Stockholders Equity [Line Items]
Stock or unit option plan expense (in Dollars)			$ 40,000
Class A Common Stock [Member]
Stockholders Equity [Line Items]
Designated shares					1,000,000	1,000,000	100,000,000
Common stock par value (in Dollars per share)					$ 0.0001	$ 0.0001	$ 0.0001
Common stock, voting rights				25 votes	one (1) vote for each share	one (1) vote for each share
Class A Common Stock [Member] | Previously Reported [Member]
Stockholders Equity [Line Items]
Designated shares						100,000,000
Common stock par value (in Dollars per share)						$ 0.0001
Class A Common Stock [Member] | Alchemy Advisory, LLC [Member]
Stockholders Equity [Line Items]
Restricted shares issued			83
Class A Common Stock [Member] | Six Hundred And Sixty Two Capital LLC [Member]
Stockholders Equity [Line Items]
Restricted shares issued					417	41,667
Class A Common Stock [Member] | Alchemy Advisory, Llc [Member]
Stockholders Equity [Line Items]
Restricted shares issued			83,334
Class B Common Stock [Member]
Stockholders Equity [Line Items]
Designated shares					20,000,000	20,000,000	20,000,000
Common stock par value (in Dollars per share)					$ 0.0001	$ 0.0001	$ 0.0001
Common stock, voting rights				1	twenty-five (25) votes for each share	twenty-five (25) votes for each share
Class B Common Stock [Member] | Previously Reported [Member]
Stockholders Equity [Line Items]
Designated shares						20,000,000
Common stock par value (in Dollars per share)						$ 0.0001
Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, shares authorized		1,000,000
Preferred stock, par value (in Dollars per share)		$ 0.0001
Price per share (in Dollars per share)		$ 1,000
Preferred stock outstanding		12%
Series A Preferred Stock [Member] | Previously Reported [Member]
Stockholders Equity [Line Items]
Price per share (in Dollars per share)		$ 10
Series A Preferred Stock [Member] | Bridge Note [Member]
Stockholders Equity [Line Items]
Debt conversion, converted instrument, shares issued		442.458
Series A Preferred Stock [Member] | In Exchange Of Bridge Notes [Member]
Stockholders Equity [Line Items]
Debt conversion, converted instrument, shares issued		442,458
IPO [Member] | Class A Common Stock [Member]
Stockholders Equity [Line Items]
Designated shares					1,000,000	100,000,000
IPO [Member] | Class B Common Stock [Member]
Stockholders Equity [Line Items]
Designated shares						20,000,000
Designated share					20,000,000
IPO [Member] | Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, convertible, conversion price (in Dollars per share)					$ 4	$ 4
Preferred stock convertible, beneficial conversion feature (in Dollars)					$ 2,567,866	$ 2,567,866

Retirement Plan (Details)

Retirement Plan (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Retirement Plan [Line Items]
Contributed and expensed			$ 124,166	$ 50,704
Percentage of participants compensation			3%
Savings Incentive Match Plan [Member]
Retirement Plan [Line Items]
Contributed and expensed	$ 40,264	$ 4,995	$ 0	$ 2,648

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Taxes [Line Items]
Tax benefit
Federal and state income tax			14,924,318	$ 6,348,656
Deferred tax assets federal and state jurisdictions			$ 14,924,318
Groups of stockholders			5%

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Expense Included on the Company’s Unaudited Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Lease Expense Included on the Company’s Unaudited Consolidated Statements of Operations [Abstract]
Amortization of ROU asset	$ 53,831	$ 28,875	$ 132,138	$ 52,863
Accretion of Operating lease liability	10,541	7,385	25,667	10,695
Total operating lease expense	64,372	36,260	157,805	63,558
Other lease expense	(2,026)	11,708	28,012	8,723
Total	$ 62,346	$ 47,968	$ 185,817	$ 72,281
Weighted-average remaining lease term:
Operating leases (in years)	9 years 4 months 6 days		9 years 3 months 14 days	8 years 5 months 4 days
Weighted-average Discount rate:
Operating leases	7.04%		7.083%

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Leases Were Presented on the Unaudited Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets:
Operating lease assets	$ 1,562,367	$ 1,616,198	$ 746,973
Liabilities:
Operating lease liabilities	133,113	141,691	91,152
Operating lease liabilities	1,482,514	1,514,044	666,179
Total lease liabilities	$ 1,615,627	$ 1,655,735	$ 757,331

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Future Minimum Lease Payments - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments [Abstract]
Remainder of 2024	$ 181,811	$ 249,808
2025	230,198	230,198
2026	231,959	231,959
2027	233,619	233,619
2028	238,078	238,078
Thereafter	1,100,287	1,100,287
Undiscounted cash flows	2,215,952	2,283,949
Less: imputed interest	(600,325)	(628,214)
Lease liability	$ 1,615,627	$ 1,655,735	$ 757,331

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)				3 Months Ended	12 Months Ended
	Feb. 14, 2024	Dec. 28, 2023	Nov. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Nov. 08, 2023	Dec. 31, 2022
Commitments and Contingencies [Line Items]
Percentage of purchase price				95%	95%
Description of purchase agreement				the Company may not require the Investor to purchase, and the Investor will have no obligation to purchase, shares of Class A common stock in excess of a number equal to the lowest of (i) 100% of the average daily trading volume of the Class A common stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable) for the five consecutive trading days immediately prior to the trading date on which a valid purchase notice is delivered to the Investor, (ii) a 30% discount to the daily trading volume in the Class A common stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable), and (iii) $2 million divided by the volume-weighted average price for the Class A common stock on the trading day immediately prior to the trading date on which a valid purchase notice is delivered to the Investor.	the Company may not require the Investor to purchase, and the Investor will have no obligation to purchase, shares of Class A Common Stock in excess of a number equal to the lowest of (i) 100% of the average daily trading volume of the Class A Common Stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable) for the five consecutive trading days immediately prior to the trading date on which a valid purchase notice is delivered to the Investor, (ii) a 30% discount to the daily trading volume in the Class A Common Stock on the Nasdaq Capital Market (or any other eligible national stock exchange, as applicable), and (iii) $2 million divided by the volume-weighted average price for the Class A Common Stock on the trading day immediately prior to the trading date on which a valid purchase notice is delivered to the Investor.
Percentage of ownership limitation		4.99%		19.99%	19.99%
Investor exercise warrant amount (in Dollars)					$ 5,439,571
Shares issued (in Shares)					1,865,875
Purchase of shares (in Shares)	16,549
Revenue percentage			110%
Holdback Agreement [Member]
Commitments and Contingencies [Line Items]
Purchase price amount (in Dollars)			$ 200,000
Contingent owners amount (in Dollars)			$ 80,000
Valley Vet Practice’s [Member]
Commitments and Contingencies [Line Items]
Revenue percentage			105%
Revenue contingent owners amount (in Dollars)			$ 120,000
Warrant [Member]
Commitments and Contingencies [Line Items]
Exercise price per share (in Dollars per share)		$ 0.0001
Class A Common Stock [Member]
Commitments and Contingencies [Line Items]
Purchase amount (in Shares)			30,000,000
Common stock issued and outstanding percentage				19.99%	19.99%
Divided common stock value (in Dollars)				$ 600,000	$ 600,000
Cash fee (in Dollars)				$ 600,000	$ 600,000
Common stock outstanding percentage		4.99%
Exercise price per share (in Dollars per share)				$ 0.0001	$ 0.0001		$ 0.0001
Percentage of ownership limitation		19.99%
Shares issued (in Shares)						1
Class A Common Stock [Member] | Purchase Limits [Member]
Commitments and Contingencies [Line Items]
Investor shares (in Shares)				12,143	1,214,293
Class A Common Stock [Member] | Investor [Member]
Commitments and Contingencies [Line Items]
Purchase amount (in Shares)			30,000,000
Cash fee (in Dollars)				$ 600,000	$ 600,000
Common stock outstanding percentage		4.99%
Shares issued (in Shares)	12,143
Class A Common Stock [Member] | Warrant [Member]
Commitments and Contingencies [Line Items]
Exercise price per share (in Dollars per share)		$ 0.01
Investor exercise warrant amount (in Dollars)				$ 600,000	$ 600,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

3 Months Ended

12 Months Ended

Apr. 01, 2024

Mar. 26, 2024

Mar. 06, 2024

Feb. 13, 2024

Jan. 26, 2024

Jan. 02, 2024

Mar. 26, 2023

Mar. 31, 2024

Dec. 31, 2023

Apr. 04, 2024

Mar. 07, 2024

Feb. 14, 2024

Nov. 08, 2023

Jun. 30, 2023

Mar. 31, 2023

Dec. 31, 2022

Subsequent Events [Line Items]

Financing arrangement borrowings

$ 518,750

Payments to increase financing arrangement

$ 90,229

Purchased shares (in Shares)

50,000,000

50,000,000

Non-refundable fee

$ 1,250,000

Consulting agreement

$ 500,000

Issued shares (in Shares)

1,865,875

Warrant to purchase (in Shares)

28,540

959,610

Restricted shares

$ 151,695.6

Common stock per share (in Dollars per share)

$ 0.0813

Purchase agreement amount

$ 250,000

Conversion price (in Dollars per share)

$ 0.03

Refinancing Loan Payable [Member]

Subsequent Events [Line Items]

Effective interest rate

49%

Original Issue Discount [Member]

Subsequent Events [Line Items]

Percentage of conversion price

20%

Conversion price

$ 1,000,000

Valley Veterinary Service Inc [Member]

Subsequent Events [Line Items]

Restricted shares issue

$ 1,390,000

Securities Purchase Agreement [Member]

Subsequent Events [Line Items]

Original issued discount, percentage

30%

Conversion price (in Dollars per share)

$ 0.03

Face value original issue discount, percentage

20%

Securities Purchase Agreement [Member] | Original Issue Discount [Member]

Subsequent Events [Line Items]

Percentage of conversion price

50%

Securities Purchase Agreement [Member] | Forty-Fifth Day [Member]

Subsequent Events [Line Items]

Original issued discount, percentage

15%

Securities Purchase Agreement [Member] | Ninetieth Day [Member]

Subsequent Events [Line Items]

Original issued discount, percentage

20%

Subsequent Event [Member]

Subsequent Events [Line Items]

Financing arrangement borrowings

$ 400,000

Payments to increase financing arrangement

$ 21,600

Gross proceeds

$ 400,000

$ 5,000,000

$ 200,000

Offering and sale (in Shares)

26,581,605

Offering price (in Dollars per share)

$ 0.188

Agent fees

$ 4,000,000

Issued shares (in Shares)

1,214,293

Warrant to purchase (in Shares)

1,654,889

Company agreement payments

$ 24,983

Subsequent Event [Member] | New Loan Payable [Member]

Subsequent Events [Line Items]

Effective interest rate

51%

Subsequent Event [Member] | General Release [Member]

Subsequent Events [Line Items]

Common stock per share (in Dollars per share)

$ 0.0813

Subsequent Event [Member] | Valley Veterinary Service Inc [Member] | General Release [Member]

Subsequent Events [Line Items]

Restricted shares issue

$ 5,000

Series A Preferred Stock [Member]

Subsequent Events [Line Items]

Purchased shares (in Shares)

1,000,000

Common stock per share (in Dollars per share)

$ 1,000

Series A Preferred Stock [Member] | Subsequent Event [Member] | Valley Veterinary Service Inc [Member]

Subsequent Events [Line Items]

Purchased shares (in Shares)

20,000

Class A Common Stock

Subsequent Events [Line Items]

Issued shares (in Shares)

1

Class A Common Stock | Subsequent Event [Member] | Valley Veterinary Service Inc [Member]

Subsequent Events [Line Items]

issuance of shares

$ 61,501

Significant Accounting Polici_5

Significant Accounting Policies and Basis of Presentation (Details) - Schedule of Estimated Useful Lives	Dec. 31, 2023
Minimum [Member] | Computers and equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	3 years
Minimum [Member] | Furniture and fixtures [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	5 years
Minimum [Member] | Automobile [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	5 years
Minimum [Member] | Leasehold improvements [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	5 years
Minimum [Member] | Buildings [member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	5 years
Maximum [Member] | Computers and equipment [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	7 years
Maximum [Member] | Furniture and fixtures [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	7 years
Maximum [Member] | Automobile [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	7 years
Maximum [Member] | Leasehold improvements [Member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	15 years
Maximum [Member] | Buildings [member]
Schedule of Estimated Useful Lives [Line Items]
Estimated Useful Lives	15 years

Significant Accounting Polici_6

Significant Accounting Policies and Basis of Presentation (Details) - Schedule of Diluted Net Loss Per Share Antidilutive - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Diluted Net Loss Per Share Antidilutive [Abstract]
Warrants	28,540		959,610
Convertible Series A Preferred Shares	27,047		16,145,600
Total	55,587		17,105,210

Property and Equipment (Detai_3

Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 8,918,856	$ 8,761,911	$ 7,632,340
Less - accumulated depreciation	(952,135)	(812,767)	(309,290)
Property and Equipment, net	7,966,721	7,949,144	7,323,050
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	1,983,810	1,839,596
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	4,607,874	4,607,874	4,162,088
Computers and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	1,425,774	1,425,774	1,321,708
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	143,874	143,874	143,874
Automobile [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	101,269	101,269	69,083
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 656,255	499,310	95,991
Previously Reported [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, net		7,949,144
Previously Reported [Member] | Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross		$ 1,983,810	$ 1,839,596

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets (Details) - Schedule of Carrying Amount of Goodwill - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Carrying Amount of Goodwill [Abstract]
Goodwill Beginning Balance	$ 7,614,553	$ 1,610,843
Acquisitions	533,037	6,003,710
Goodwill Ending Balance	$ 8,147,590	$ 7,614,553

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
Accumulated amortization	$ (1,327,322)	$ (1,119,308)	$ (370,245)
Intangibles assets, Net	2,305,014	2,513,028	2,729,574
Client List [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	2,071,000	2,071,000	1,851,000
Noncompete Agreement [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	398,300	398,300	354,300
Trademark [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	1,117,200	1,117,200	852,700
Other Intangible Assets [Member]
Schedule of Intangible Assets [Line Items]
Intangibles assets, Gross	$ 45,836	$ 45,836	$ 41,819

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets (Details) - Schedule of Future Amortization Expense of Intangible Assets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Expected Future Amortization Expense of Intangible Assets [Abstract]
2024	$ 664,166	$ 786,776
2025	600,139	664,166
2026	379,382	600,139
2027	82,564	379,382
2028		82,564
Total	$ 2,305,014	$ 2,513,028	$ 2,729,574

Business Acquisitions (Detail_7

Business Acquisitions (Details) - Schedule of Final Purchase Price Allocation - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Advanced Veterinary Care of Pasco [Member]
Consideration:
Cash paid prior to the time of closing	$ 1,390,000	$ 850,000
Note Payable	400,000	164,000
Acquisition costs included in general and administrative	39,535	25,315
Recognized amounts of identifiable assets acquired
Inventory	74,405	35,000
Land	144,214
Furniture, fixtures & equipment	64,058	144,904
Trademark (5-year life)	264,500	97,600
Non-compete agreement (2-year life)	44,000	25,500
Client list (5-year life)	220,000	157,000
Total identifiable net assets assumed	1,256,963	460,004
Goodwill	533,037	553,996
Total	$ 1,790,000	1,014,000
Lytle Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		1,342,469
Note Payable		100,000
Acquisition costs included in general and administrative		43,605
Recognized amounts of identifiable assets acquired
Inventory		28,894
Buildings		660,000
Land		120,000
Furniture, fixtures & equipment		22,991
Trademark (5-year life)		40,300
Non-compete agreement (2-year life)		23,200
Client list (5-year life)		116,000
Total identifiable net assets assumed		1,011,385
Goodwill		431,084
Total		1,442,469
Southern Kern Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		2,000,000
Acquisition costs included in general and administrative		34,812
Recognized amounts of identifiable assets acquired
Inventory		25,000
Buildings		425,156
Land		74,844
Furniture, fixtures & equipment		176,862
Trademark (5-year life)		57,800
Non-compete agreement (2-year life)		38,600
Client list (5-year life)		249,000
Total identifiable net assets assumed		1,047,262
Goodwill		952,738
Total		2,000,000
Bartow Animal Clinic [Member]
Consideration:
Cash paid prior to the time of closing		1,305,000
Note Payable		100,000
Acquisition costs included in general and administrative		14,960
Recognized amounts of identifiable assets acquired
Inventory		15,000
Buildings		230,000
Land		60,000
Furniture, fixtures & equipment		171,984
Trademark (5-year life)		49,800
Non-compete agreement (2-year life)		13,900
Client list (5-year life)		90,000
Total identifiable net assets assumed		630,684
Goodwill		774,316
Total		1,405,000
Dietz Family Pet Hospital [Member]
Consideration:
Cash paid prior to the time of closing		450,000
Note Payable		50,000
Acquisition costs included in general and administrative		20,193
Recognized amounts of identifiable assets acquired
Inventory		21,000
Furniture, fixtures & equipment		59,151
Trademark (5-year life)		37,800
Non-compete agreement (2-year life)		12,200
Client list (5-year life)		32,000
Total identifiable net assets assumed		162,151
Goodwill		337,849
Total		500,000
Aberdeen Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		524,683
Note Payable		50,000
Acquisition costs included in general and administrative		17,762
Recognized amounts of identifiable assets acquired
Inventory		20,000
Furniture, fixtures & equipment		145,982
Trademark (5-year life)		18,600
Non-compete agreement (2-year life)		9,700
Client list (5-year life)		25,000
Total identifiable net assets assumed		219,282
Goodwill		355,401
Total		574,683
All Breed Pet Care veterinary clinic [Member]
Consideration:
Cash paid prior to the time of closing		2,077,000
Note Payable		75,000
Acquisition costs included in general and administrative		15,000
Recognized amounts of identifiable assets acquired
Inventory		45,000
Buildings		1,045,000
Land		155,000
Furniture, fixtures & equipment		170,013
Trademark (5-year life)		63,600
Non-compete agreement (2-year life)		31,800
Client list (5-year life)		196,000
Total identifiable net assets assumed		1,706,413
Goodwill		445,587
Total		2,152,000
Pony Express Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		2,908,652
Note Payable		200,000
Acquisition costs included in general and administrative		6,077
Recognized amounts of identifiable assets acquired
Inventory		44,000
Buildings		234,221
Land		265,779
Furniture, fixtures & equipment		253,072
Trademark (5-year life)		276,900
Non-compete agreement (2-year life)		120,400
Client list (5-year life)		556,000
Total identifiable net assets assumed		1,760,372
Goodwill		1,348,280
Total		3,108,652
Williamsburg Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		750,000
Note Payable		100,000
Acquisition costs included in general and administrative		19,196
Recognized amounts of identifiable assets acquired
Inventory		61,196
Furniture, fixtures & equipment		28,202
Trademark (5-year life)		79,500
Non-compete agreement (2-year life)		56,300
Client list (5-year life)		190,000
Total identifiable net assets assumed		415,198
Goodwill		434,802
Total		850,000
Old 41 Veterinary Clinic [Member]
Consideration:
Cash paid prior to the time of closing		1,415,000
Note Payable		50,000
Acquisition costs included in general and administrative		12,820
Recognized amounts of identifiable assets acquired
Inventory		15,804
Buildings		570,000
Land		300,000
Furniture, fixtures & equipment		103,239
Trademark (5-year life)		44,900
Non-compete agreement (2-year life)		17,400
Client list (5-year life)		44,000
Total identifiable net assets assumed		1,095,343
Goodwill		369,657
Total		1,465,000
Valley Veterinary Service Inc [Member]
Consideration:
Cash paid prior to the time of closing		1,390,000
Consideration paid in Common Stock		400,000
Acquisition costs included in general and administrative		39,535
Recognized amounts of identifiable assets acquired
Inventory		74,405
Buildings		445,786
Land		144,214
Furniture, fixtures & equipment		64,058
Trademark (5-year life)		264,500
Non-compete agreement (2-year life)		44,000
Client list (5-year life)		220,000
Total identifiable net assets assumed		1,256,963
Goodwill		533,037
Total		$ 1,790,000

Business Acquisitions (Detail_8

Business Acquisitions (Details) - Schedule of Unaudited Pro Forma Consolidated Results of Revenue and Net Loss, Assuming the Acquisitions - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Unaudited Pro Forma Consolidated Results of Revenue and Net Loss, Assuming the Acquisitions [Abstract]
Revenue	$ 4,723,308	$ 18,438,565	$ 18,716,433
Net loss	$ (1,488,111)	$ (14,840,964)	$ (2,564,788)

Debt (Details) - Schedule of _5

Debt (Details) - Schedule of Notes Payable to FNBD - Master Lending and Credit Facility [Member] - FNDB [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 9,713,423
Notes Payable	9,309,286	$ 8,863,423
Issuance Cost	84,424
Notes Payable One [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	237,272
Notes Payable	228,785	237,272
Issuance Cost	$ 6,108
Acquisition	CAH
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2041
Interest	3.98%
Notes Payable Two [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 231,987
Notes Payable	10,161	231,987
Issuance Cost	$ 6,108
Acquisition	CAH
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2031
Interest	3.98%
Notes Payable Three [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 216,750
Notes Payable	208,997	216,750
Issuance Cost	$ 5,370
Acquisition	P&F
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2041
Interest	3.98%
Notes Payable Four [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 318,750
Notes Payable	288,761	318,750
Issuance Cost	$ 5,370
Acquisition	P&F
Entered	Dec. 27, 2021
Maturity	Dec. 27, 2031
Interest	3.98%
Notes Payable Five [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 817,135
Notes Payable	746,733	817,135
Issuance Cost	$ 3,085
Acquisition	Pasco
Entered	Jan. 14, 2022
Maturity	Jan. 14, 2032
Interest	3.98%
Notes Payable Six [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 478,098
Notes Payable	444,593	478,098
Issuance Cost	$ 1,898
Acquisition	Lytle
Entered	Mar. 15, 2022
Maturity	Mar. 15, 2032
Interest	3.98%
Notes Payable Seven [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 663,000
Notes Payable	645,392	663,000
Issuance Cost	$ 11,875
Acquisition	Lytle
Entered	Mar. 15, 2022
Maturity	Mar. 15, 2042
Interest	3.98%
Notes Payable Eight [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 425,000
Notes Payable	413,713	425,000
Issuance Cost	$ 7,855
Acquisition	Kern
Entered	Mar. 22, 2022
Maturity	Mar. 22, 2042
Interest	3.98%
Notes Payable Nine [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 1,275,000
Notes Payable	1,185,648	1,275,000
Issuance Cost	$ 4,688
Acquisition	Kern
Entered	Mar. 22, 2022
Maturity	Mar. 22, 2032
Interest	3.98%
Notes Payable Ten [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 246,500
Notes Payable	241,429	246,500
Issuance Cost	$ 5,072
Acquisition	Bartow
Entered	May 18, 2022
Maturity	May 18, 2042
Interest	3.98%
Notes Payable Eleven [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 722,500
Notes Payable	683,262	722,500
Issuance Cost	$ 2,754
Acquisition	Bartow
Entered	May 18, 2022
Maturity	May 18, 2032
Interest	3.98%
Notes Payable Twelve [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 382,500
Notes Payable	364,708	382,500
Issuance Cost	$ 1,564
Acquisition	Dietz
Entered	Jun. 15, 2022
Maturity	Jun. 15, 2032
Interest	3.98%
Notes Payable Thirteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 445,981
Notes Payable	428,747	45,981
Issuance Cost	$ 1,786
Acquisition	Aberdeen
Entered	Jul. 19, 2022
Maturity	Jul. 29, 2032
Interest	3.98%
Notes Payable Fourteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 1,020,000
Notes Payable	1,008,039	1,020,000
Issuance Cost	$ 8,702
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2042
Interest	3.98%
Notes Payable Fifteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 519,527
Notes Payable	503,471	519,527
Issuance Cost	$ 3,159
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2032
Interest	3.98%
Notes Payable Sixteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 225,923
Notes Payable	219,347	225,923
Issuance Cost	$ 3,159
Acquisition	All Breed
Entered	Aug. 12, 2022
Maturity	Aug. 12, 2032
Interest	5.25%
Notes Payable Seventeen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 637,500
Notes Payable	637,500	$ 637,500
Issuance Cost	$ 2,556
Acquisition	Williamsburg
Entered	Dec. 08, 2022
Maturity	Dec. 08, 2032
Interest	5.25%
Notes Payable Eighteen [Member]
Debt (Details) - Schedule of Notes Payable to FNBD [Line Items]
Original Principal	$ 850,000
Notes Payable	850,000
Issuance Cost	$ 3,315
Acquisition	Valley Vet
Entered	Nov. 08, 2023
Maturity	Nov. 08, 2033
Interest	5.25%

Debt (Details) - Schedule of _6

Debt (Details) - Schedule of Notes Payable to FSB - FSB Commercial Loans [Member] - First South National Bank [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 7,623,235
Notes Payable	5,767,302	$ 6,531,377
Issuance Cost	69,439
Notes Payable Nineteen [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	1,105,000
Notes Payable	997,010	1,035,558
Issuance Cost	$ 13,264
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Feb. 25, 2041
Interest	4.35%
Notes Payable Twenty [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 1,278,400
Notes Payable	960,849	1,074,251
Issuance Cost	$ 10,085
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Jan. 25, 2031
Interest	4.35%
Notes Payable Twenty One [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 469,914
Notes Payable		53,964
Issuance Cost	$ 753
Acquisition	KVC
Entered	Jan. 25, 2021
Maturity	Feb. 25, 2023
Interest	5.05%
Notes Payable Twenty Two [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 2,086,921
Notes Payable	1,902,452	2,061,346
Issuance Cost	$ 25,575
Acquisition	Pony Express
Entered	Oct. 31, 2022
Maturity	Oct. 31, 2025
Interest	5.97%
Notes Payable Twenty Three [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 400,000
Notes Payable	387,433	398,258
Issuance Cost	$ 3,277
Acquisition	Pony Express
Entered	Oct. 31, 2022
Maturity	Oct. 31, 2042
Interest	5.97%
Notes Payable Twenty Four [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 700,000
Notes Payable		700,000
Issuance Cost
Acquisition	Pony Express
Entered	Oct. 31, 2022
Maturity	Aug. 16, 2023
Interest	7.17%
Notes Payable Twenty Five [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 568,000
Notes Payable	520,697	568,000
Issuance Cost	$ 4,531
Acquisition	Old 41
Entered	Dec. 16, 2022
Maturity	Dec. 16, 2025
Interest	6.50%
Notes Payable Twenty Six [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 640,000
Notes Payable	623,861	640,000
Issuance Cost	$ 5,077
Acquisition	Old 41
Entered	Dec. 16, 2022
Maturity	Dec. 16, 2025
Interest	6.50%
Notes Payable Twenty Seven [Member]
Debt (Details) - Schedule of Notes Payable to FSB [Line Items]
Original Principal	$ 375,000
Notes Payable	375,000
Issuance Cost	$ 6,877
Acquisition	Valley Vet
Entered	Nov. 08, 2023
Maturity	Nov. 08, 2024
Interest	8.50%

Debt (Details) - Schedule of _7

Debt (Details) - Schedule of Notes Payable - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Notes Payable [Abstract]
FNBD Notes Payable	$ 9,141,096	$ 9,309,286	$ 8,863,423
FSB Notes Payable	5,667,674	5,767,302	6,531,377
Car loan			6,653
Total notes payable	14,808,770	15,076,588	15,401,453
Unamortized debt issuance costs	(116,540)	(124,170)	(135,240)
Notes payable, net of issuance cost	14,692,230	14,952,418	15,266,213
Less current portion	(1,203,402)	(1,469,043)	(1,549,861)
Long-term portion	$ 13,488,828	$ 13,483,375	$ 13,716,353

Debt (Details) - Schedule of _8

Debt (Details) - Schedule of Notes Payable Repayment Requirements - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Schedule of Tabular Form of Maturities of Notes Payable [Abstract]
2024	$ 1,203,402	$ 1,469,043
2025	3,776,189	3,776,189
2026	1,008,110	1,008,110
2027	1,052,832	1,052,832
2028	1,098,387	1,098,387
Thereafter	$ 6,669,850	$ 6,672,027

Debt (Details) - Schedule of _9

Debt (Details) - Schedule of Bridge Notes - Bridge Loans [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Bridge Notes [Line Items]
Bridge notes beginning balance	$ 3,899,156	$ 3,899,156	$ 1,031,917
Issued for cash			2,600,000
Amortization of original issue discount	116,656	116,656	386,245
Warrant discount			(429,284)
Amortization of warrant discount	125,975	125,975	303,309
Debt issuance costs			(164,000)
Amortization of debt issuance costs	62,758	62,758	170,969
Extinguishment of bridge notes in exchange for Series A preferred stock upon IPO on August 31, 2023		(4,204,545)
Bridge notes ending balance	$ 4,204,545		$ 3,899,156

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Deferred Tax Assets And Liabilities [Abstract]
Net Operating Loss Carryforwards	$ 3,684,694	$ 1,731,713
Accrued Expenses	112,936	11,197
Stock Based Compensation	98,625
Charitable Contribution Carryforward	621	412
ROU Asset	(400,605)	(204,479)
Lease Liability	410,405	204,982
R&D Sec 174	1,830
Total deferred tax assets	3,908,505	1,743,825
Amortization/Depreciation	89,165	134,382
Total deferred tax liabilities	89,165	134,382
Valuation allowance	(3,819,340)	(1,609,443)
Net deferred Tax Assets (Liabilities)	$ 0

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of U.S Federal Income Tax Rate - U.S. Federal Income Tax Rate [Member] - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation [Line Items]
Tax benefit at statutory tax rate	$ (2,872,031)	$ (1,021,920)
State benefit, net of federal benefit	(210,273)	(291,977)
Beneficial conversion feature	868,825
Other permanent differences	3,713	(13,535)
Valuation allowance	2,209,897	1,308,517
Other	(131)	(11,179)
Total	$ 0	$ (30,094)

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Income Tax Benefit - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Current income benefit expense
Federal
State		(30,094)
Total current income benefit expense

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of Lease Expense Included on the Company’s Unaudited Consolidated Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Operating lease expense:
Amortization of ROU asset	$ 53,831	$ 28,875	$ 132,138	$ 52,863
Accretion of Operating lease liability	10,541	7,385	25,667	10,695
Total operating lease expense	64,372	36,260	157,805	63,558
Other lease expense	(2,026)	11,708	28,012	8,723
Total	$ 62,346	$ 47,968	$ 185,817	$ 72,281
Remaining lease term:
Operating leases (in years)	9 years 4 months 6 days		9 years 3 months 14 days	8 years 5 months 4 days
Discount rate:
Operating leases	7.04%		7.083%
Previously Reported [Member]
Discount rate:
Operating leases			7.03%	4.08%

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of Leases Were Presented on the Unaudited Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets:
Operating lease assets	$ 1,562,367	$ 1,616,198	$ 746,973
Liabilities:
Operating lease liabilities	133,113	141,691	91,152
Operating lease liabilities	1,482,514	1,514,044	666,179
Total lease liabilities	$ 1,615,627	$ 1,655,735	$ 757,331

Leases (Details) - Schedule o_6

Leases (Details) - Schedule of Future Minimum Lease Payments - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Future Minimum Lease Payments [Abstract]
2024	$ 181,811	$ 249,808
2025	230,198	230,198
2026	231,959	231,959
2027	233,619	233,619
2028	238,078	238,078
Thereafter	1,100,287	1,100,287
Undiscounted cash flows	2,215,952	2,283,949
Less: imputed interest	(600,325)	(628,214)
Lease liability	$ 1,615,627	$ 1,655,735	$ 757,331